var title_f25_0_25600="Long bone venous drainage";
var content_f25_0_25600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Venous drainage from marrow of long bone with intramedullary needle in place",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 282px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEaAcEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivNo/HOo6Xq3jh/EH2a50rQLi3ghj0+zZbiTz0jdclpSpI80KcAZxnj7tHiH4lXNpZkaf4f1FdUg1Sws7ixuxCJPKuZAA6kTbPmG5Vy3D43AAEgA9Jorkrbxo1zrz6PD4b1xr2GOGW6H+jBLZZM43v520kYOQhY+mahk+INlYyX0fiHS9U0J7SxfUSL0Qv5kCMFYoYZJASGZRt4PzDjmgDs6K4a4+JWn2NtfPq+k6xpl1bRwSrZ3UcXmzpNIIoyhWRk5chSGZSpPzYHNTT+PVg+xwS+HNeTVbuaaKHTWSBZnESqzurGURMuGGCHOecDg4AOzorh9S+I1lYpK50XXZltbOO/vzHbIDYROCR5qs6ncAGJVAzADOOlPk+I2li+lSOz1GXS4buOxm1ZI0+yxzuVCoSXDkZdAWCFQWAJ60AdrRXNW3jLT7i3imSG7CyatLowBVc+dHI8bN977mY2weuCOKj8NeMofEN4EstI1ZbGQyrDqMkcf2eUxttYfK5dOQcb1XOOKAOpooooAKKKKACiivOvjx4sm8J+Aria2tL+d7txbPLaRlmt4m/1kmcYUhN20nA3Y9KAOP8efEnxjpmo2ur+G7XTr3Qru/Gl2GmSKTc6iwDb54yv3U3DaOowAxHIrvfC/xI0vVtQTSdXt7rw94gK5/s7U18tn943+7IP90/gK5D4N2sPjPVYPHC2jWmgafb/2X4asZMZgiUBJpiASAzFSn+6pHPBr1LxH4e0jxLp5ste0+3v7YnISZM7T6qeqn3GDQBq0V5rHpHi3wKijw5K3ibw9Epxpl7MFvIBnOIpiMOAOAr88Y3V1fhDxZpniq1nfTjPDdWr+Vd2V1GYri1fGdsiHkex5B7E0Ab9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHndx8PdQu7vxbJd63amLXrm2udkWnsrQGAxhRkzHdlIgDwOSTwPlq54j8Bvq2o6xfwaoLa6vJNOntybfzFgls5WkUsNw3qxIBHy8DrXcUUActp/hi7ju9evL7VFe81e1ht5JLOAweS0aOu9Mu5H38gEnGOpridM+CtvD9rW+v7Dy7nR5dJkbTtM+yyy73jcTySGRzJIDH34Oeg5z6/RQB59deBdY1Fr671fX7C81Ke1jsoy+kKbZYVfe6yQNI28ucbiGXoMAVmj4VSR6L/Z8N5oD28t1NdzWd1oKzWSs6IoEEJlDQ7dhIw5yXYntj0DxTqEuk+GdX1G2VGntLOa4jWQEqWRCwBwQcZHrXnF58QfEOg2c82twaZfSS6GNWtY7GCWPY/mRx+W+WcuMyodyqDw3B4oAfcfB21Cw/ZptGu5vsUFnNca5oyajNmJSokjZnXYSMZDBx8q8dc6jfDq4D3djFrSJ4cvL+PUbix+xASmRWRiiShwFjZo1JXYT1AYA8YM3xJ8Radp+ofbdMa7lzaRWd4uh39nEZZpDGyNFIDJJs4b93ksCBgGrum+OPE17eQaMtnCl/dXpgttTu9JurO3aEQNK7/Z5WEhZSuzAfBLA5HIoA1IPAWoQatE0evRDRotZl1pbM2OZTJIzOyNL5mCu52IwgIBwc07w18P5dL8Wrr15e6bLcpHMjPYaWtlLdGQg7rllcrKVxxhV5JNcFYXk+lavod7qZjuLi017XZpzbRlFkKW8xOxSWIzjgZOPU113w98beINd1ewi1PTybK+s2uTJFo95aLZuNpWNpZxsmDKxwybeVPGCDQB6bRXF+KNK1TStXfxP4XWS5uSqrqGlF8LfRqMBo88JMo6How+U9iOh8Oa5YeItJh1LSpvNtpMjkFWRgcMjqeVYHIKnkEUAadFFFABUF/d2+n2NxeXsqw2tvG00srnARFGWY+wAJqevO/j1omua98OdStdA1WDTlETyXnmoT50CqSyBh93OPTkccUAeXaZD40vfilcnwDq9ppC3Nqup6jpFxan7LZByPKSQLkefInztt2ng8nrXqMfxIGhXS2HxD099CueAt+gaXT5+OqzY+T6OFI968+/ZY8YeDbfwfa6LHqiw+JrqdpLuO9O2S4mJwuxjww2hQFBzwTjmvXPiNqrWPh82VkltPq+qN9isLacBlkkbqSp6qq7nPsvvQB0FzfWtrp0t/PPGllFEZ3m3fIIwNxbPpjnNch8NdLklOpeLdRhMWp+IWSYRNybe2VcQRex2/Mw/vMR2rn7X4LWlrY2elw+JddPh9WV7zSpJg8F1ghivIyiEjlQcEfnXrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFfULODUbC5sryPzLa5iaGVMkbkYEEZHI4J6VmXPhXRbplNzYRzBbFtM2yMzKbZipMZBODyi8nnjrW3RQBzMPgfQo4LyJ4Ly5F2qLLJeahcXMgCNuTa8kjMhVvmBUgg8jmmjwJoP2ZojFqDOZhP9pbU7prlXClAVnMnmL8rMuAwGGI6E11FFAHN6Z4I8PaYtitnp+0WU01xBvnkk2yTKVkY7mO7cGP3s9afong7RdEvo7vT4btZIozDCs19PNHBGcfJFG7lI1+UDCgAAAdBXQ0UAFcP4j0O/wBE1ebxP4Rh825lwdT0oEKuoKBjemeFnA6N0YDa3YjuKKAMzw5rlh4i0mHUtKm822kyOQVZGBwyOp5VgcgqeQRWnXD+I9Dv9E1ebxP4Rh825lwdT0oEKuoKBjemeFnA6N0YDa3YjpfDmuWHiLSYdS0qbzbaTI5BVkYHDI6nlWByCp5BFAGnXzt+0p4hvvEfiDRfhh4Wu9t/qUga/KtgKh5VWPpgFyPQD1r3rX9Qj0nQ9Q1CaWKKO1t5JjJLnYu1SctjnHHavl34Waivw/8AEer+MvjFpupWGsauSbO+lt98fILOgC5KORgAEDAGOOaAPWtf8L6PaeFdC+Fml28Uy3kQEzOq74LZOZbrhSBIWwFbGN8gPQGt7wd8OLLwzrz6mNX1rVGS3+zWkep3RuBaITl/LJGRuwM+wx0qb4c6fcXEV14p1mKRNX1rDrHMPmtLQEmC3A7YU7m9XdvauzoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArh/Eeh3+iavN4n8Iw+bcy4Op6UCFXUFAxvTPCzgdG6MBtbsR3FYvjHxDbeF/Dt3qt2DJ5ShYoFPz3ErHCRL/tMxAH1oA4a71u2+JPiHRtM0a58zw7ZKup6yWjwS6v+4tHB+629Gd0IziMDvVjwzbW3xE8QTeKdUtYbrQbKRrbQopk3pJgjzLvaeCWZdqHsq5H3s1lS6PqOneFbXwiLkt4t8WyS3Wr3sQ/1CMF+0SjHQKpSFOnJU+teraXYW2labaafYRLDaWsSwwxr0VFGAPyFAFqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvNLi5tfE3ja71a/ukTwt4QLEMWIjkvQpMkjHGCIV4HX5mY9RXR/ETXLnRtCSLSfJbW9SnSx0+OViAZXONxwCcIu5z7L71xx8N2jppnw10lpG0exjS7124YfNOC25Ymb+9M+5m77QR/FQB0nw8tZtRn1HxfqVvJDeawVW1imXD21imfJQjJwWy0rAY5kwfuiu1oHHSigAoqnd6rp9nKIry/tIJD0SWZVP5E0ralYrEsjXtsI24VjKuD9DmgC3RTIZo54w8MiSIejIwIP4in0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBOBk9KK4P4l3E+smDwVo9y8F/qyFryeI/NaWQOJJPZm+4vqWJ/hoAxrHWdNu7jV/ifq9wo0LToJLPRjJyoiViJbhRk/NLIAi4AJRF/v4rC+GGseL9V8P/bPD3hOOwvtWla91DVtccxxySN93yokzJIgTaFJ2DA+prpBp2l+Ide/s+SC3j8EeE0WAQSYEE92oHBycMkKYGDxvY55Sm6r4sk8UeM7Twv4H8VaRaQrZPd3V1a+Xdy8OEEcYztU85JOSBjigDM1OHVdRuJIbjUfF3iV4m8u4XQGi0yzjIOGQOXVnYEMCBIT2OK0PC3gD4c+JNPN/Bokl26yNDOmqTTyzwSr96ORZXJVhkce47Gs/Q/BmtaN4qutG8IeMNStNMt7ZLi+N9Gl5vuJpJG/dggBG+Us3++hxzWz8J9Gu/DviTxppl5qj6s7XFveteTIFlZ5YsMrAccCNcY7GgDdt/ht4Jt1KxeEtCGepNjGxP4kUQ/DXwRDIzx+EtBDN/04RkD6DGB+FdbRQBxM/wAKPAktx548L6ZDL13W8fk/+gEVH/wrmG1iVdE8TeKdMKf6sJqTXCLz02Tb1x7YruqKAOBWT4geH5W+0JpvizTlUfNAPsN6Dnn5STE/GOhTnPFbXhrxnpOv3bWETy2esRxiSbTb2Mw3EQI7qfvAf3lJHvXSVzXjjwjaeKrODM0ljqtk/n2GowYEttL6g91PRkPDDr2IAOlorjfAvie+vLufw94pgjtPFFjEssqxn91eQk4FxD/sk8EdVPB7V2VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFR3E0VtBJNcSpFDGpZ5JGCqoHUknoKAJKKzLTxBo16haz1bT7hR3iuUcfoauwXdtOpaC4hkUHBKODg+nFAE1FRiaIjIkTHruFPBDDIIIoAWiiigAooooAKKaXULuLKF9c01pol+9Kg43csOnr9KAJKKrTX9nCgea6t41PQvIAD+tQPrmkpnfqliuOubhB/WgDQorFn8V+HYEDz6/pMSE7dz3kajPpknrVS48feELaIyTeKdDVB1P2+I98f3qAOlorlR8RfBhAK+KdFfPI2XiN2z2NVI/in4KkGYtftpF/vIjsPzC4oA7WiuJi+KPhGYv5Oo3Muz7xj065YD8RHQvxL0OQMba11y4UHGY9IuMH80H0oA7aiuIl+IICEweFPFs7YJ2rp23p/vMOtEnjbVWMItPA3iOQvncZfIiCYGR1k5z0oA7eiuEHifxnMHa28Aui/wG51aGMn6gBsU7+1fiBMq+X4Z0W2Yjkz6ozgf98x80AdzRXDTQ/Ee4QhLvwrZZbqsE8xC/iygmsfxRaa7ptut74p+IUmn2G8IkGlaekcszngIhO9mY+ijP4UAeok4GT0rndY8beHNJkjiu9XtmupGKx20DedNI3osaZYn8K8Q1m7tY5nttTub6KOQbo/+Em1eS4lzu4P2C3+c56gPgdMirUWg2+neELa+8GeKpp9R1SaS10yPRdPtbETTkMSsgKFgqbGLbjkAeuKAO91PW/FesWUt8m3wT4cgQzS31+qS3zoBn5YSCkQ6/fLN/s1x/guC/wDBnhE6p5tzqXjvxnd7LI6hzIE+YxmQZ4SOPLsB0ztwOKz7f4X6jqfxA0Wy8V+MdT186dCNT1aGY/6KvzjyYgucfMVkPI+6nbIr0XwvLBq+sat4/wBVPk2FtDLZ6a0nSO0jJMs//A2UnP8AdVfWgDC17R9IsPFPhnw74ynSXwz9jklg+15EN/qZkLSNcE/KWIYuqtwWd+4ArK+Omo+GNI8OGHwtYA+LLJftNhJodsDJY44Z5GjGEQqWUhuDnp3FP4neGNV8efDTXvE2u61qGn2Rt2v9M0UbI4o0QExmbIyXcAEjI2l8c4pPhL8U/CnhjST4d1rSIPDuo2KKLptPi+028vy/6xpIt2Ce+7OPWgDg9Rk1m0+GieKtM+L08+s6qYJLqwilRSZZfLjZRhtytGuATgcJ2r1DxD8MPC3gXwJrGrNfaodfNts/tmbVJopXuG+WNmKyKoAdl69B1zXK/EOX4H+IrKaXSZ4oteU7rU6FbOk8koztARU2tzzkjtnNXfhjN4b8SaLFc/FrW7q78RWWZJ9M8QyfZobcZO10gbargr/EQ3U9KAPoXTmL6fbFpknYxrmVDlXOOSD71Yrzj4C3mlXngm6fw/cQSaWNVvvssMI2i3iNw5RCv8PykMBxwwr0egAooooAKKKKAOM+JGi3M0Nj4i0OHzPEGhO1xboODdQkYmtjwfvr044cIa6Lw7rNl4h0Kx1fSpRNZXkKzROCOhHQ+hHQjsQRWjXB/D9f7G8VeLfDSbEs4J49TsYw4+SG4DF0Vf4VEqSkDtuoA7yiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKiureG7tpbe6ijmglUpJHIoZXU9QQeCKlooA5Ob4beCZixk8JaESwAJ+wxjIH4VHL8MPA8u7f4U0b5iSdtoi5P4CuwooA4dPhN4CQsV8J6SNw2n9wMf/r96F+E3gNW3L4W0wH2iruKKAOJT4VeCEl81fDtnv9cscfTnimt8J/AryO7+GrFmdtzbgxBP0zXcUUAcP/wqfwLuVh4ZsAVGBgMP607/AIVT4G3lz4Z09mPUspP8zXbUUAcQnwn8Br08LaWR6NFkfkanT4Y+B0k3jwpo27nk2qnr9RXYUUAcoPhz4LAUf8IrohCjABs4yAPypw+HfgxVCjwroYAOR/oMfB/KupooAxI/CXhyMAR6BpKgDaMWcY49OlWYdB0iAjyNKsI8DA2W6DH5CtKigCrHp1jGcx2dsh9ViUf0qwsUajCooHoBTqKACiiigAoorF8X69H4d0SW9MTXNyxENpap9+5nbiONfcnv2GSeAaANqiuW8PeJL3UfEEujXWnqk9hYwyalcxSZhju5FVvITIy2FJbPYFfWl8YeKm0ee30zSrM6lr92jPBahwiRoODLM/8ABGCeuMk8DJ6AHUV5D4tt9V8ReL/F9ppFzDBr+ladbro6S/KyrKd00qMc7WcAxbwMqVByK9U0u+ttT0+3vbG4gubaZA6TQOHRx6qw6ivJta1uOx+J3iAW80J8W3P2PR9Iim5EcEiiSSXb/EqkyOfXywvGaAIdE8YaB4TlttF0vwJqth4ouVJWynijjefBJaRrpm2uuc5YsSc9K4z4kabqGueBfEGl2tvpS3ml3kuq6jqhufLS3unyxtrZEBd2IZUy20MT3JGOy8Y+EvA/h3Srhdatz4o8W6hE0FsmoSm5u7uYj5QidIxnB3KFCjqa8h+OqeHvhy/guz8P6dZ2/iuxWG8v5IWJ3NHtZRJz8+6Rd3POAD3oA9R8HeGLrwj4C0nwcly0finxEGvdXu3Yl7W3AXzWLAnG1SkS843sWHet/W7/AFLxz4RvtC8C6HbN4entWsk1LUbmS1hddu0GBUVndQP4jtU44JFUdL8QPpfg9/HXjvTol1rxG0Nha2K4j8mBwRFb+Yx+RWO+VmYjG/n7oFeIiDxrfeKJfDttqHiKbwXp8i+bF4fujem0RlJWASjG8rkLtJOB9KAPUvDWjQWHhXxHqXxl1SbxHb6LeizQmaSa0ZQkIGyHgPIJJChZgTuBGRgmsnSPEfjT4U2d7j4eXEvgTzpJrZSYhd20bEt+9MRcYGT98ZAwC3FRGx8R6b4b1Tw54D0XWtc8KNZSi4h8QWyo0Ertkm3ztaRslmKkYzjBzW/oHgLSvFPw/wBQsPCHxC8Tz3Ri8iZLq+YCN8cxywMN0ankEfzxyAc34K8Va34p+Icvjb4d/DW3ksPshsLpprmK3MkgYuWV8YD8qDgNkdexFK+u/GfxX8X6T4guvhrb3eh6FcSwPZtdxK8zgkOPMfbvCsv3QNuQQetQ+GL74dzeMrjSdI8Ra94H0+OyRJ7WC+aFJ7sOwl3SMWXKhYxuGN3PpzpfDW9tvD2v6/pfhL4sWH9lxzF7e31eDzI3JAZ2WQsoJycHaeeSR3oA9J+G15HqPxS8QT6d4fvfDsMelWsd/Z3cCQGScyy+XIoUkMAiuu8Hngdq9arxX4San4uufGsep+LDpVzH4m0hZ7VrByPIhtmBXKnqGN4T1JBr2qgAooooAKKKKACuM8KB7r4heNb4RxiCM2mnpIpyWaONpHz6Y88D8PrXZ1w3wYkN74Gj1eSMJPq95d6jJg5yJJ3KflGIx+FAHc0UUUAFFFFABRRXHeINe1iXxjb+GfDYsIboWf8AaF3eX0bzJDEXKIqxKyF2Zlb+IABe/SgDsaK46bxNqOiG003WLJtZ1+4Es0dvokQUNBGVBlYTSAJyyjBc5JAGaoTfFPTMBtO0jW9SjGmLq0r20MYEMBaRTu8yRTvUxPlQCfTPOAD0CivPYPiFOdf8Qxvot5PoWnWUN8l9B5P+raF5SWDShju2gKAmc53YHNa9p4tvLzS4r+z8IeIZoZdrRrus0d0K5D7XuBgdsHDe3egDq6K4DSfGMmueNvDiabLKmjajo93dvbzRKriWOaFAG6kFdzqQDjPrgVu6t4v03SL/AFW11ETwHTtO/tR5GUbJIQWDbDnkqVwQcfeXrmgDoqK4a8+JGn2jTNJpWsG2tEgbUbkRR+Xp5lVWCS5k3FgrqW8sPtBBNPk+ItjHq89m+k6wLW31JNKm1AxxC3SdyoQE+ZvIJdRkKcEjOKAO2orjbL4g6deanbQR2Oprp91eSWFvqjRp9lmnQsCinfv6o6higUlcAnjNqx8b6Zd2OhXaxXccOsCZoS6LmMRozsXAY44Q4xmgDqKK5nwh4uTxOsctvo+rWlnPbi6tru5SLyriMnAKlJGKnodrhWx26101ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGJ4m8VaL4ZSA61fpbyXBKwQhWklmIxkJGoLN1HQd65OTxDf+J9e8NHTvCmvwWVpqJnmvNQhS2RU+zzR5CO/mHmQfwCu113TG1GynW0uPsOoNE0UN8kSvJBu6ldwxXJSeB9dsbdZ9F8ca6+ox/MBqZjnt5jj7roEBAJ7qcjtmgB/ha6bw94t8QaPrX7s6jeS6rYXrkBLmMou+Mns8QULg87ApHAOOCuP7Y1XRxqlvoV/q1x4ovWkv/7PdIwulxbligEzlQN/yEgH5g0nIyK686do3xe8BeH9S8TQPBbW9wbue1WXEfmxeZFIjt3jDB/TIFNhuNU+IIEXhu9l0LwTEDCL21QLcagBgYgyP3UQwRvAyf4cDmgDpfDOuzXInt7nw3e6BZ2UQObuS3CgDoFWKRsDAJzwOK81uNN8Ia5Y3fi/4h2SeZrN2BpSLva48mNdsIi8r5yWAL4H94VvaroNhbyv4L8EwfZLm+CSazfLI0kkFqDnEkjEs0kgLKoJyAWPAFU/HOr6f8N/Hln4l162aXQpdPTS7J4QHexkViWVY85IdduWGT8gB4xQAaDf6P4c1C2ufD3w21OztLu7is5NWuYY4JD5jhA22RjOy5I6qPX3rw/9prR9atviBf6Vos8mqW+vPHqMthbw+bNFJGvljOAWAwMjt+Ve2rCvxx0CWR9WbTNCU7oLWwuFN0JQfkkuP7m0rkRjuck8CsLwh47l8Iapa+BNO8P6XquqghH1DT71Ybe6lC873cEmcgZZSSc0AeS2kXhPxvqfh7w/4n1PxJ4bhs7R5Lu41zUCwuJFCqkcQk+RMEuc4HAK4yQR6t4c1TQvhgbmLwDqGqeKvDdtbS3OpWVn5dytm4AImE3yquQrbkyTxkCtF5fiB4l+It+x8O+GTbaVAtmpvpnljtpJVSV+QuXfb5WcAADHPJrd1yy8a+F/C19q0nizQY4bKF7mSzOjiK3YAZ8sOJNwB6ZwTzQBB4kvNdtPD9x4n8VeN4vDFvsaa0sdPiilRB1RXd1YzuRtyECjJ49a830Uaj8fYP7X0bUtL8IavZxG1u2sneS7u1IAJkwU2xHnaPn5yM16Bq2l+CPD3gk6lDb2eha3qmnO2nx3xa4mt5ZYvuRRMWIwSAVQD09K8x0i10YeD28T22qJoPivQ9I3Q2Gi2jWTJ91d0/mqTMN5AduVAz1oAl8T+BPDenfCfWPDviCx0jR/Geh2xvYb5ODqKKeJUY8sH+4ynO1iOBlagsvjR4E1n4R3Gg+ItBig1OCzaKC1hsw0LyhMI8ZH3OcE5xj3rrdc+BOr+P8AS7TUfGHjuXUtVFv/AKO9vbx/ZkDcjbtxuB4+YYzWz4JvPAWi2a+D/Fuj6FoOv2cIt54rmNNlym3HnJMQNwfryQwOQelAGD4A8C6f4F8NeBPFeg6ldf2tqctjbXXmv5kVxBdMnmRBcfLjhgRz8nOc19GV4Z4V8LaBonxN8P2Ph/U7zXtD+z3NzFZG++02+lTx7As2AdoDB2RQeQ3I7ke50AFFFFABRRRQA2QFkYKcEjANcd8GLiC5+FPhV7ViyJp8ULkrj94g2SDH++rV2dcJ8Kz/AGZHrvhiZVim0nUZ3hQE5e1nkaaJ+ev33T6xmgDu6KKKACiiigArlfEXhi8u/Edpr+g6pHpurQ27Wkvn232mC4hLbgroHQ5VskFWGMnqDXVVxWv65rs/jb/hG/DbaZbTQ6aNRmuNQheZXDSNGkaqjoRyjEsScccGgChr3w7n16axv9ZvNE1TV7ZJYt2paItxa+W7K21YfMDKVK8NvJwzA5yMWdO+H4sxfgX1uou9ETR9lvYrBHHted/MVFOAP3+Ng/u9TmuR0/WfEHh698aarGdKbTovEltFeWzRSNLI0sNnG5jk3AKF3qRlW3c521tzePbuHxtY2Nrf2OqaZc6m2myLBpF1EbZtrnBuy7Qu6soDKAp5OMYoAujwBewi/hs9bgSz1HSYtMu45rEu5McLxrJGwkXb98EqQ2cYBGc1N4s8Avrtn4egF7ZNHpUZje21CxN1a3OUVQzw+Yg3LtypJIGTwayvDPjPxJdXfhu51YaOdM1u/urBIbaCVZojGszI5dpCpz5BBXaMZBB7VV0X4geIY7LQNV12PSpdP1aC7cW9lbypLEYYnlB3tIwbcI2G0KMEjk0Abvgv4eDw1daBMNSW4GlWF3ZbEtREJPPnSXcAGIULsxtAPXtjFXPH3gWDxfe6LcSXslobGb9+qIG+12xKs9uxyMKzRxknngEY5rznVvGviDXfAfiOLU9PJsr7wzf3Jki0e8tFs3EJKxtLONkwZWOGTbyvTBBr1eCyuNR8E2VrZajPptxJaQhLqBVZ4/lXoGBH6UAct4i+F1rqfiLUNUtk8PhtQkjlnbUdDjvp0dVVD5UjOAgKovDKwzk961bvwN9o0/UrX+0dv2zXIdZ3eRnZ5csL+XjdznycbuMbunHNKPQfiFp0ZFl4x03VQAQq6npYQ+2XiYZ/75qcTfEpFUNY+EZWA5Zbu4QH8DGcUARad8P7mzubC1bWlk8O2Goyanb2P2TEwlZ3cK82/DIruzAbAeBljjmLRfh/qem3WjL/AMJFG+n6N9pFlCunhZQJUdQXkMhDFd/GFUHHI71ZmufiUrKYtM8JMv8AEDe3AJ+n7ukW8+JbK3/Eo8KIwPAOoTnI/wC/VAD/AAP4Dbw3rtzqs1zppmmthbNHpmmiwjl+fcZZUDsHl7bgF4JGPTua4UXfxJVCX0nwo5B+6l/OCfziqKLxB8QAjRzeB7Ezg8SprKeUR+Kbs/hQB39FcDBefE24jO7SPClk47yX08ufwWMVJNonj2+jVZ/FumacCBvFhpW9ge+1pJCPXkrQB3VFcJ/wg2sTSSPefEDxO24ghYBawgD04hNEnw7eXJk8aeMjJ2ddQVMf8BWML29KAO7oriW8B3Tspk8b+LmUHO0XMC59iVhBxTJPh7K5OPGvjFVyThb6P+fl5oA7miuHPw6gdw8vifxdI+zZu/teRPxwuBn8Kjb4awNMZR4p8YrIVCkjWJOwA6dOwoA7yiuDPw+vI53ltPHfi+HcMbHuYZlH0DxGnx+DfEMIHk/EDXC2Mfvra1cdMZ/1Q570AdzRXBT+ANQ1F/8AideOPE1xCMbYrWWOyAI7kxIGP50q/C7RSv77U/E80hGDI+u3YYjPfEgH6UAd5RXC/wDCq/CzoRcxarck85n1i8cj6Zl4oPws8NBgYTrcAAwBFrd4oH4ebQB3VFcKPhZ4c+XdLrzgHgNrl4QOMf8APWmN8LtICgQ6t4pgIXaCmuXRwOf7zkd/0FAHe0Vwa/DuZGzH458ZqB0BvonA/wC+oiT+NLJ8P7ySIxHx54wCE54uYAw/4EIc+tAHbzzRW8Ly3EqRRIMs7sFVR6kmuA1n4gx6wbnRvhvJBrevEbPtMZLWVlkf6yWYAqcdQi5YkYwOSLUPwt8NSGGTXIr3xDcREkS61dyXY/79sfL/ACUV2dlaW1jax21lbw21tGNqRQoERB6ADgUAeReMtOudC8KaF8PvDvh7WtctZgn9ozQYiR7feWm3TOQgklbdldw4ZuRkZ6ayXxvqNtb21rY6R4Q01IxGE3C9uY1GAAiqFiTAGOrgenatPxn4uXQ5bbTdMtH1XxHeg/ZNPiYA47yyt/yziHdj9Bk1hp4M8XavM114j8c31mzgbbLQYkgih56b3Vnf6nH07UASazPp/wAMfDsCWBifUdWvlg+2alPt865kBzNPJ3ACk4GOAFXHGMTSpvh94duJNZ8SeMNN1zX1UpLe3l4kzx/xMsMKk+Wvsozgck1Y8T2Or+ErT7XrFyPGHhCMhr231WGFrm0UcecjBVWQL1IYZ4JBNW9c0231/Wn8IaDHa6bowtFm1eeyRY5JIpCQlumB8ocBizf3cY5NAHN6v5msaL4s+IGh2r6XZT+HpbWzZComvFyZPtLKpITAGEz82GbIXgV22veF9N1X4UyaTocCrCLAS6Y6fI0cypuhlDDBDBgpz35z1NYfiDwxYfDxDrvhq3FtoRZIdZ0hAWt5bdiEaZU/hkUEE4+8oOeeaqa23izwl4P1PRHl0iLR4oZIbTxBe3nki1gYEKrx4JaRAQFxw2B34oAV7rV7DTbbxxpviLQ9Gs/EFpaXd/Z66GMCTmBBujcOpDbFVSvfZmorN9L8Q+HNW8Wz+IIfG11pUMtxb2UMey0t50QsoWAEkkkDDOWOOQRWt4J0eLxLqVprt9pLW+g6VbJZeH7K+hHmKg27rpkYEqzbUVM8hVJ431J4+ki8G+MNJ8aBfK024K6ZrUigYEbH9xM/HRHO0n0f2oAzvB134F0SwTxRrfibQr/X75FnudWuLiMOSVBCRqTmNFGAEABwOcnNTXeuWl7rNt4vu9KvbjThA+m6RaR2266vzKQ0kgjbGIyqDG7sCxxkZivNHubvxlqcPgjwz4Os49KkjW4vr2yBkluXRJSqeWMrhGjJY85Ix0qLUPE13caPpGteJbeCxuPD3iI2upPauZIUQo8fmgkbgh82M88igDmrnTfFfh/VLe98P6b4k8K+DZFZr2zs5LW9e2Y8iSOA79id2CZPovrqaRb6fr/iG90Dw54igvmvbKPUdR1i7SO8ublXOxI4lOI4wqjn5TjcOM5Ne3jnpXis3wv0eD4rajLFo2oWceqwfbLbWNKuHgaynXiVDtOAHyGGQQTkY9AC1Y/CbTPhzo2qan4L13VNIuktmlmknkjmgm8tWZfNRlxgZPI2kAnBr0/w5fvqvh7S9RljEUl3axXDRg5Cl0DEfhmuQb4e3uohLfxP4v1fWNLQjNkY4oEnAOQsxRQZBwMjIB78EivQKACiiigAooooAK4Tx2T4c8Q6T4wjVRaxD+z9VY/w2sjArJ0/5ZybT/us1d3VDxBpkOtaFqOl3OPJvbeS3fK7sB1Knjv1oAvKQyhlIIIyCO9LXFfBjV31r4ZaFcTyGW5hh+yTuRjdJCxjY/iUzXa0AFFFFABWD4i8I6N4huobrU7aY3UUbQrPbXUttIY2xujZomUshx90kj2reooAwP8AhD9CGnXtgLAC0vbmO7njErgPLGIwjZ3ZGBDHwMD5enJzVi8AeHItWj1GOzuFnjumvo0+2z+THOxJZ1h3+WpJZicKM5rqaKAMW28L6PbQ6XFDZ7Y9MuJLq0HmufLlcSBm685EsnByPm9hhLbwpottDpMMNkBFpXmfY1MjsI96sjdT82Vdh82etbdFAHKRfD7w5HBcwfZLuS3ntJLEwzahcSRxwSLteOJGkIiUgAYQLgAAYwK6e2gjtreKCBdsUSBEXOcADAHNSUUAFIzBVJYgAdSaWsbxT4Y0bxXYR2XiGwjvrWOQSrHISBuAIzwRngmgCHUPGnhfTlLah4k0a2AOP3t9EvPpy1VJviL4Khi8yTxd4eCeo1GE5+mG5q1p/grwtpqgWHhzRrfAC5iso1OPc7cmtFNG0tJRKmm2SyjGHECg8dOcUAcmPi74Cdcw+JrGdugjt90sh+iKCx/AU23+LXhKW5iiludQs45ZBElxeabc28JYnABkdAq5P94iu8CgdABxjp2rgfi5fRXukp4OtFW41nxADbxxdfIhz+8uH9FQcg92wBzQB39FYviHXtN8JaCbzWLtlhhUIm47prh8YCIOrux6AdSa5Gz8PeIfGgjvPG9xJpelOCU8P2MrIWU9BcyqQXPqi4X60AdRrPjXwvojFdX8RaRZyD/lnNdxq/8A3yTk/lWJP8W/A8WzZr0dyXUsBaW8twcDqcRo2K6DR/CXhzRCh0jQdKsnQBQ9vaRo2PqBk1tgADA4A7UAcOvxT8KurPHcanJGAGMkej3jLg+4ixUkfxK8Pyj9xHr0zdlj0G+JPT/pj712lFAHGN8RtJBZf7N8Ubx/D/wj17n/ANFVHN8RrKPaR4f8Xuhz8yaDcnH4bc/pXb0UAcRJ8TdDiTM9n4khkIyIpNAvQx9v9VjP40jfFHw2jKkw1yGZukMmh3queQOB5XPXtmu4ooA4k/E/w0jBbg6zbk5x5+iXsYOOepirZ8L+L/D/AIqE3/CPavaX7QY81In+ePOcblPK9D1Hat2vPPDpTxJ8ULvxRpWxtHstOfRxcgcXk3nK7FD/ABJHsK7u7M2MgUAeh1FdXMFpA011NHBCgy0kjBVH1Jrl/Hnja28LxwWltby6n4gvcrY6XbcyTN/eb+5GO7ngVh6H8PX1uKHVPiiYNc1gt5iWTZNlY5GNkcX3WOOrMCSR7ZIB01z468JWsipdeKdBhduQsmoQqT+bU628ceE7r/j28T6FN/1z1CJv5NWjbaHpNqCLbS7GEHqI7dFz+Qqtc+FfD10rrc6FpUyv94SWcbBvrkc0AZ158RfBdk2258WaCjYzt+3xFvyDZrM/4W94GMrRx64JSrbWaK1ndV+rKhAHvnFdbpmiaVpQA0zTLGyA4At7dI//AEECtCgDiLL4s+Arx1WHxZpKs3TzpxFn/vvFdBqaf8JB4enj0TWDam5TEV/ZlJSnI+ZeoPH8607iCK4iaK4iSWJhhkdQwI9wa4vUPhb4XnuVu9Ms5NCv1fzBdaNIbR93uq/I30ZT+poA5zQbfVPhb9obXLOTxBptzKZLjxDbIWvEyf8Al5i5ZkXJwyE4A+6OteoaTqVlrGnQX+l3UN3ZTruimhcMjj2IrhZ7zx54Sjd7u1h8YaWhLebahbe/RPeP/VyEf7JUnniue05tN1fVrzUPhVrjaZ4giBnu/D96rx285J5MsDANGxyP3iY5xnOeQD0D4nPFH8OfE7XDFIhptxlgu4j922OO9c58N9I1W38VXmrX1qY7O80PTI0lLKS8yI+8EdQRuHWvQrBriSwtnvokiu2iUzRxtuVHwNwB7gHIzU9AGZ4m0uPW/Dup6ZNu2XltJAdpwfmUjg/jXE+HvC+o63c+FNU8YWqFdO0pVNhcMH8q+yAZivKk7Rwc8ZOOua9JooAKyvFWjx+IfDOq6PMyol/ayWxdk3hC6kBtvfBOfwpnjHWv+Eb8J6xrf2f7T/Z9pLdeTv2eZsUtt3YOM464NcPN8XLUReCha6XJNc+IbhbeeEz7Tp/7wRSbztO4rIdoHGdpPGKAOw8LeFrXw9cX11DNcT3t+tv9qlkc4dooViDBei5CjP8A9YVYsfDWlWV9rF3BaL5mryJLeK5LJIyqFB2ngcAZx1qlZeOPD17rQ0q2v2e6aWSBGNvKsMkkYJdEmK+W7KAcqrEjB9DWQvxF0678TaZZ6XK0umTW11cz3T2c6IyxBSGhkKhJF5bJTd26Z5AO8orkfFfjS007wnf6hpU0U19/Yd1rVjHLE+yWOKNW3N0wMyR5BIb5uOhxT0HxtLPe68NUt2Ntp6WTILGzmuJWM8IdspGHYgMew4HX1oA7qiuTf4heGksre6a+n23F09jHF9inMxuFUs0Ri2bw+B90qCeMZyM2k8a6C2mXd+15JFBaTx2s6zW0scscsmzYhiZQ4LeYmBt/i+tAHRUUUUAFFFFABXKfEfXLrStDW00Uo3iDVH+x6dGf+ejdZCP7qLlyfb3rq64Pw4B4i+I2ua47I9ropOi2SjnEmEe4f65KJ/wA+tAHSeD9At/C/hjTdFtGZ4rOER+Y33pG6s59ySSfrWxRRQAUUUUAFFFFABRRXEXPiXxjDc3ap4CkngjkKwyR6tADKo6NtOMZ9KAO3orgZPG3iOCNmuPh3ruQcYhubWXPHtJTz491COItceBPFKEH7qQwyHp/syGgDu6K4h/iA0RYT+EvFqkdNmneZn/vljUU3xLs4SFfw34v3kZCjRpSf5UAd5RXCJ8TtJZXL6T4mi2Yzv0a4HJ7fdo/4Wn4fBXdBrahu7aTcYHJ4PyexoA7uivP5Pi74TQNum1PcoBK/wBmXGRnpxsqG7+MfhFbd0028l1DVmU/ZtLit5FuLh+iqqso6nv0AyaAN3x74uh8L2dtDbwNf67qDm303Toz89xLjv8A3Y16s54UfhWXYWth4A0bUfE/iy7SfWrza9/eKpYu/RLeBeuwH5UQcnqeSaZ4Q8P/ANh/2j4z8b3Fv/wkN1EZLmd3/dadbgZ+zxk9EXHzH+I5PpXB+H/iL4Q8TeJZ/Eniu/eFLG4aPRdPntpSkMYxi6I24aV85B/gUADnJoA9A8KeHr7VtZPivxjbxjUDxpmnt866ZCcHvx5zcFmHTAAOBXeVwcvxc8DxEB9dQMei/Zpi35bKD8XPAwZQdejy3/TCXjnv8vFAHeUVwX/C3vApzt1+JiBkhYJSfyCVL/wtbwWP+Y0uM4/49pv/AIigDuKK4n/hang3BI1kMBjJW2mIH5JUb/FjwYqBhqzuOvyWc5/9koA7qiuDk+K/hdd/z6oyqwUsumXBGT0H3O9LJ8T9HWQLHpviOfgHMWj3DAZJGPu+xoA7ukZlVSzkKoGSTwAK4W5+JumW1tLcT6L4oSCJGkkdtHnAVV5JJx0xWJaXbfGIxyWxvrTwDF98kGGTV5O6f3hAvIbpvOR0FADri4vvitePb6TdT2HgOCQpPfQttk1dlJDRxN1WAEEM4+9yF4ya2dW8Q/2Tc23hLwHpcN5qkKKjRj5LTTIsfK0zDpxyIx8zDJ461zvxA8VeIL21uPDnwm0mS6ltMQXeoW7RxQ2ijrDCzfKZQMDgELn16O8Ka63g/S00yz+Gnim1GGmmeJYblppccu8gky7t6n2HHAoA7LwX4RTQPPvtRujqviO8/wCPzVJYwryc5CIP4I16BBxx611NcGfibp8Sj7doXimzbusujzHH4qCPyNOj+LHg7zWjudTks2Dbf9LtJoQT9WUCgDuqK5ux8d+FL7b9l8R6Q7MMhTdorYzjoTmt21vLa7BNpcwzgdTE4bH5UAT0UUUAFFFFABVcWNoL83wtoBemPyjP5Y8wpkHbu64yBx7VYooAKKKKACiiigDB8e6PceIfBGvaPZPEl1f2M1tE0xIRWdCoLEAnGT2BrktV+F9sNTi1LRSsd7PrNjqV558h2BIGLMsQCnG4szYPBZicjjHpTHAJwTjsK8ePxUGs+Edb1CXS7X7La2X2poLPXil5ERIF8qdERZIH78FhwRn1AJdJ+GN5aXNpZXEUM+m2txNLHeSa5fO4DiTaVsz+5RwJMbtxH3jgbsC/pvg7xHJLoVpqY0a203SNJn0tJLWeSWWUvEkYk2NGoQYTOzc2M/eNWr74haha6hrDf2BE2i6TqkGmXN4b/EpMohw6ReXztM65BYcdMnIGnL428u1v5v7Pz9l16DRMed97zZYY/N+7xjzs7e+3qM8AHJP4F8V6hpD2OonQ4Fg8KXnh+3aC5lkMksqwhZXzENq/uuVG4j1bPF268D+JIk1l9K1C2gkvX0/5Y7qS3aWKCEJLGZVQtFuI4ZQTgds06L4sRCbWpbqxsorHSlunuIl1JTqEQgzy9qUBUPj5SHbqCcZ4Z4i8e3llomqw+JtAazuU0sapBDZas4M0QdFdTMiI0bqzpnbuB3cE80AR+Efh9rOl6xY319LZqsWvXGqvGL6e7dYpLD7MqebKu92D8ktj5eRj7ot6p4Wk1D402l8i3UelQ2kd9eqUIguLuMulvhuhZVd2IHTZFntUPjTxZq95b3S6NZLBpVlrthp82o/bmjmZ/tcAkVIlQ7kO4xnLrnLcEddPw98QX1rxlc6JHZafFHBc3Fs6vqai9TysgSNalAfLcj5WVm4IJA5wAd9RRRQAUUUUAFcD8DZRefDu21LZtk1K9vb2Q4+8ZLqVgfyx+Vd3MxSF2TG4KSMnAzXB/AJGj+DnhMOcsbIN1z1JP9aAO/ooooAKKKKACiiigAooooAKKKKACiiigAooooAzvEWs2Xh7Q73VtUkMdnaRmSRgMnHYAdyTgAeprjfCOnfa7uT4heLfsUV9LZgWio4ePTrLl8eZ0ZzkszjjsOBziawmneP/AIjazofim6hj0Dw+ISmlSTiM3kzKJDPIOCY1BCgZwTuz6Vj+CvCln4w1nWhpWo3cXwwtrpYrXSoHxb3syAGUg/e8jf8Awg7Wbd26gHS6bb3XxRv49V1FpIPA8EyvYae0e06pt5WeYNz5W7BRMDOAT2FeoKoVQqgBRwAOgoVQqhVACgYAAwBS0ABAPUUUUUAJgBsgDJ74paKKACiiigAoorzjxvrXiPXdZvPCfgI21tdW0aHU9WuuUsxKpKRxqOXlKjd6KCMnJ4AF8SXjeO9buPCOlSTDRLfKa7fQkqD0/wBDR/7zA/OR0Xjqabr9/cavdv4G8Cn7BFaxrDqepQx/u9PhK8QxdjORjHZAcnnArk/CV/4vFvdfDfR0sxPopjtbjxJB8sUcJUHhDnNyQTkcjPzH39g8NaDp/hvRoNM0mExW0WT8zFndics7seWYkkknqTQA7w5omn+HNFtNJ0e3W3sbZNkaDn3JJ6kk5JJ5JJNaVFFABSOqupV1DKexGRS0UAZN/wCGtC1By9/oumXLnjdNao5/MiuevfhT4Juwc+H7W3fn57UtAw/FCK7eigDhLf4crp4H9j+KfFFltJKo1+bhBk/3ZQwpDonj+xl3WHi7TtSiAGItU0wKc/78LL/6DXeUUAcPHrnjmxYrqnhKz1BAf9dpOpLkj/rnMEx/30aVviRptmGOu6T4h0VFIBkvNNkaIZz1ki3oBx1JxXb0UAY2heKvD/iD/kB63puoN1K21ykjD6gHIrZrnte8E+GdfdZNX0OwuZ0OUnMIWVD/ALMgww/A1iD4eSae4l8NeKvEWmOmfLgmuze249jHNuJH0YfWgDvKK4N5viNpTAta+H/ENsp58h5LG4YeytvTP/AhTG+KOl6fGh8VaXrfh1mJUtfWTNECP+mse5D+dAHf96Kp6Vqlhq9ol1pd7b3ls4yskEgdT+Iq5QA2RBJG6bmAYEZU4I+hrg7r4Y2GoW93HrGta3qUk9k2nJPcyQ+bDAzq7KrLGNxJReX3Hjryc99RQBy934J026sdbtZJ7wR6vqMWpTlXXKyx+TgL8vC/uEyDk8tz0xTvfh7ZXWrSXY1bWIbWXUodWewilj8hrmJo2DHMZfBMS5Xft6kAHBHaUUAcTc/DrT9QuC2u6lqusWyxXEMNteyRssCzqVkCuqLIcqSBudsduQCIpfhnp91p+oW2qavrOoyXdkunC5uZIvNgtwwbYhWMDkgEswZjgZPFd3RQBx2qeAbXULyR/wC19Wt7GS+i1KTT4HiED3EciSBiTGXwWRSV37e4APNTW3gqBNftNVvNY1fUDZTS3Fnb3ckbR2zyKysVYIJCNrMAGdgAenAx1dFABRRRQAUUGigBGxtO7kY54rgPgBO9z8G/CkkhJb7GEyR/dZlH8q9Arz34A2slh8J9Hspm3SWkt3bMf9y6lXp26dKAPQqKKKACiiigAooooAKKKKACiiigAoor5dvmm8NeG9fuGMjaR4l1i8gcckQX0WoSbD7CSJdv1iX1oA+oqK8u1LxdqVtYeLmOoxx3Fl4ls9PtAyRgrDJ9jJQAj5siSbk5PJweBjn7eTWND8KeLtQ0rxHerdHxN9jWOWC2eOIy38KM+BGGLFHIwWxhsgA4IAPRfEvhLwZ4o1lItf0vSb/VoohKElCmcRbsBiB82zII546iumsrS3sbSK1soIre2iXbHFEoVUHoAOBXk3jLxJ4j8I32qWdpqd1q7waLFcxtdQ24cTSXYiMnyLGuFVs4JA+Xk9TVWfXPGts0mmzX1/ZGW/06CG61GPT5LtBM8iyho7dmTZ8gKsQp+8OcZoA9porxDXJdWv7u20q/8Q3xk0rxhBZw36xWyysj2gkUsPK8vcpkKghQDxkE17XaxtDbRRSTSXDogVppAoaQgcsdoC5PU4AHoBQBJRRRQAUUV5t+0BF5/gCKH7PBc+ZqtgnkTnEcmbmMbXOD8p6Hg8djQB6TRXlOp2Wp+GdEtodG0fw94PudR1aztGl0QJcb0dyrFg9vGMgHjg9T07576x4o02PXL6TxNdXkGi+IbTSlt5rS2UXUMrW24yssYO4C5wCmwDYMg5NAHr1lfWl/HJJY3UFykcjQu0MgcK6nDKSOjAggjqDXHeIfh1a6t4mk1q01rW9HmuUWO+j0258lbzaMIX4JDAcZGDjHpXGT+J/Fl8lyLTUbow2+qaxFMNOWy+2JFBNsgKx3GFeNQGDY+cnbz1qU+L9ZkvtP1J9bvT4fk/s0Jc2NtaPGxnVNwu4WPnxM5cbfLOFDA845APUfDHh7TPDGkR6botsLe1QlyMlmdz952Y8sx7k81rV5Do3jK/uPHvh2OwvtcvNA1m6vLdX1GGySFxFFI+YPLCzYVo9uZFIIPXPWLRNe8S2Pwv8AD/jfVNfutRR1trvU7VrW3SMWrArIU2RhgV3rISW58sgAA4oA9jormfh3f6lrHhtNX1V2H9oyvdWsDRhTb2zH9yhwASdgDEnnLEdAK6agAooooAKKKKACiiigAooooAKKKKACkZQylWAKkYIPIIpaKAOL1n4aeHNQuDd2cE+jajnIvNJmNrID77flP4g1n+R8QfDLKlpLZ+MNOyAFuWWzvI1H+2B5cn1IU16JRQBw+k/E3Q7nURpmtJd+HNVP3bXWIxb+aeP9XJkpJ1H3WJ9q7jr0qlq+k6drVk9nq9ja31q/3obiJZFP4EVxb+A9R0PL+APEM+kwjkaXep9rsvoisQ8QJz9xse1AHoNFedp8QL3w+RB8RNGl0nDbf7VtM3GnvyQGLgbos8cSAdetd5p97a6jaRXWn3MN1bSjcksLh0YeoI4NAFiiiigAooNFABRRRQAUUUUAFcB8GblpdF8QwHAjtPEWpwRgdl+0u/8ANzXd3M8VrbS3FzIsUESGSSRzhVUDJJPoBXDfBGOd/AMOqXcLW8+t3Vzq5gLZES3ErSIoPcbSp/GgDvaKKKACiiigAooooAKKKKACiiigArPm0PSZ7FrGbS7GSyaUztbvboYzIX3lypGN28ls9c89a0KKAMi98M6DfamNRvtE0u51ABQLqa0jeUBSCvzkZ4IBHPBFLL4a0KW/nvpdF0x7242edcNaxmSTaysu5sZOGRGGehUHsK534qQ31nZaZ4l0SxuNQ1PQ7kS/ZLdS0lzbyDy5o1A6nDBwPWMV51rXg2/so/D663BDeWhsJ5rwTaHcavH/AGjNIJJWMUEisGO4hZCCAFIyCRkA9rktra41e4FxpCuWtRE17JHEyyxljmHrvIHUgrt+bgk5xBpvhXw9pcRi0zQdJs4jKk+y3s44x5i/dfAA+Ydj1FeK6j4Z1eWwntpbTV79G8M6TaedNaOkkrJfuzKwBYhwhBI3Egck969J8EaHHoHjbxXbabpv9n6LJFZSwJFD5cLS7ZRKy8YLYWPdjnpnrQB1F5oWkX1veW97pVhcQXjiW5jmt0dZ3AADOCMMQFUZOeFHpV22t4bS2it7WKOG3hQRxxRqFVFAwFAHAAAxgVLRQAUUUUAFU9W0vT9ZsXs9XsbW/s3ILQXUKyxsQcjKsCDg1cooAxdM8J+HdKjMemaBpNmhlScrb2ccYMifcfCgfMuTg9R2q7JpOmyR3Ecmn2bJcTLczK0KkSyrt2yMMcsNiYY8jYvoKu1wfxVj1LTodK8U6Bp8+pano8zK1nAheS4t5hskQAcnDeW//bOgDob/AMJeG9QVVv8Aw/pF0qyvOBPZRuBI5y78r95jyT1J61GNA0WfxKb6bwzZC/tkjMOqSW0Bc8EBUcEyAqAByAORgnnHkHiDwVfab/YttqyRX2nR6Uwcy6DcauP7QklZ7iURwOpjdt4KyEcYIBB6s1Pwzq1zp+pWt1Z6tfibTPDUDzTWrpJOY7wmbcFLYdVO5wGO3qT3oA9otPCvh6z1Q6nZ6DpMGolzIbuKzjSUuQQW3gZyQzDOejH1pNZ8NafqfhWfw6qtYaXLELcxWIWLbFkZjUAYVSAVOB0JxjrWF4E0SPQPFPiy007Tv7P0Z5LWW2iii8uAsYsSFABtzkDOO/Xmu3oAbHGkUaRxIqRoAqqowFA6ACnUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2REljaORVeNgVZWGQQeoIrz+9+GNpYaidU8DX03hnUS26SO3G+zuMnJEluTt59V2kV6FRQB5uPHmr+GrtoPiLoy2dkcmPWtM8ye0IyeJRjfCcDOTlfevQLC9tdRtIrqwuYbq1lG5JYXDow9QRwanZQylWAKkYIIyCK8/1f4cizupdT+H+oN4Z1ZzveKFN1ldH0lg+7z03rhhk0Aegd+2aWuC0/x7Jpd5BpfxAsl0PUZDsivFbfYXbcD93Kfuk/3HwfrXegggEEEHkEUAFFFFABRUdxPFbQPNcSpFCg3O7sFVR6knpXm+q+Kb/xveTaF8PLoR2i/Jf+IkG+K3HeODtJKR3BwvXrigCz45n/AOEx1f8A4QbTJ2FsyiXXriFv9TbHOLfI6SSnjHUIGPcV39rBFa20VvbRpFBEgjjjQYVVAwAB6AVl+FPDemeFdITTtGgMUAYyO7sXkmkJyzux5ZiepP8AKtigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooArajYWmp2clpqNrBd2snDwzxh0b6g8Vwn/CvdQ0Ms/gTxPfaVEAdunXg+2Wg9lVjvQf7rceleiUUAcGmt+P7RnjvfCGnX+04Wax1QRh+euyRcj6ZNNOsfEPUAqWfhbSNJ3ZzPf6mZ9vv5caDP8A30K76igDz6P4ez62Ul+IGtT66AQx06NPIsQw6ZiHL4/2yfpXd2ltBZW0dvZwRW9vGNqRRIEVR6ADgVNRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The veins that drain the medullary sinuses of the long bones are supported by the bony matrix. They do not collapse in shock or hypovolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barkin RM (Ed). Pediatric emergency medicine: Concepts and clinical practice, 2nd ed, Mosby, St. Louis, 1997. p.151. Copyright &copy; 1997 Mosby.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25600=[""].join("\n");
var outline_f25_0_25600=null;
var title_f25_0_25601="RA MCP osteopenia";
var content_f25_0_25601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of osteopenia of metacarpophalangeal joints in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 228px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADkAlYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3r4neP9L+HOg2+ra3b31xbz3S2irZojOHZXYE7mUYwh7+leeL+0v4TYZGi+JCP+uNv/8AH6pftq/8ks0r/sNRf+iJ6+V7CQPbqw7igD7Bsv2hPD97HI9t4f8AErrH94+XajH5z1Ivx+0JxlfD3iQ/8Atf/j9fMfhGcp9sQHGVVsfpWvHIwJGME84AoA+gLr9oXw9axeZPoHiRUBxny7U4P4T1Sk/aa8JRqWfRfEoA6/uLc/8AtavB5ilxE6SYMTjn5c5FclfW7W8jRSYOOhHRh2NAH00P2qvBB6aV4k/8B4P/AI9Sn9qnwT/0CvEn/gPB/wDHq+Mb2E2906ds5H0pgOaAPtH/AIap8E/9ArxJ/wCA8H/x6lj/AGp/BMjhU0rxIWP/AE7wD/2tXxYelPtTtuUPTmgD7cT9pXwq4yuieJCP+uNt/wDH60k+POjPbxTr4b8SmKUZRtlrz/5Hr5DtT8gPqK9Q0FvN0KwVWAURls+pJ5oA9qHx80QuU/4RzxLuHYpaj/2vU/8AwvLStjP/AMI14l2qMn5bTp/4EV4UURLkK4IUnAXHQbvWrl2fLgZhlsDjPU9uaAPVn/aP8MIxVtC8Sgj/AKZW3/x+qEv7U3gqGRo5NJ8Sq6nBH2eD/wCPV82Xjh7l8Z61xWvLs1SbjGcH9KAPsUftVeCCcf2V4k/8B4P/AI9V8ftKeFTjGieJOf8Apjbf/H6+HV+8PrXcQsNkf0FAH1xp/wAftC1AMbPw74kkCnB+S1H856nl+OWkxECTw14kBP8As2n/AMkV89+BBi1Y4G5mJx61v3e1pG6EZyPegD2n/hdum+Xv/wCEZ8SbcZziz/8AkisqX9o7wzFK8cmheJA6HaR5VscH/v8A15nuxp5JIwuQBXlN25a8uG9ZGOfxoA+l7v8Aae8H2gX7Ro/iRN3T9xbn+U1V/wDhqrwR/wBArxJ/4Dwf/Hq+SPFDZkiH14rCoA+2rb9qHwddEiDR/ErEdf3FuP5zVdg/aN8M3Eixw6D4lZm6Dyrbn/yPXx34diC2rPj5nP6V3Xg6FTeCZwCI+g9TigD6Wn+PWiwf63w54lX/AIBa/wDx+ov+Gg9Azj/hH/Emf+udr/8AH68Z1JBIMsC3JJ/n/wDWqhZ2TNls5IPQ/XrQB7rdftBaBaxLJP4e8SojdD5dqc/lPVU/tJeFgMnQ/EmP+uVt/wDH68R8cxrHYaevBVgcfXvXDzDqOeOBQB9Nz/tReDIGCy6R4kUn/phbn/2tTR+1P4KPTSfEn/gPB/8AHq+O9aIN2o9BVZOn+FAH2b/w1L4L/wCgT4k/8B4P/j1H/DUvgv8A6BPiT/vxB/8AHq+Nf1pe9AH2V/w1J4L/AOgT4k/78Qf/AB6j/hqTwZ/0CPEn/fiD/wCPV8b0q9ePpQB9kf8ADUfgz/oEeJP+/EH/AMeo/wCGo/Bn/QI8Sf8Afi3/APj1fHP50o/zgUAfYh/ak8GAEnSPEuAMn/R4P/j1emfFD4gaV8ONAt9X1y3vp7ae6W0VbNEZw7I7AkMyjGEPf0r87Zf9U/8Aun+VfYX7av8AySzSv+w1F/6InoAng/ag8HTsixaP4kYucD9xbjn8Zqvy/tE+G4m2yaD4kB/652p/9r18U6exjjRx1Vs5/Gu11W5XfEyHO6MN69RQB9Nt+0j4WXrofiQf9srb/wCP1Xm/af8AB8JxJo/iQc4/1Fuf/a1fLEkpI5B9KpXUYmRiw68H6+tAH1af2qfBI66V4l/8B4P/AI9Sf8NV+B/+gV4k/wDAeD/49XxtcxFSwYYIqnQB9qj9qrwQf+YV4k/8B4P/AI9Uq/tReDW+7pHiU/8AbCD/AOPV8TLwRWlbHlcUAfa9n+0V4bvE322g+JXX18q2H856lf8AaC0BBlvD3iUD/rna/wDx+vmjwEvmoY37NkfSuqvrQB3UA496APb0+P8AoTjK+HvEhH+5a/8Ax+qFz+0v4Utn2z6J4lRv+uNuf/a9ePm08u2R+/Q+teceKUK3XzDB9KAPp5v2pPBi9dI8S/8AgPB/8eqM/tVeCP8AoFeJP/AeD/49Xx9MOTms6T75oA+1E/ao8EucLpPiQn/r3g/+PVf079pDwvqU/k2Wh+JJJMZx5VsvH4z18QWhxKK734enHiKAdcqwoA+uX+NumoAW8MeJRnkcWn/yRUQ+OmkZx/wjfiTP+7af/JFeV3xxCuccisqHi6XjqeaAPXb/APaI8O2Cb7vQPEka+vl2x/lPWaf2o/Bi9dI8Sf8AfiD/AOPV4D4+G20+rYrzi4wAaAPsA/tVeCAcHSvEmf8Ar3g/+PUf8NV+B/8AoFeJP/AeD/49XxbIcuaZQB9rD9qrwQTgaV4l/wDAeD/49T4/2pPBkhAXSPEhP/XCD/49XxXD1PatCxQmZfrk4oA+04/2jvDMilk0LxKVHfyrYf8AtemL+0j4XZsLofiUn2itv/j9fOtvDssYyFySvpUdrYffGOeen8qAPo0/tJ+FgQDofiX/AL823/x+qkn7UvguNiH0nxICOv8Ao8H/AMer5o1hfswzjBBNcTctuYnPUk0AfZJ/aq8Ef9ArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6vis9aSgD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD9RPD2qwa9oGmavZrKltqFrFdxLKAHVJEDAMASM4IzgmisX4T/8ks8G/wDYFsv/AEQlFAHlX7an/JLNK/7DMX/oievkrQpA1uUJ5U4r62/bT/5JbpX/AGGYv/RE9fHmhyFLopzhhQB3Php8XkoPRoyD+dbx3lsqjM3+yeK5nR7mO3ug0v8AqnG1j6e9dtbahYuuLSB7gIOWMgQGgCna2M85KBSp7/7I96yfEcEMVmirLHJKsgACnOBjnmtq/ujcYjMflQdTFGeW/wB5v6VnajpZuLT7QEEbDhFUdqAPN9diztkAwRwayVNdVqNvvilRhz39jXKMCjlT1BoAUmkQ4dT6Glpp60AdlavmBG9q9E8A3Hm2LQtz5blV+nWvM9Offapjk4zXd+ApAjOTkAtk/WgDprqJjcZKnBwPyqTU2L6a8nBYxn+tS3RHmtnJ7kk1FO26xlHcZ6CgDyyPkLnjIrmPEi4vwfVRXU3SlLiRSMYc8VzHiYYvE/3KAMhfvD612sDfuUPfbXFL94V19m2bcc9BzQB6f4QiC2MbAH7n/wBetENk7h2Hc1Q0JjHocbKcHygBx39qnVykak9wRQBoPzpZIPUk15PcArcS+zt/OvVI2H9kknPAJ+leTSSbndj/ABEt+tAHOeJGzcxj0WsitHXX3XY/3azlGWAoA67So/LsIR04BrsfBLsdTeIfcKhj+eK5W2Gy3jHQhRXYeBI/3ksp7nGfQUAdLrHKgDqcjPqPWptLQJHuIA3KCc+tNugJGJI79R2HpU24Jbsy4AAoA47xpeie8ghXpApJ+p//AFVzTn92ferOoSmW9uZWbLM559qq3BxH0oA5HVX3X7ewAqJfekun33krDPLGhelADx0p3Yc00UoOKAHD/IpQePak/l6Uo69/xoAcOaPekHWlH+c0AEv+pk/3TX2F+2p/yS3Sv+wzF/6Inr48lx5T/wC6a+w/21P+SWaV/wBhqL/0RPQB8eWX+oUdeTXSbi6xc9gBXM2TAIAexrqNKmt2CCdgu3g/40ANMR9elH2eQruUED1xW9HHpoj37pnYD5cIev8AnvVJ2DBj5rY6BYuBj69TQBzOsQhQmFwehrCmXa9dVqNmGUupfj+8c5rnrpBgmgCmK0bYkYxWbV+1OQMUAek/DsjzHJ7EV6BexbpFIHUAn2rzb4cMTfzRjklQRXq8gDFe5wKAMiRco6HjC5+tea+MEHnbsYOea9QKDzGHqCK4HxnAPLZxjO6gDgJlG081lzDDmtm5TapGMe1ZFyMPQAkHDZrv/h8P+Kitj/st/KuAgHzV6J8OU3eI7fP8KEn8qAPXblC49goJNZznE67ecGr2q3ZgxGoAIGCQOSaybeXzLmMH+960Acd8Q/ljK8n5684uDwc16V8TBtZBjgtXmd2cGgDOf75ptK33jRQBNAOCa19Ij8y8jUdTxWXbj93+NdJ4Sg83VFPZFzQB6NZwobZN3UAYoSEZbHQA1YA2qoGM45pduI3PUgdaAOD8YSBTtzyQQBXEy8gmup8ZSbrxVB6Zrl5jgdKAKhpKU9a6PRvDkc2gXuuazdNYaaivFaEJukvLnHEcakj5VyC7dFGB1IFAHN0UUUAFFFFAH6VfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFAHlf7af/JLdK/7DMX/oievi+3k8q4R/Q819oftp/wDJLtK/7DUX/oievix+tAHWwS/KD2/pXX+DUF1Jcw8eZs8xAfbrXAaTKZIVyeRxXYeDr5bDXrSSZiIySjH0BGKAOnnsym3nBP3fY1eVSbVo2BAI79q0ryFZk3KcI3Bx+lUbNN1q8Z4ccfWgDzPVVT7ZKq/w8HjvXIarF5dxuHRq7bXozFrVwvQEg/pXM63HlVNAGGDSGiigDoNJfNooz7V3vgMiR7hT1DD8a850l8Q49Ca7nwBP/wATWSPP30z+RoA726kLXBBPsaWFg0UqZyc1TmnYSlsff6Z+tJayMZ1OCA2QaAOC1oBdWuR0w/8ASuQ8RnN4uOm3Fdd4h+XWrsHOQ+T+VcpriGWRGXkjIoAyE5cfWurswVgOehXiuf0u0+03qI4+QfM30rqCNwbaMDGFFAHpOnsE0K33cZQcj6VGZOSqE4x17067HlafZwLwVQEgfTFUldkYkcZyKANueQLoN5jqqsf0ryWV8Kq+3NenOzPoGpgHOIif0NeYBdypjHQUAc9q5zeH2AqrAu6ZFHciresRPHfurjkgEY707S4M3KFvXNAHUrwOccCu78FxiLSo5WxhgWOa4CViEOM89vWvRrFBa6baxHkog/lQBeMzbH54zu/Gpr87dNYjoEyfyrOWT5So6NUniGUReGZW6Ept/EnFAHnituweeec1X1GQLEzZ6CpxwBisrX5dlqw7nigDmlO52JxzzUw9qijFSD9KAHd6cOlN5pRQA/rRjNNHr1pxPrQA4Hn3FLxTaVf1oAJf9U/+6f5V9h/tq/8AJLNK/wCwzF/6Inr48l4if/dP8q+w/wBtX/klmlf9hqL/ANET0AfGdoxDgeta9oQZEBzyaxImw6mtq0bDoffvQB1mnsfJxy20dDTJsIORyTUmnrtQkE7GIGPar8tt50RVV+Y9QB0HtQBiXSfulyB06etcrdrktxXXapE8ZQngHmuXuh85HbmgDFcYarVoelQzjDGn2x4/GgDuvh3P5fiGBc8SKV+te03IAzgYGMivAvCknla3YuP+egFfQF4qtFG5bnb09aAM75dx3kCuB8aKFimHoQTXdMyl15Azxk1xnjpNqS46EUAecXIyD3rJu1yQRmtaYcYqrs3MAaAILG2csHcYXr9a9J+FduZPEmcfciJ/WuNjjBYDqBxivR/hCgXV7+bH+qgzz9aANzxHcE6pMnGI+Kp2M2LlXJ4yCPwqpq85+1SsTuLsSfrTLeQnaSe3FAFX4oxfu4pBypbIx715bdqTn+leu+PYxc+HraZB90fNjsR1FeWXKDJ4oAw26mkqxcryDjBqDHNAFy3GI15967X4fwBrmeQjpha5CNMbR7Yr0PwHB5WmvMeN7E/0oA6iJlLliOBTnO6F+OPX0quCAuOlI8gFtMeu0CgDzHxRKJNVlwTheKwJjxzmtHUpTNdzyHnc5NaXh7Qbae0l1vxBJJbeH7d9hMeBLeSgZ8iHP8WMbm5CA5OSVVgBPDHh23bTJPEXiQyQ+H4JPLREO2W/mHPkxZ/Dc/IUepIByvE2v3XiC/W4uVjhgiQQ21rCNsVtEOkaDsBknPUkkkkkmn+KPEFx4gvY5JI47azt08m0sociK2iByEUH8yx5Ykkkk1i0AFFFFABRRRQB+lXwn/5JZ4N/7Atl/wCiEoo+E/8AySzwb/2BbL/0QlFAHlf7af8AyS7Sv+w1F/6Inr4sbpX2n+2n/wAkt0r/ALDUX/oievi05oAvaLLsuCh6NXSkgL6VxsDmKZHHY118Tb4wexFAHqvhC++36TH5h/eKu1sHuKmP7qRmUexFcl8P7kx3M0QOeQ2PWupvpQtxJt4Tdzx0oA5Hx3Z7Jo7uP7oXa3HbtXEaou+3Lf3ea9W1ONdQ0+WF+W2n9e9eXMCVkhkzuGVP4UAcu4wxptTzwlJGX0OKgwaAL+mPhWHvXa+BONejGeXjYVyGjWplR5GOEB6Dua7HwSg/4SS1AGBsb+VAHY3so+0EHkDK80y3k2zRlSRtIFR3B2zvnHPIB+tRg4Zip9xQBzXi+Mx+Ibn0YKwrmb1QxwRXX+N1zqNrOvImh6+pBrlZ0LFfU8UAJpcYVnbA9K1rGJri8tYf+ekqj9ao2qbUx19a6LwlCH1qKZx8lqjSn+QoA63VCWuJAvAX5BWYWDYB9jVuRvNyz5BYkkmqoGXUjGMjn1oA0rP57HUYCSxa3fHvXmseQif7tej6U/8Apar/AAuCpJ9DxXnssRileNhzG7L+RoAytXRZJlY9QMZx2o02LEm48YqzcJub2HtTrZdq80AX9NgN3qdrCBndIC3sBzXd3cp88KBwOPpXP+DLba1zfOOEAhjz3J61qyMXYkkdCcUAWrV+FByQDx7io/F0w/4RyAc5eQAj1wabEwIU4Az0FV/GGRomnDPBkP5gUAcpu4Jrm/EMmZUjB9635MhTn865TVX33zd8cUAQRipKYvTHUU78hQAo/wAinCminDrx1oAUU4HjNNHHalBOfSgBwxSj3pO1KOvegBJf9U+PQ19iftq/8ks0r/sNRf8AoievjuX/AFT/AO6eK+xP21f+SWaV/wBhqL/0RPQB8VjqK2bY8LzWOBzWta5AX3oA9B8K24vLZc7sjJrf8jyplQL90/rWP8NJA0k8Uh4U5H411l1Htkxjgdu9AHF+L4gERwMAHFcNOOTmvTfE8IezLbcjFec3EfzkGgDCuVyc0Wyk1PdJjcajtOKANjR2Md5btj7si/zr6F1aYQafbnjLLjrXz3pi7pov99f517t4rby7PT13Zbyyf0FAFF3yyA9+CRWF4yiWSz3RksORmr0UvyAs3Q5NR36C5sZk9t4+lAHlkidRjpUSwkHkc1qXNuY5GU9QaiaPDZoAbAnQ+nGK9I+HsYsvD+q30nBmdYEPTgcmuBtYmdgqfeY4H1rvvOWLTLext/8AUQDBI/iY9T+dAFHUW8x9wAOOPpVdJABjoPepbpc8HPHT35qs3A54zjtQBsIwvdJmsH++6tsb3xXmE8eDhxgg4NdtbTtFMjKT8nTNY/iazVbtriIDy5zv47N3FAHH3MOc4qCG2/eDPQVqvHyeKYIwCDQAyOPv1NerafbCx0O1jHDFQa4Tw5YG/wBVgjx8ine59FFdpqN0HmZVPyDhe3FADPOZpcEjbT7+aODSZmdgNwKqCerYJ/pVKMgOST/9avUfg34Y0vxFaeI9Q8TPHBodvatZedM6xqksi5Zwx4VkTbgn/npQB4JoGiQ3kE2r63NJaaBavtmlQDzLiTqIIQeshHU9EHzHsDl+MfEU3iK/icwRWdjbR+RZWMH+rtogSQo7kkklmPLEkmuj+LUtp/wkv2LRtXstR0SyQxWKWUbpDbpn7vzD5nP3mcFtxOc9h5/J96gBlFFFABRRRQAUUUUAfpV8J/8Aklng3/sC2X/ohKKPhP8A8ks8G/8AYFsv/RCUUAeVftqf8kt0r/sMxf8Aoievi3mvtP8AbU/5JbpX/YZi/wDRE9fFhNADT1rp9Jm820T1HFcwa2NBlwHQ/UUAdp4SnEOtIDwJBiuwv23Xcg6MSR1/nXnFpN5OoW0oJ+VxXe6nJieRVzubBHuaAHW9wQVzyM4964jxTa/ZNYd1wIp/nX6966pWbIYnBzu/GqutWZ1HTpI48G5hJli/2vUflQB53qMO5w69+tUUhJPIrakUMn19qgEPsOaALGnjy7MDGMsT1rqPA6Aa8JG6RW7t7elc3EuEAGOK6rwkhjW/k6FlWEH9TigDYuDg4I5aq8LfKyg/MOvNPuXUuVB4xxk/zqqCBOS2FYAkgfzoAb4oiE+kRTjlraTBx/db/wCvXJhM/e6g/nXZhVngnt34jnQpn0Pb9a49kaOXY4IZTtI9xQA5I8DNdT4fT7PYPIQQ0/J/3R0H9a5naTG3PGOPeu/mt44Ut4ygyI1bI6HigCB5VKjjcxOcmq+8JIu07h19q14tNd0JEMjD0VO9Q3Fj5LFXUrjGQy4oApWr4kwuQcjHsa5zxBEI9Xuto+V28zp6jmust4UEwyBkYPBzwayPGFusepRcctH0xz1oA5ZkyT+vNOSMs+I1yxOAB1zUzJtBGeT2ra8MWBnmmmA/1CggHpuP/wBagDXs7cWtpBbrgLGuW92PWmnqQDx09cipHSUEblAA6ZqsRJknb3yCD3oAkhfJHU98fypvinEmgREY/cz/AKEdaIQy8FcZI780mpfvtKu0Oc43jPsc0AcfMcRnNcheHN5Ifeutm5Q/SuQuci6kz/eNACr+VOHtTB79Kd7UAKPrTgaaCDThQAop1NHelHHOOtAD+tFJTh7daAEk/wBU/spr7E/bV/5JZpX/AGGYv/RE9fHch/dPn0NfYn7an/JLNK/7DMX/AKInoA+NtR0+80u+ez1K2mtbqMjfFKhVhkAjg+oII9jVy14K1t6P4hstU0yDQ/GBlezhXZY6lGu+fT/Rcf8ALSHPWPORnKkchoNZ0K80C8jhvBHJFKnm291A2+G5jPR436MO3qDkEAgigDpPh1P5euFO0kf8q9F1RQsrkdWA715Z4NlEPiGxY/xNt/OvVtcUCReOcDrQBharD5lmePzrzPU1CXBA/GvU7j543Ru6+lea+IIfKuW470Ac7dxFkYqffFRWduzMBWgkZdvX1q3BEF4xigCzpFpuurdAMs0igY+tex+MmCXMMWRmOMA/lXm/g6FZNdtC+fLjbzGI7ACuq1m9e8vZZdxIagCosuQO3HSrFu5KDOSV4wfSshiyscHJ6Vaim2bCMkjr60AYuv2fk3xwDscblNZXlHPTOK7TVIPt1iqoP3sfzL/tD0rk9jLIeCD6UAW9EhLXI45A4+vSukgiUnaQaw7DMMyOOADzXb6b5LqsqxMzHnaBgH8e1AGd9idwSI3I9hVK4tCAQ6sDxgEc12r3s+GCRWytnj95yRVK8vDICl5BtQn74+YCgDiVhEbbTn3wP0p+u2yHR5JCuFDLt9jWveWG2VWhG5GPDDkH6Vm+KLqP7FDp8ABkVt87A8A9l/qaAOFlT5jjFMSLLBVGST2q5NH85OK0tCtPMneUrkIuf6UAX9MQaVYmNADdT8ysD90dkH9aY7lm5GSeOtTrAzc4zjpQbf6k4oAqSSYBA/HiktmLwPazSyyQHe6RyOWWN2HVVPCnoMj0p80RGPlODVXJjYEdOvWgDibhSrEN1HFZsn3jW/rcWy5YjgP8wrBl++aAGUUUUAFFFFABUipRGuTVgLge9AH6PfCf/klng3/sC2X/AKISij4T/wDJLPBv/YFsv/RCUUAeVftq/wDJLNK/7DUX/oieviyvtT9tT/klulf9hqL/ANET18V0ABqzpsnl3A96q1LaDNzGOetAHRrlhkc4Iwfxr0W7O+Y9WJUYP4CuBtwOAAMDFd0WDKvy5Y/w0AQb1DMUO4N1z0NIlxwrJhWHOR2xQbSVs8bVIxn0pPs4RiOSQR1OKAOf8RWW2X7VEuElPzAdA3r+NZKJgDPNegWtpDcSC2mXdG4wWJ4ANcZJBtkeLkhGKg9zg4oAiRRkEY68iuy0O0I0hCSQrZcgdeeK5GNfnwc8frXVaFq0SwiC7cRhF2huxHr9aAL5skkYsqj6n6fzqGawePLEAkf3ee1X4/EOmRDyrKG4upF5ykff6moJ/Ec3JOlzKo5560AVbaFRKnyYU8cGsPxPb+Rrlwv+6x4x1Fb/APbtlI3miNhIvWMrtzXP6jPLqF9NdTn55W3EDsOgH4CgCrHH+7xjqORXU6Z4i8m1tYZ7WSe4gXYjIeSO3Fc+qEAcYrpPClqPLmuGTLucIfQDrQBor4k1lhlbNgh7SYp3/CTkAx6lBJbo3XI3L+VOkIUfLg8VEFEi7XQOrdR2NADXn01W+0LcIsSndhGz+Q6/hXM6xftqmoPOybF+7Gn91ff3p2qWUdpqLpGML1weSD6VDsAbOaAKTxlpccc11ng4F7S+tUA3s6t7kY7VzmOp/wA4qxZ2j3dzFboSrSHGfQUAd5/Z+mx4F1dlZAfQHH5USaWkqF7KaGcHsP6VjLo1pHHtZZZD/eaU5J/pUPkzae3mafKzbeTE7Zz9D/SgC5Jb7JVjdTuAJORTJY4hbXjyAeWkTbiPpUM/iKzu0DXUc1vcAYdQu4HHof6GsjVNXE9rNb28TIk2A7yHkgHsBQBy0w+TnPFcle/8fkn1rsLgda5C/GL2X60AMWnU0detKKAHD/OaUUn8qWgBRTh7Gm04dsdKAHD3p3rTQc9DS9+9ACSf6puf4TX2N+2p/wAkt0r/ALDMX/oievjmU/un7cGvsb9tT/klulf9hmL/ANET0AfFg6V1/hTxALWxOlatbnUNBmfzHtd+14ZCMebA5zskA9irDhgeMcieKu6cSR+NAHczaSdIutP1KxuVv9FmnAt71F2/MOTFKv8AyzlA6qeo5UsOa9M16VWuIU3KSI1YgdRnvXlXg+/ubTU1t4JLL7Pe4guYdQfbazJ1xKSRtA6hgQyn7pBr6D8feBLHTPh7p3iHQbuPUDaPi9uIp1nEkDkBSJFA3iI7RuwMqXY80AedTsodcflXH+JrYuS6DjP5Gt27uffGTjNVZgJgBJjkYB/xoA42CPC8jk98VKkftV67tDbzlWUjvTVTOBQBs+G4zDHJIPvNx+A7VrpGxHK4J56VX0SMG22rgsCRj610dhYNIwaVikY65PegDn5LZjIOzdfqaDbvtYkDPUe1dc9pYJHzICeowpPFVjY2siFYZC3pjg/kaAMa1jIUK2Dzx/jWNrdp5d2HAGG5P4cV1cNmUkw5woBzngAd8+lY2rSLdXTGP/Vqu1Bjr7/jQBQtLcN875KA8jP3vaugtmLov/PNflwBWbbRHysAegrY02ItayjBJyuMUAT7AyjA24/TmppLUpavMFZsfeC+n+e1MjXawDD3zWzp8avpV0uQrOCnJyPWgDh9SM8ETG2nlWBuHjDcA1z0sWFz3rr5Y/Nt5I2GTg4zXMzKNvAHpQBjSxnPTFbWgYhnKNt2yJjJ6ZqmY8uAcYrQs7XzpQCMAmgDo4be2RiTbtK3UY6UTvb5IktdgPGSOKkkzagR2rFIyuflOB0qH7VLGfmAkAxw3SgClfWKeW0lsSVPORzWDPBJuO4c+g7V0N7eSWQE9tbRGJuuWPB7isDUtW8zmCEI5/jY5I+lAHK+IlzPj0FctOMSGuovsuGZ+WPJNc7fIA2RQBUooooAKcoyabU8K8igCzawmWRUXqa1TBDDHjALjrVK0BR1ZRW0LYSQl1bJH3hmgD74+E//ACSzwb/2BbL/ANEJRR8J/wDklng3/sC2X/ohKKAPKv21P+SWaV/2GYv/AERPXxZX2n+2r/ySzSv+w1F/6Inr4soASrFh/wAfSVXqexH+lJ7UAdXaEBlJXOCD+teixRqjY2Ddw2a87tgCfUYrfsdUuoAisRMijCq+eB6ZHagDt4LI+Q81yQsfcE8f/XqhJfwLIVtrQy+6Lmsy1FxqjLd37mUdIYRxGgHfb3/GtONHj4I+U8UAZupaysBAS0uEmxwZFCqTXKbCRu5Ldc1397ai40yYsAy8HBH51yd3p728fmbgyduORQBl7f3m4fnVu1g+0XMMJON7AZFQ4+YkjvWlosbPq1ps52yBjkcYoA6KGJLeARxRpGg/hA6n3PU0Rj5+4I9K0tUjhS8kCZYFiAo7HFUYyNxCgDnAyP50AZ+u2KSWQulQLIH2ggY3jHOawtnHrXoWoQLdeFvMTlraYN+BGDXAuNsjL3U4oAaqFiFUFieAK77RbL7Pocak5cd8eucmuJsCTfQrjknA/Ku/nkMNrDDs+WMdB3JHJNAFCVUViC3y4JB9qs2EKfaYMjjOAc96oySRSMD33EfN0+v/ANaprE5uI3BUENgg55/CgDG8XW/ka3NGQMhsHt15rFYfMO9dj8QlWXUYp1HLovU88d65RVBIJ7UAQbcyc/lXUeDtPEhnvJfliVTg92rmXBDMRwSK9EspI7TS0UYDPEqqCPlC0AZsm4lzjAzT7K2Djcyg7j8pPaoZpWALfKME49D70lrdtGyLG2N3YDO33oAw/FltHBfLIgC7wQw6cjvWDN0zwDXa+NbMNp1tqEXIaUpLnnBxxXHSJhfTigDIucknjmuPumLXUhPXca7W7Xr15rkNUj8u9YY6jNAECmnDpnpTRyKdQAop3FJ0/ClHp+VAC9etOHvTR1704UAO5z9KCwA6celMLcU+zt5b2bZF93+JvSgCJ2LB1RSeMnA6Cvsv9tP/AJJbpX/YZi/9ET18ttp0drpN1tXBETkk9ScGvqT9tP8A5JbpX/Yai/8ARE9AHxYelXtO+6fTNUGNaGnjKfjQBtWaebKiDkswA/OvQtXuRBcOunyzWxNuIJmt3MTSrjDKxUjcDkjByMGuN8OxD7YkrcLF8/49q3lVpH3kZbr9aAGwkoip8x28Zbkn61KpIJ6j0OKeLZv4eKlELHPp6HjFABPAt3D5ZCiVR8pPf2NYghaO4KsvTtXSwxKjD5hmo9WtlWeFgCGYc8dfegCrYF0lQxgk54x3rtrG5AAWVPNfG4gnCg/hXJWabZVIHTmunt1LQh1xvU4bHp60AaTXjcARRJwQAFpPI+0h1YBHxwVXaePeqm9tw5O0nofStPRoxK7qxxuAxk9DQBzepi7SMJNNJJC3QMf0P+FZIj3OF9a7XW7Mxz3Fs/CH50zXIEbJVJ7HmgC5bw4APbFaduSlpMBlN+3PvzVVQyJj+HrnNWYB5iXDHhhg4PPFAESyeWSed2K3NAnha6QXLAoWH0/GubmfDhiuRngZrR0OUm9BK8LyT6igCHX4haa5dQg/KjnGPQ81yN8gjuZUHZuK6nxRqGNTOUVpdoLD3Irl7qT7RcGTABPYUAVVj59z2rotFsi1zbRkfO7Y/GsezA+0jPJ5x9a6bTphbyCQLl16fX1oAZet/pDgc7TjkYzUOEZMk/N6daXUJWabKgDuR6GqkDsGYsMDqaAL0tu/9nzFVBj2g/N0x/jXDarCIZSFzsbkV6TaFb+z+yZCy5OzPAY46GuE8QWzQBY5RiRGYEUAcrccg1zuoj+ddDeFVB9a6X4V694G8P6iL/xlpuoX98j5g2RpJbw+jFSwLN9QQOMDPNc2LxEsPSdSEHNrot2OKu7HmV5aXNlKIryCWCQosgSRSp2sMqcHsQQR7GpdM0vUNVn8nS7G7vZv+edtC0jfkoNep/F3x3o1/wCK31jwlFpN219GrTTXentJcROoC4Im3R9AMFB2555Pnuo+LPEGqxeReaxevbAcW6ylIh9I1wo/AVz4XEYnEUY1HT5G1qne6fXS36q5UlFO1y4PA+q2/Ory6dpK91vr2OOQf9sgTJ/47VmHSvDdsQt1r11fyD+DTbEhD/20mKED/gBrk40+atbTYt8wUnGe/pW/sasvjqfckvz5n+IrrsdXaXGkRACx0FH/AOmmpXkk5Hvti8pfwIb8aiKhLiW5aKPEh3PHBGI0AwB8qjgdM0kW3aFQdOMHvV2xwFyRkfr+FaU6EKbur3823+bYm7n238J/+SWeDf8AsC2X/ohKKPhP/wAks8G/9gWy/wDRCUVsI8q/bV/5JZpX/YZi/wDRE9fFlfaf7av/ACSzSv8AsNRf+iJ6+LKAEqzp+PtS1Wqey/4+UoA6y0+6PWtCPkdzWdZMCME4q+jemc46UAegeHYoE0SGa4woYnZ7gU+6uIgpC4wyngdR6Gks5Ek0LT40U4ijKMAOM9f61lXu1JOV2gcn/CgDY0qZGYLKAUPsTyeoNYPiW2aC4kt1YmJMNH9DVnTZmmmCqGB4AGevpVfxK4h1aW3JLSxgKw9OOlAHPbQGPatbw2yrdSFuxVj9Kz5I+MjPSrHh841qBW+5LmI/iOP1oA7C8cSSSEgrtO4Y64H/AOuspJTvK4HrgnIPrWrcwNLZxnO2VDtORndj1/xrNFtJuyxxnmgDVjvDBpN4gX9yyMeP0/HNcQ/MrngjNdn4pT+y/Ddlb5zd6gfNbj7ka9vxNcjGnyDp6/SgCTRYzJrlgozjzcfhXe6vGcBo14X7wB9Ohrj/AArF5niS05+7ub6cV2d8xVnyc8dh1/8ArUAYGyVpGAiyB1Hp+PrWnpVnNPcLDHGDJJ6fzqvFGWLYzjOcCtia8/sfw3eXycTyr5UJ7gnigDlfF11HPq00UDh44QIg46Hb1P55rHQdqijG0Yxz69fxqVBk5NAEU+QhOCMDNdvIp/sTSZyCVltVb8RkYrip+FNegxKR4K0TIwyxZGe3NAHMuSJP3b9OgHr6Cp7NN+N36nPfrmlmtkmKRoCCTkkVfs7Rky07JFGTnLHk49B60AO1jCaG0D52FGY59e2a4JgcepxXTeJrzdB5K7sSHCqTztB5J/GucPOPWgDMvBjHrXJ+IE23SH1X+tdldLuHFcv4nj+WJxnqRQBiJ04FOFNjNPHHIoAXt6CnU2l9aAHDpQTgGkJwOabGklw+yMFj/KgB9vE91cLFH36n0FdhptklvEqoPlH61R0WwW2TLZLsfmP9K3olOO1AEGpgf2XeHIz5L/8AoJr6Q/bV/wCSWaV/2Gov/RE9fPjeWmk6uXUFzaSKme3yH9a+g/21f+SWaV/2Gov/AERPQB8V1qaWMoPrWXWxpAzGKAOs0ADLKe4yPeuptLZ3dAFyen1rmNLTAVhnrx7V2WkXsxIjWNWYDlzwB7mgDRXS47dCbmROxA3Zx+Qqz9gtXXEU0JfOcFtp/Wpba4RVJ2I7kZ3MoP5DtSXcAubbzdi8HacDHGPagChNpbWyNNIFWEfxsw/IetY15L9pufMAYIowq+1XbqxG3dExfH8JPT6VRVCH549QaALOmxhpTweBj866mwULbzD+JV34x1xXOaa3lykYOc+ldBZSMZsE58wFOe+Rxn8aAIduFXP5nuPenRyukymMkAY5FRyg8Bhh16g8URI5fIx0FAHV37JqWiNM5xdWilhz/rFx0rzmUF2JPfmu4hl8mxd2bMbqYj7kiuFck8AigDorOA3WkW8o+8pMZ9OKktl8l3wMgA/jVnwdGJ9EnQ43K5bGKkltmSQkLxjpjqaAMS4hBn3KNynjaOcVueGNO2zvJNkqF3N+HTmiKzbzNu3ryfrW5rzf8I/4MmnIxPMNq49TwKAPJtUma81K6mz96Q81SbaG46CpV+RFGct1PuahLE9KAGFysisDjac12awbVV8feG5SPTrXFqu5fcivSdLt/tXh+xfAyECmgDlbobpX2jqarCNlkypJyOM1v3NpiZ9qAAHp7VUaHYcEAsT19KAH6LGY5hc3EqJFCN5DHlj0wK5nxvcedqOBjcFy2PX/APVXUazD/ZOkCW5GJpTmNO59Ca85v2Z5GbcWYnLHPegDFvjwfWsK85DVsX7YJBGCKx7nJUjvQBQqxbLk5xUKqScVfto+nFAAEw/Fbmg2pnmIA4HWs4REuAoyTwK7rw3p4gtxI4wAMk+tAFf7CYyn3vMH8I+tOuFNurY4K9frW5ZwNc3uAOvOB3rnPHVytihtVI81uTg5xQB9w/Cf/klng3/sC2X/AKISij4T/wDJLPBv/YFsv/RCUUAeVftqf8ks0r/sMxf+iJ6+LK+0/wBtX/klmlf9hqL/ANET18WUAJUlscToR61HUlsMzoPegDqrIE8n/wDVWogwFNUbIZGDWlGuV5oA6nwpcCW3lhbJePDEZ5KHjP4GnX8BMpXI2nkk1jaBciy1q2kcZjLeXIM9Vbiup1W38q4kjYE88NnqvagBfC0Mbazah8MgkBP4GuZ1cMdf1PzeW+0vn8+K6jw5+7uXcD5lHHsawfFEZj8S3hwAHIf8xQBQK5XOOabZ/LqVpIOMTLzj3qZBlOD9ahH7uZWH8LBgfxoA76/XDMOAB0war6dF5k6rkADgkDkitC8jD2UMigHcMn/GotCTNzz1JGBQBlfEmUy+Iox/DHbKqjsBXNAfID7Vu+OH8zX377IwM1iEfKOKANXwav8AxUCEjOIzx3rodWYgMp5O4njjj0rA8Gf8jAo/6Zn+ddLqsIFyQgB+bg0AU7eMssagZJPPvVX4gXG02GnocLGpdhnv0FbmjwiWbL52r8x98Vx/iic3OvTsT9wBaAMoD9KlRTnp9fpTQOgqYDgY+lAFa5yVIXkkYr1DV7Zbbw3pcAyCkAX+Vef6Xb/adVs4scNKCceg5r0XxRIFdI+yIBj0oA5eKHhs9TgZ/u1a+VYWlmciKNcnPfFJFE0pRE53ccd6oeMJ/JhjsY2yX5c+oFAHNXUz3ly878bvuqP4R2FVpFKrnjirSJgYOMH9KUpkHcBigDKnXcMCue19N9mwP3k5rqb2AoPMUZA5I9Kx9XhWW3LqT0w2O9AHEIak71GV2SFT2OKkHWgBR+lBOPrR7035mYImSxOAKAHwQvcy7E6dzXT6fZJBGFUAevqaj0uxFtCN2Cx5J96014GQaAHwR7yFRfmJ4FdFZaWnlZuDuPXr0rM0lMTrkHcVrrEVliAK/N1yRQBh6/pkcOiXsqEq32aXOD/sk17n+2r/AMks0r/sNRf+iJ68k8SRh/DOpAg7ltZD+SGvW/21f+SWaV/2Gov/AERPQB8WYrb0YfItYgrd0X7iCgDsdMVSi56V1unRgRrGifO3J+tcppuNoAP1rt9GXfax3GQGjJJJ74oAljkChgBwOCK0tNkjw0cv3X7Y+aq9wyPbrLFyzNngY/SqDzsrhtxx7mgDQ1nTJrB/MYfuH+44P6e1YV7HHkSA89Dit2S9e4tzFO7SAjqT0PXiufuT+7lGeFGaAHxOqkMCMjp710VsgZYnQ/Kw3LXHxSEcA12nhLF5p7RNzJCxI+npQBavLVZpVkwQxAzjvToLePd5aw5PXk5rQS1K/LIOh6EdK0fDtoJdRTI70AYfjVo9L0uwsAgW4mBlcf3V6VwruvT8K6b4mT/aPGNyOdsMaRr7cZrlD0x1oA7/AOHMayW86cHLYroNQtkJIA+c9/Sue+F45mB/v12F3CDdHPJB6DtQBHpGni4uIUbHBGeK5f4y3qve2lhGdsca7yB+Qr0Hw8ux5ZDnIU14v8Sbo3Hiy+OThNqD8qAOWuJMA7ce1VQ3ysffpSyH16+tImSMYoAsRJlc45r1zwfbCTwtbjHQZryyBP3QAr27wrB9n0OFCACEUEUAYl9pwaVVAwagi0lWv42dfkX5j9BXV3EQ3DAGf5VkeJ7hdM0O4mJwxQ4oA8j8damb/W58H9xEfLRc+lchIeSxrUvFLFmYksxyT61nTR4BANAGRqEXmDK9RWHMpyQa6eVQARWJeRgucdaAMuNMOcDJrTto8KM9etRQW7eYSRj61t6bYGQh5fljHf1oAs6DphuJlkkGI17mu0fYsPlxnCjr7msaGcLHsT5Yxxx3qSG5MkyRL94nFAHRaYyWOnXF3LhdoOD3968Z8Q6g+oahNcMTh24+leh/EXU/senRadC2HZfmx6d68pmbc1AH6TfCf/klng3/ALAtl/6ISij4T/8AJLPBv/YFsv8A0QlFAHlX7av/ACSzSv8AsMxf+iJ6+K6+1P21v+SWaV/2Gov/AERPXxWKAD61Lac3Mf8AvVFU1n/x9RZ/vUAdnYqDkgdOa0k45PXvVGxGQD3rSRc+1ACOo6jr16dK7uZxd6TZXg+bemxj7iuJK5HWus8KP9q0K/syfnt285O/B60AWNI+SdhkYIzWV42iK6pDNjO+PBNaNqdsikfgfSk8ZRiSztpgc7DgmgDmYDlev/66SZMg578UsA2kADNSMDu9KAO7sT9o8O2kvGQo/lUujpi6QgHrmo/B6i58NbCclMj8jWhpke255HQE/pQBw3ikhtduMnOMfhWYelaHiLJ128z/AHgP0qltAHrQBq+B0J8RKMf8sz0+tdhrkYS9cY+70Pc1zHw+Td4ojUD/AJZt1NddqiltVlOc4b9KAG2K/Z7OSQ8FhXmVzKZ7y5mJyXkJz+Nem6q/2fSJD0+Qn9K8tgBbBPpk0ATohPQfWnsfT+dOA49+lMc4yeSPU0AdD4Dtjca00zHKxLx9a3dZdpZ3yeeppvgS2+zaRLPIPmlBb8+BUxh826OSTuP4UAJp0PkRNMw27VwM+tcFqNz9t1CefgqW2qfYdK7jxfdfYdKaJGPmOPLHHc9T+VcHFGAAB/kUAKq81IsfBHekC8+ntTl460AMaPJwQPSsHUIfs8rxHlHGV/wrpTtYdevpWfqlss8JHRl5U0AeXavD5F64GdrcioEORitrxNaMjJJjK9CfSsEEg0ASM2BWroNpuczuOf4R/WsmNGkkVcE5OK7LToDHGoI6DGKALSRjaMjj+VWIoweSCMUsSE4z2rV0fSp9Um2wjbEPvynoPagC54TsGubx5yuY4xtHoT3rqHhVJkCMSX4wOS1T2y2mnQCCMbsfLxwKs20ZklyiZY9OMlRQBmeI4Fi8J60cHcbKbgnn/Vt2r0T9tT/klulf9hqL/wBET1xvjuSDT/B2rm4Kh5bOWKMd8shH9a7P9tMZ+FulD11qL/0RPQB8W471t6UGjMYdWQkBhuBGQehHtXu3wdl8JeGdPkh8YaDpVp4htrR74lw004iQA5dZCRFIwOQi4JGchcjPjGseILrxL4n1DWL4/wCkXUxk25yEXoqD2VQAPpXlYPMp4vEVKUabUI/ab3vta2631uXKHKk7m9pz46dq7XS5wtnFGehGcH3rgrGTG3nrXVaJMJZVgYgMR8hPc+leqQb3n7o5I+iAgiqrDJORjHp3qbymBYHgnqD/ACoKBcdiT/OgCxp0Du7/AN4LwPc1z2pTDz3jjbKKcFuxI4/KvQtGtBFYanddPKtzg46HHWvLfMLDJ7jOTQBOhIIBxmux+H0xTUpEz99Qa4tGODnH0rovBsxj12EcAEYIoA9UuLch23DJ9au+GotlxI/p0ouQWijcd17VZ0QBI5PXvQB5N48/5Gi7bOd2DxXODnIPSug8aAjxBdbuvFc/39qAPQ/hcv7u4Po4/Hiu31GFhJuXHI9OlcT8LiPLux/tj+Vd5fHEg64IFAFrT18vT3J5J4zXgPjCXz/EeoyDnMpH5cV9BviLTFGcjGTmvnDU5PNu7iQ87pGJI9yaAMuRckZApYVDS4pznFS2iAjPrQBo2UQkniQc7nAx+Ne52iCKwVQOCRXjvheAz63aJwQG3EfSvbGULZqT9elAFWNPMnx1A6+1edfFS/3eTaK33m3ED0HQV6OhEdtJIeuK8R8ZXX2rXbhh91DsH4UAc3MvPPJ64qrLDuJI4q4ykn/GonHUCgDHuoHCnGKz1tFEm9ufTNblypAIXrVNYskLjjIoAitdN+f7RMCIzyF9auMc4Ix7D2q9d8zELkqqhePSk+xuV3IuVHXFAFYk+Wdp5xjBq/4YhD6mkkmQkYLk+wqqUIIBHTt61JLdGz0rUpFOH8rYD6E8cUAcV4r1JtS1a5nJyhYqn0FYNS3DZbFQ0AfpV8J/+SWeDf8AsC2X/ohKKPhP/wAks8G/9gWy/wDRCUUAeVftrf8AJLNK/wCw1F/6Inr4rFfan7a3/JLNK/7DUX/oieviugA7VLZnF1F/vVFT4DiaM/7QoA7vT8kD6VqopxkZwelZ2mDKiteNeOelADAvIwDwK2/BlwLfX4lP3J1MbD171kgcE1LYyeTfW0q8FJVJ+lAHX31v9muWXHIbin63B5+jADkEfrWtrcKOY5iQMoCTjk1TY+dYtGNp2AnigDgoBk4P04qUpxnHT+VOuY/KupEz1Oc1JjcgOM/hQB2Pw5bdY3kRGcSH9RW5bIBdfnisH4cjDXoPHzD+VbdvcK8+RwQcGgDgvEa7dfu+nJBwfpWeRgZ4FbXi+Ix62zkY3xjr7VjHgeoFAHR/DWPd4jklxny4CfzOK6jU1/4msgONzNk/4Vi/DOHE2oT54ykYP61vSlZNXlYEjBwAf5igDM8YybNKnAPHl4zXn1tHhRxiu78bAixnj6YGPbrXFRJ8oGf0oACM8dQKYsTTTRxAZMjBfpU7LgDOOK0/ClobvVRIwysX8zQB3dlEttpMaHAGAo/KotNjPzzEfd556ZqfVG226QLxtwc1LdILLTgGwDt3Pn6UAef+NLnz9TjgU5WJdxHuen6VjIuOSMZNSXEjXV3NcNnMjkjPp2pQh6+npQA0DHTnFHQf4U7aSAPwxSsoI7/hQBDyOlQvNt64qwycde9VZ0BQkn9KAM3V7WC5g5AVgRz/APWrnJ/D8cvKssZHIK9DXRXS5U9eRiqwUgEjp3oAzbHTbe1XKks3diK07aIyMq7SfRVGSa2bTw87xJNeyeQrcqoGWI/kK1bTyLJQlpGEfu3Vj7k0ARaZoA+V9Ubyo8ZECn5mHue1brXqRxrFaqIYV4VQMD/69ZrylzuZyVzyTTdzHJPVeBk/pQBehdwQTzz2rqNMeKx06W9uSFB5Ut0CjvXO6bCZpo0HY9cdKyfG2t/arj+zrVv9Hh4kYdGPoKAMPxvrEutRXssjEQLE/lR9gNp5+pr6C/bDu57D4d6Hd2crQ3MGuQyRyL1VhBOQa+YtZmVNMuc4AMTKPxFfS/7aP/JL9K/7DMX/AKInpNKSs9gPjSWWSaeSWaSR5ZCWd2YlmJ6kk9TT7R/LnVs8d6rlgMmmGQ800rbAdvZybQvIA61s29wVIKtgjBBHauR0afzrUZPzpwa37YkgYPBoA9Ztoxqmn2+ooBmQbZl9HAxn8aQW4UqpTdz1qt8LJxNBd2MhyG+ZR6HFb81v5chQjkH86ANS2i2+DNcdQdzRsBn2WvErfO0E9cV7/bwbvCN5DjPmqw/MYrwRQyAo3y7Tg/hQA+PODWx4ecRatavxw4H51kKQeT1q/YNslR+cKwagD3Yn/RYyM8VZ0ofu5SeSBVXT2+0aYjDkFQ2far9koWCQr0xigDx/xuc+IZ/UAA1zfRhxW944P/FRXQ55A/lWDtxjGKAPRfhaMx3npvH8q9CvIyxjxjGPyrz/AOFfMV31z5g/lXo87YKD8TQBH4gfyNJlY4+SI/yr5wlGSM/WvoTxxL5fh29cdfJb+VfP0g+SgCnIAfqegq5bqBGOc1WI3SdsCraZ7YJA5oA6vwDbiXV94GAq4/M163c8W0agceteb/DOEvJNIe59PSvTJl3SRoRx1PNAGTrsv2PTJHY4CoW/SvBLmTz5nkY/M7EmvYPiVdGPRpAvWRggrx2fCE859KAIGGM5NRP9zpzSkErzmkXKEcCgB0NoJQWfpnAFVLq0McvyZznoOa04JABtC8k9K0bO1V3MrDlD8xNAFGyt7sKJZtNR0HUpLtf64zXR6Mui3zfZ5ZXsLwDgTJjP4+lW4LUQXIWTB3evYe+Kh1LTVZl3R71PzYzgj6HtQBleJNJ+wTMJo1R2+7s5Uj1B968/8QSFLF4yfvsOPpXfa695ZaYRcE3Fl0STup9G9P5V5hrM/nSM3IXsD2oA5ibPmHNR1JMd0jH3qOgD9KvhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7Atl/6ISigDyr9tb/AJJZpX/Yai/9ET18VivtT9tb/klmlf8AYai/9ET18WUAFCHDqfQ0nrRQB6DpRyi+hFbcY71gaIxMKdOnOK6KPpQAbc5wSPbFRsCFJXqOQanxkcnGKjlHytg9qAPUnCXGj2rscEoOR9KxoiIpSCQc8HHSrljMRpVtEW6RKPocVlyybXZj/CeV60AZmvWZWTz0GQOoHp61nKTtHoR1rpmUSIvPXgA+lYtxZlbhBEwETHDf7BoA6XwIDHaXM2Dh2OPwFWANk/zHG48UulyLDZeSo24AHsPeoyfMnBIwBxkenrQBV8b23mQxXAA3occenpXG5ywHbvzXoniEbrRo2GcNlSR6155axSXF0tsnEsjbOnTnGaAPRfAcBt9A888GQvLn2HAP6VDasXu0+bJLZ9+tbOyK20U28X+rjRYgSefxrAsJAt6jDB5BBAoATxkSyXQ6Y5xXIoOAOfpXYa+vmtMpySU/pXJRDKjI7UARS8A13XhOwNnp6lx+8Yb3Pua5jR7A32pxR7SUU7mxzx2rvbhhbQLEpIzxj3oAS1Q3moqW/wBWvT3Aql4/ujBYtGpxJMdgx2z1rX8PQ5lLEcIM/WuM8d3P2jXREPuwr+poA5yOMADjFSYAHPFPCAYowMcdaAIwBnoc4oYHOBxUgHXrxTSuevFAFdl6D/8AVVaVTtIOc1ewDz+FQXCZVvpQBQawnmj37DtPIPTNVDCVnVH+VtwBH411rBjGMZ2EAjjpWPqdo8hTC49zQBvXqGdg0QZkAAAzVSS1eRSVBSQDGOxo0O1u2Kxx3PzDpuXj6V1lpZTKRHeQNG+Mhux9/cUAcWo2DbLkYOMY/pVqFDlWHOemDxitjVtLKSqwUK2OMdD9KqWMCeeokO0Lyc9FXvQAzVL/APsfRiycXVyCkQ7gd2rgJZAisWb3JPetHX9SOp6lLcnAiA8uFfRB0rifEF+0j/ZYj/vn+lAFPV75r2R1Q4gXOMfxH1r6+/bUOPhbpX/YZi/9ET18c7NsL4/un+VfY37av/JLNK/7DUX/AKInoA+K+tFHFFAGpoUuycqejcV1lqT+FcRYsRKCO1dnZvuVSM8jmgDtvAt2bTXISDgPxXqOrQ7pFfPyscj3rxTSpfJuIZASCjA4r3BZBc6PBKCGIH9KANTSWD6GydOOleKeIrb7Nrl3HjgtuH417LoTbrZ0+przb4hWpi1aObHyyLjPuKAOWRcd6uWy8kHrVZOWBAP41btzk+1AHtHgeQT6Fa54Ozb+VbsSlbeQe/SuS+Gku/SSg/5ZyEV2TciVR1zmgDxPxwv/ABUlzgdcdfpWEFxyetdJ4+Qr4lmz/cWue4KHJNAHoPwpbMN4vpKv8q9IuR80TDvxj8a85+E0f7q7PX96Afyr0HUJtrxLnGCDigDK+JEnl+Gr33TH6ivCpD8vQV7b8Tm3eGrntkrz+IrxG4B7DrQBDEh3Z6/hVleBxwTTI16fSpQAOlAHqPwztyunKxH3+f1rtrg7TKfQYH1rE8E2v2bSLYHjEQY1pxkyFi38TZP0FAHnvxUuMSWluDwMuQPyrzKcc5Iwa7f4jTebr7qMkRoF69+tcW68+vPSgCuV4z09qacA1NIMHFREc4xQA60H+lLu55/OuktZWdUVMBQcgY/nWBpqb7zABOBmux0+w8vbIynYBj6mgCo11JG2A5D/AMh60pmbywZXJyO3Wq8sRWZ2bliTgetNuSFiZ8kcYH0oAxvEV3ILGVUk2qRhl9Qa801BuW56V13iC8wjx5zmuJvW3HGaAMuQYNMqaXnPtUNAH6VfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFAHlX7a3/JLNK/7DUX/oieviwdK+0/21f+SWaV/2Gov/AERPXifwZ+CC/Ejwje67L4kXSY7W7e1aNrLzRhY0cuW8xcff6Y7daAPGDSV9E+Cv2e9A8b6fPfeF/iOl9bQSmGRhorxlXwDgq8oPQjnGDz6GvnagDuPDr5t4TnA211EByox071xnhiTdaoMjIOOa7K1J2igCUqeuDnvTVTfJGmPvMB+tS9jzU1iFN/ACOMng/SgDrAd1qAPukYIHPFUcZnYlhwefQ++auw5VVU4yAMVWmQKzHkq3UAUAIJGWUYycDn39q0Rp0dxZvcrtFynyiPPb1z61TAzKzFVAJBwfTHatfTHCjB2tgY29M0AYdu5VyrBtjfKfr71oRSbXZN2c+oziop7UJcHYSpzux1/OkRijMSMNnpQBpS/6TY7cBflwM9sf1rntNjWPU7qdFy7OVBPOOnSt1CYULsST1XPr6VStLcf2gxRMgAFxnqx7UAbMkmdLVXztdjz649azre3D3qeVjfkED+6fSrt+Y8vEBuREOMHB6dqraYpFwsi9B8xxnn/JoAu63AEdZcHa67T7EdRXDOvlSup4AJ9+9dxrU7R6aqyABmfP49Say/C2kC8vWvbxSY92Y0Pr6n6UAanhjTRpumtdXHyzSjcR3A7Ci9lzdRqpPQEn69q1dRuo5G8qItt4HT73PJrDnPmX0nlksoIK49MUAdRowEdhLKeM/wAq8ovJjd6jdTk5DyMR9BwK9SYtbeHbgkESCJmIz0GOK8ot/uAn0zQBL2HYdaT8aeORxzTSPxoAB054ppGePWnn7pxyffvTCMj3oAYf0qKRTj5qnwAM9u9V52G0kUAMtSxnVQzcDgZ4rcsNOab95IMj/a703w7pLy27X06sqN8sSnjI7muhFt5UbiVWUKPu/wB4nt7UAMi0+JIWQALnpjqcVNb3d1ZnycmRQcqrnIz7HtmnWs6BtspC5Gd2M/gaL1IpnBhcEY4/xoAs3F1aX2niVAA459/cfUGuJ8YXCWtmYITsnuDtZR/Co6/n0qbxLJd6POskBAhuxkjH3XHUj69a4m7kZ3LSMzueSzHJNAGPrV4LW1ZhjceFHvXKRKzMWflickk9atazcm81AgH93H8ox696iRcCgBZP9S+P7p6fSvsH9tX/AJJZpX/Yai/9ET18fzf6h/8AdNfYH7av/JLNK/7DMX/oiegD4ro4r1f4dfCnTfE/w61Txjrfir+wtO067NrN/wAS5rrA2xEN8rg8mUDAU9M/TsPDX7PWheJL66stJ+IEzXtsiSy29z4fmtpFRx8rbJZFJU+oGKAPn+zOJePSuu0pswjNcfbf60c811Ojk4wTQB0tr6ADHvXtHgGcXuirEx5A2/jXi1r0BJr0v4Z3gR5ICeh3AHvQB21kfIndMEBTj6CuY+JNo0uniYDPlsGH0rpb3Md43HDc/Wq2vRC80pY2XPmKVNAHjackDPXpV+2y3Gc+4qo0bRysjjaykr75FaFmCRk0AeifDB+buIZ+8D+ld8x2zup6N6V538NDi/uVHQqp/Wu6W8B1BU4wzYoA8u+IqbPEI4+9ED/OuU2nB5rvfibbf6bbXAGVYFAfTFcUAMdOvWgD0X4SR4s7ts8ed/QV1WqSbbwAjgNisT4UwiLQ5JGGFMpOf0rS1KTfcOwIIBOSe1AEHxLw3hiYg8Epz+NeMSLukwBkete1eNo/O8GSnkjYrfrXjbJ83SgBgUDGc8U+1iNxdwxAZZ3C4+pp+3gZ45rf8CaeLzxJbYGUizIx+nT9aAPV7ZBa2YHAwuwCo7WTMTseOKNSmCkIvIXiq08nkaXcSEfdU0AeQeJ5/tOs3kgPBkI/AcVgsMtgir943mOznqxJ/OqJyWoAhkxu9RUZGSalk6mopDtHFAHR+BbD7bqMzMMpGo4Hf2rrrxdjhW4xwAKXwHYDTPDrXkgAll+YZ9+lVprhmkyhy7E/hQBkSxn7WzD5jyenesrxPImm6eN5+duEFdnHZpBbNc3DARxgsxPGf89a8Z8Yay2q6nNNnES/LEB2WgDntUuzJIzMTz1rCd9xJ6mrV4xZsZqtgUAQOM8nioT1q3IBgVVYYPtQB+lHwn/5JZ4N/wCwLZf+iEoo+E//ACSzwb/2BbL/ANEJRQB5X+2p/wAkt0r/ALDUX/oieuL+Btrr+ofs0+LNN8JWn2nVb7VpbVR5qRCON4YBI5LEdF3dOckV6H+11ouq678N9NttD0y+1K5TVo5Gis4HmdUEMwLEKCcZIGfcV8w6LovxZ0K1e20PTPHem2zuZGis7e7hRnIALEKAM4AGfYUAfUnwo+H2v/Dv4gXUMSWl34Z1HTYVmuLWMW6w3MI2LmJpXYllBLMOCzZwMV8KmvVv+L3f9VJ/8nq5Q/Dnxv8A9Cb4k/8ABXP/APE0AUvC8uGkj9CGrvbNtyA81zmkeAfGtreB5fB3iQIRgn+yp/8A4iuys/DXiSMYfwt4lH10e5P/ALToAVBnqPzpQCjqyfeU5H4VoRaDroHPhnxKD6f2Ndf/ABupV0PWwefDXiT/AMEt1/8AG6ANRZVlEcqcZUOR3FNjUyk9cjjHtTLSw1lIGjk8M+JQR91ho13+X+rrSs7TUIoxv0DxLuPLD+xLw8/9+qAFis2MYJPzYyN1PmtI4o/MZ/LkUY3Zqy4v44yIdA8SFjyP+JHeYB/79VDa2V7JMHu9F8R5brnQ70gflFQBmDUJdxSVA6g4WQ/1H9afLLkboh87DlW9K6W9sreaywmieIVmwcFfD96Dn3/dVzkmmanHuEWieI2XHGNDvBk/jFQBSuJL6ZAIoiSnC7RhQfp3rYsGi+zhYcicnL5OMnv1qK1tdST7/h7xIADkY0S7/wDjVTT29653Hw54l34++uiXefxzFzQAPHIJUYEowHzD3z6VpWEW4syhuAMe/wBRVG3/ALSUhJ/DviVowOCNEu8r9P3daZlvIY1ittG8SEufmlbQb35Qe4HlcmgDJ1iJrmeKJeVj7epNaYlFnYrDGygk5d8Y5qGdLpQBBofiUkfxnQ73JPr/AKqqsi6jkqvh7xKUxjP9iXnP/kKgB0NyXkDMDgHPtgcCmwSp9oLtkHPBHHWkEOoKMjQvEhIHT+w7z/41UC2+pKQx0DxKzY5/4kd3j/0XQBuLN5ttdwFjumhcAevHBrziAYjX6V3Not8k2+TQfEgIHB/sO859R/qq5mbR9XWeXyvDniRo9xK40W7HB/7Z0AUQPp/jQy/NVz+yNZwP+Kb8SZH/AFBbv/43S/2TrX/QueJf/BLd/wDxugCi3uOetITxnj16VdbSNbJP/FOeJef+oNd//G6Y+ka6enhvxL9P7Fuv/jdAGfIwAx0q/wCGdDk1u73yjbYRn5j03n0FWdG8N39zcBtW0XxLbW6/wLol4zP7cRYArqrm71GOEWumeGvElvbKNoxod3kj/v3xQBYuZY4FEcIREjAVO5x7CsW6uvMARVCLk8dyfX/69Nmi1ZzuPh/xKW/7Al5n/wBF1GLTVCQH0DxJ6kjQ7zp6D931oAjjjZdzMDgc5znNBlyCACCT0z3q19n1Jgd/h/xEQecf2Hece3+qqhfwa1GpNr4Y8TTOegGjXQA+pMdAGP4w1ANZW9pLzIr+YrZ+6OmK861++Fravt4duFHvXW6h4f8AFlzPJM3hXxIzuc8aRc8ew+SuTv8AwN43vbre/g7xKI14Uf2XP+f3KAORt04ye/erS8dK6JPh/wCMxgf8Ih4k9/8AiVT/APxFPHgHxn28IeJP/BVcf/EUAczN/qpP90/yr6//AG1v+SWaV/2Gov8A0RPXzNJ4A8ZGJ1Hg/wASElSB/wASq4/+Ir6p/a70TVde+G2m2uh6Zfalcpq0UjRWcDzOqCGYFiqgnGSBn3FAHm3wZ0LUfE37LPjPR9DtvtOo3WrFYYd6puIW1Y/MxAHAPU16z8LvCetaT8Qb/Vn0y90rRptKhtZY9TvUvLme5Rh86uJJCsYXICl8eijt8oaJovxa0G1e10PTPHem2zuZGhs4LuFGcgAsQoAzgAZ9hV//AIvf/wBVJ/8AJ6gDy6D/AForptJOJFwRUkfw58bBwT4N8S4/7Bc//wATWxZeBvF8RUv4R8SjH/UKuP8A4igC1aHtXX+CLrytbhywAkG0+lYlv4V8TLjd4W8S/wDgouf/AIitbStE8Q2t9BKfDHiRQjgk/wBj3XT/AL90Aet6lz5T4DcYqtGwkRUPY8Uye7nltVT+w/Em4D/oBXvX/v1VJJbxeRoXiQ9/+QFef/GqAOL8W6cbTVncKQkvP496p2y/KM+nNdv4itptTtFVND8SCUcgnQr3g/8AfrvXLR6TrS8f8I34k/8ABLdf/G6AOr+HAxeXDjgKo/GuinJiui+4DnIrnfCzX2mW5WbQfEoZxlv+JHeH8P8AVVbubq8mdf8AiQeJMAn/AJgd5+H/ACyoAk8TobnSowwyBkknsfWvPnHBABLGu6kuLyayEUmg+Jd2c8aHef8Axquat9N1NbwNJ4e8SeUDnP8AYl3z/wCQqAPRPDQGl+GLeHA3sASPTNVJZQ8rDPrmqK318EcHQvEuSRgf2HecAdP+WVRefebW/wCJD4kyT20O8/8AjVAHU3QGoeH7m25YmIqPqBXjjIf4h3r0iy1G6t0b/iSeJctjj+w73/41XHarpmoNqE72egeJGgYll/4kd4MZ7f6rtQBjMvJAxx+lek/DWx+zaZcai64Mx2oT/dHH864aHSdWZkSTw/4jRScFjol2do9eI69Fn1D7PYW1jYaN4l8iFQuf7BvRnA/65UAXJX3SAHHrzVbxbMLfwvckdwRVaO/l35fRvEnHQ/2De/8Axqqfi26ub/RGt7PRPEskrEZX+wr0d/eKgDzC4OE5qoPve/atibRdcZePDXiU/wDcGuv/AI3VU6F4hJH/ABTPiQf9wa6/+N0AZz5B6AVa8P6c+q6xb2yglM7nPsKmk0DxC3A8M+JMf9ga6/8Ajddh4IsLrRrSa4u9C8Sfbn+6n9h3hx6ciLFAG94hmW3hhs4QAI1wQPWszRrI3lxgEhc/MfQVFdf2nNKzHQPErFjkn+xLzn/yFWnaT3Nlpcnl6F4ke7cfdGhXgx6DJixQBxvxa11ba2XTLNtu8fNg9F/+vXid7Pgnmu58ReHPGWq6hPdN4T8Ss0hyB/ZNxwOw+5XM3fgHxvKfl8HeJSD/ANQuf/4igDlnfcxOaXJro0+HnjYdfB3iT/wVz/8AxFPHw98a/wDQneJf/BVP/wDEUAcwc55qCWutPw98a/8AQneJf/BXP/8AE1G3w78bnP8AxRviX/wVz/8AxNAH338J/wDklng3/sC2X/ohKKl+GVtPZ/Dbwna3kMsFzBpNpHLFKhV43WFAVYHkEEEEGigDpaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the left hand in the AP projection shows a normal patient (A) and a patient with radiologically mild rheumatoid arthritis (B). The patient with rheumatoid arthritis demonstrates osteopenia around the metacarpophalangeal joints (white arrows) and mild soft tissue swelling (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image B courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25601=[""].join("\n");
var outline_f25_0_25601=null;
var title_f25_0_25602="Weaning from breastfeeding";
var content_f25_0_25602=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Weaning from breastfeeding (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25602/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25602/contributors\" id=\"au1765\">",
"       Lisa Enger, RN, BSN, IBCLC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25602/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25602/contributors\" id=\"se4794\">",
"       Teresa K Duryea, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25602/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25602/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/0/25602?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Breastfeeding without any supplementation (infant formula, juice, water, solid foods) is recommended for the first six months after birth. Partial breastfeeding is recommended until the infant is at least 12 months old, and thereafter for as long as a woman and her child choose to continue [",
"     <a class=\"abstract\" href=\"UTD.htm?25/0/25602/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Partial breastfeeding is defined as breastfeeding while also providing other sources of nutrition, usually beginning at approximately six months of age. At this time, soft pur&eacute;ed meats, infant cereal, and then pur&eacute;ed fruits and vegetables may be introduced slowly. Cow's milk is not recommended until a child is at least 12 months old and fruit juice is not recommended until a child is at least six months old. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      \"Patient information: Starting solid foods during infancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More information about breastfeeding is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE WEANING PROCESS",
"     </span>",
"    </p>",
"    <p>",
"     Weaning is defined as the gradual replacement of breast milk with other sources of nutrition.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      When should I wean?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weaning may be initiated by the child, the mother, or it may be a shared decision by mother and child. Most children who self-wean do so between two and four years of age; it is uncommon for an infant younger than 12 months to self-wean. The duration of the weaning process varies from child to child. Some children will wean quickly while others will take months to completely wean.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Do I have to wean?",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many possible reasons for wanting to wean, although it is rarely",
"     <strong>",
"      necessary",
"     </strong>",
"     to wean. There is no particular age by which weaning should be complete and continued breastfeeding is not harmful to a child's development. Women who are told that they must wean should consult with someone who is knowledgeable about breastfeeding to help them explore their options. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Finding a lactation consultant'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The World Health Organization advises women to continue partial breastfeeding for up to two years and beyond [",
"     <a class=\"abstract\" href=\"UTD.htm?25/0/25602/abstract/2\">",
"      2",
"     </a>",
"     ]. The benefits of breastfeeding persist for as long as it is continued. Some of the benefits persist even after breastfeeding is discontinued. The benefits of breastfeeding are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pregnancy and breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breastfeeding is not a reliable method of birth control. Most women are able to become pregnant, even while breastfeeding, within the first three months after giving birth.",
"    </p>",
"    <p>",
"     Women who become pregnant are usually able to continue breastfeeding if they wish. However, the woman will need to consume extra calories (approximately 200 per day) to satisfy her own needs and those of her fetus and breastfeeding child. This is especially true if breastfeeding is exclusive (the infant is not eating or drinking other foods). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Weaning and guilt",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weaning can be a very emotional time for the woman and child. It is not just a transition to another feeding method, but is the conclusion of a special relationship between mother and child. Even if both are ready for the weaning process, unexpected feelings of sadness may occur.",
"    </p>",
"    <p>",
"     Some women who need to wean develop feelings of guilt. Although this is a normal reaction, you should feel proud of any breastfeeding you have done, knowing that you have provided a wonderful start to your child's health and well-being.",
"    </p>",
"    <p>",
"     During the weaning process, your child may need more attention and cuddle time to take the place of nursing time. You may find that some days your child needs to nurse after having nearly weaned completely. Being flexible and understanding will go far in the weaning process and make it a comfortable time for everyone involved.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HOW DO I WEAN?",
"     </span>",
"    </p>",
"    <p>",
"     When the woman is ready to initiate weaning, one option is to gradually eliminate one breastfeeding session every two to five days. Other ways to wean include shortening nursing sessions slowly or lengthening the time between nursing sessions.",
"    </p>",
"    <p>",
"     It may be possible to wean a child from nursing during the day and to continue breastfeeding at night; this may be a good option for women who are unable to pump breast milk while working. The midday feeding may be a good time to start as children tend to be most interested in nursing at the first and last feedings of the day, when their need for comfort is greater. Pre-bedtime or nighttime feedings are usually the last to go.",
"    </p>",
"    <p>",
"     However weaning occurs, mothers should watch their breasts carefully for any sign of pain, redness, or tenderness. These can be signs of plugged ducts or mastitis (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Stopping breastfeeding \"cold turkey\" is not recommended because the breasts will become engorged, painful, and may develop an infection (mastitis). If breastfeeding must be stopped immediately for medical or other reasons, it may help to hand-express or pump milk a few times per day until the breasts feel comfortable (not empty) and the milk production slows, usually over a few days. Do not wait to express milk until the breasts are painful or very full. Wearing a well-fitting, supportive bra can be helpful. Hand expression is discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Bottle or cup?",
"     </span>",
"     &nbsp;&mdash;&nbsp;An infant can be weaned to a bottle then a cup, or directly to a cup, depending upon the child's age. Children under 6 months of age may use a bottle while children older than 12 months can usually use a cup. Children between 6 and 12 months may use either a cup or a bottle. Weaning directly to a cup avoids the problems associated with bottle feeding. A trainer cup with two handles and a snap-on lid with a spout may be easiest to manage.",
"    </p>",
"    <p>",
"     When introducing a bottle, it helps if the baby is not extremely hungry, so that he or she may be more patient. It also helps if another caregiver introduces the bottle; some babies initially refuse a bottle if the mother is near.",
"    </p>",
"    <p>",
"     Initial feedings from a",
"     <span class=\"nowrap\">",
"      bottle/cup",
"     </span>",
"     may be easier if the",
"     <span class=\"nowrap\">",
"      bottle/cup",
"     </span>",
"     contains expressed breast milk. Breast milk is sweeter than formula. Infants may be more willing to accept the bottle or cup if the taste of the milk is familiar. If the child is older than 12 months, cow's milk may be given instead of formula. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      \"Patient information: Starting solid foods during infancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The child should not be left with a bottle of milk or formula while sleeping. Falling asleep while bottle feeding can lead to \"baby bottle tooth decay\" and is not recommended.",
"    </p>",
"    <p>",
"     When partially breastfeeding, try to offer the breast before the baby is hungry and impatient. After bottle-feedings have started, some babies get frustrated with breastfeeding because milk flow is not as fast from the breast as from a bottle. This may be prevented by selecting a bottle nipple with slow flow. Another suggestion is to pace the infant with the bottle so that a feeding takes at least 10 to 15 minutes, similar to a nursing session.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      LIFE AFTER WEANING",
"     </span>",
"    </p>",
"    <p>",
"     As weaning occurs, you may find that your breasts begin to feel less full and may begin to become smaller. Most women's breasts will remain slightly larger than pre-breastfeeding. Some women will have stretch marks similar to those on their abdomen from pregnancy. These will fade to pale, silvery colored areas over time.",
"    </p>",
"    <p>",
"     Once breastfeeding has stopped entirely, your breasts will stop producing milk. Even after breastfeeding has stopped, there may be milk in the breasts for several months to years. You may notice drops of milk on occasion or may be able to express drops by hand. If your breasts become painful, hard, or reddened after weaning, you may have a plugged duct or breast infection; talk with a healthcare provider to determine if treatment is needed.",
"    </p>",
"    <p>",
"     As you produce less breast milk, you will need to consume fewer calories to maintain your body weight. This may mean eating fewer snacks or reducing portion sizes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784791127\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569059\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=see_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569093\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=see_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=see_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30985?source=see_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/breastfeeding\">",
"      www.cdc.gov/breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/Breastfeeding\">",
"      www.womenshealth.gov/Breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthychildren.org/english/ages-stages/baby/breastfeeding/pages/default.aspx\">",
"      www.healthychildren.org/english/ages-stages/baby/breastfeeding/Pages/default.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Massachusetts Breastfeeding Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.massbfc.org/\">",
"      www.massbfc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breastfeeding On Line",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.breastfeedingonline.com/\">",
"      www.breastfeedingonline.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Working and Pumping",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.workandpump.com/\">",
"      www.workandpump.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Working without Weaning: A working mother's guide to breastfeeding,",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Kirsten Berggren",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Finding a lactation consultant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certified lactation consultants, or LCs, are available at most hospitals as well as privately, and can be an invaluable resource for instructions about breastfeeding, pumping, milk storage, and bottle-feeding breast milk. The websites listed below have information about finding a lactation consultant or breastfeeding counselor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       La Leche League",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lalecheleague.org/\">",
"      www.lalecheleague.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Board of Lactation Consultant Examiners",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.iblce.org/\">",
"      www.iblce.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 703-560-7330",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Lactation Consultant Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ilca.org/\">",
"      www.ilca.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 919-861-5577",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/0/25602/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/0/25602?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25602/abstract/1\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global Strategy for Infant and Young Child Feeding. 2002. Available at: www.who.int/nut/documents/gs_infant_feeding_text_eng.pdf (Accessed on June 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25602/abstract/3\">",
"      Li R, Fein SB, Chen J, Grummer-Strawn LM. Why mothers stop breastfeeding: mothers' self-reported reasons for stopping during the first year. Pediatrics 2008; 122 Suppl 2:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25602/abstract/4\">",
"      Maier AS, Chabanet C, Schaal B, et al. Breastfeeding and experience with variety early in weaning increase infants' acceptance of new foods for up to two months. Clin Nutr 2008; 27:849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_0_25602=[""].join("\n");
var outline_f25_0_25602=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE WEANING PROCESS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HOW DO I WEAN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           LIFE AFTER WEANING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25603="High prolactin levels and prolactinomas";
var content_f25_0_25603=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25603/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25603/contributors\" id=\"au5918\">",
"       Peter J Snyder, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25603/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25603/contributors\" id=\"se4042\">",
"       David S Cooper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/0/25603/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25603/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/0/25603?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH PROLACTIN OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Lactotroph adenomas (prolactinomas) are benign (non-cancerous) tumors of the pituitary gland that produce prolactin and thereby cause higher than normal blood prolactin concentrations. They can cause symptoms, either when the high blood prolactin concentration interferes with the function of the ovaries or testicles or, less commonly, when the adenoma grows large enough to compress nearby structures in the head, such as the nerves to the eyes.",
"    </p>",
"    <p>",
"     Prolactinomas occur in both men and women but are more commonly diagnosed in women who are less than 50 years than in older women or men.",
"    </p>",
"    <p>",
"     Prolactinomas can usually be treated successfully with medication alone. Medication lowers the prolactin level in the blood substantially, often to normal, and also usually reduces tumor size. However, a minority of these tumors do not respond to medication and must be treated with surgery or, less commonly, radiation therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF HIGH PROLACTIN",
"     </span>",
"    </p>",
"    <p>",
"     The pituitary is a small gland in the middle of the head just below the brain (",
"     <a class=\"graphic graphic_figure graphicRef63094 \" href=\"UTD.htm?18/19/18739\">",
"      figure 1",
"     </a>",
"     ). The pituitary contains lactotroph cells that produce prolactin, the hormone that stimulates lactation (formation of breast milk). Prolactinomas develop when one of these normal cells develops a mutation that allows the cell to divide repeatedly, resulting in a large number of cells that produce an excessive amount of prolactin. About 10 percent produce growth hormone as well as prolactin.",
"    </p>",
"    <p>",
"     Most prolactinomas occur sporadically but, rarely, they occur in families as part of a condition called the multiple endocrine neoplasia type 1 (MEN 1) syndrome.",
"    </p>",
"    <p>",
"     Most prolactinomas remain small, less than 1 centimeter (0.4 inches) in diameter and are called microadenomas. A minority grow larger, occasionally to several centimeters, and are called macroadenomas.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of prolactinomas fall into two categories: symptoms that result from elevated blood prolactin levels and those that result from compression of surrounding tissues.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Symptoms caused by elevated blood prolactin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Elevated blood prolactin interferes with the function of the ovaries in women and the testicles in men. Therefore, it causes symptoms in premenopausal women and in men, but not in postmenopausal women, whose ovaries have stopped functioning.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Women",
"     </span>",
"     &nbsp;&mdash;&nbsp;When a high blood prolactin concentration interferes with the function of the ovaries in a premenopausal woman, secretion of estradiol, the main estrogen, decreases. Symptoms include irregular or absent menstrual periods, infertility, menopausal symptoms (hot flashes and vaginal dryness) and, after several years, osteoporosis. High prolactin levels can also cause milk discharge from the breasts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Men",
"     </span>",
"     &nbsp;&mdash;&nbsp;When a high blood prolactin concentration interferes with the function of the testicles, the production of testosterone (the main male sex hormone) and sperm decrease. Low testosterone causes decreased energy, sex drive, muscle mass and strength, and blood count. If levels remain low for several years, bone strength may become decreased (osteoporosis). High blood prolactin also causes difficulty in getting an erection, as well as breast tenderness and enlargement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Symptoms caused by compression of surrounding tissue",
"     </span>",
"     &nbsp;&mdash;&nbsp;Large adenomas can cause symptoms by pressing on nearby structures in the head. Pressure on nerves to the eyes can impair vision, especially peripheral (side) vision. Pressure on the pituitary gland can decrease production of the hormones that stimulate the thyroid gland and adrenal glands, leading to underactivity of the those glands. Pressure can also cause headaches.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      DIAGNOSIS OF PROLACTINOMA",
"     </span>",
"    </p>",
"    <p>",
"     A prolactinoma is diagnosed based upon an elevated blood level of prolactin and evidence of a mass in the pituitary gland, as seen on an MRI scan. Because other conditions can cause an elevated prolactin, those causes must be evaluated as well.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Measurement of prolactin",
"     </span>",
"     &nbsp;&mdash;&nbsp;The prolactin level can be measured in a single blood sample. The result can range from slightly elevated to a thousand times the upper limit of normal. In general, larger adenomas cause higher prolactin levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Magnetic resonance imaging (MRI)",
"     </span>",
"     &nbsp;&mdash;&nbsp;MRI is the best test for identifying masses in or near the pituitary gland, although MRI cannot determine if the mass is a pituitary adenoma or another abnormality. Furthermore, some small adenomas (microadenomas) cannot be detected by MRI, and not all adenomas secrete prolactin or other hormones.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Evaluating other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other causes of a high blood prolactin level include certain medications, especially those used to treat psychiatric conditions and estrogens taken by mouth, and underactivity of the thyroid (hypothyroidism).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PROLACTINOMA TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     The goals of treatment are to lower the level of prolactin in the blood to normal and to decrease the size of a large adenoma, especially if it is compressing surrounding structures. It is important that the clinician and patient discuss the possible benefits and risks of treatment.",
"    </p>",
"    <p>",
"     Not all prolactinomas require treatment. If it is large or causing symptoms, it should probably be treated, but if it is small and is not causing symptoms, it does not need to be treated.",
"    </p>",
"    <p>",
"     When treatment is necessary, most prolactinomas respond well to therapy with medications called dopamine agonists. If an adenoma does not respond to any of these medications or if the medication causes intolerable symptoms, other treatments should be considered.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      MEDICATIONS TO TREAT PROLACTINOMAS",
"     </span>",
"    </p>",
"    <p>",
"     A dopamine agonist is the best first treatment for a prolactinoma of any size. Two dopamine agonists are currently available for this purpose in the United States, cabergoline and bromocriptine, and another one as well in other countries, quinagolide.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Bromocriptine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bromocriptine has been used for 30 years to treat prolactinomas. It is taken twice a day. While it is usually very effective in lowering blood prolactin levels, it can cause side effects, including dizziness, nausea, and nasal stuffiness. Many of the side effects can be avoided by taking the medication with meals or at bedtime and by starting with a very low dose (one-fourth to one-half tablet).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Cabergoline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cabergoline is taken once or twice a week, and is much less likely to cause nausea compared with other dopamine agonists. It may be effective for treating prolactinomas that are resistant to bromocriptine. For all these reasons, cabergoline is the best first choice, except in women who are trying to become pregnant (see",
"     <a class=\"local\" href=\"#H22\">",
"      'Becoming pregnant'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Effectiveness of dopamine agonists",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dopamine agonists are very effective for decreasing prolactin levels and the size of most prolactinomas. Cabergoline, which appears to be the most effective dopamine agonist, lowers prolactin levels in about 90 percent of people who have prolactinomas, often to a level that is normal. It also usually decreases the size of micro- and macroadenomas to normal. Prolactin levels usually fall within the first two to three weeks of treatment, but detectable decreases in adenoma size require more time, usually several weeks to months. When the adenoma affects vision, improvement in vision may begin within days of starting treatment.",
"    </p>",
"    <p>",
"     If the prolactin level decreases to normal or near normal levels, the effects of the elevated prolactin are reversed. The upper normal value for serum prolactin in most laboratories is about 20",
"     <span class=\"nowrap\">",
"      ng/mL",
"     </span>",
"     (20",
"     <span class=\"nowrap\">",
"      mcg/L",
"     </span>",
"     SI units). In premenopausal women, ovarian function returns, estrogen levels increase, menstrual periods return, and fertility returns. In men, testicular function returns, causing an increase in energy, sex drive, muscle mass, blood count, and bone calcium. The ability to have an erection returns and, eventually, breast enlargement regresses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Side effects of drug therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The major side effects of dopamine agonists are nausea, lightheadedness after standing, and mental fogginess. These side effects are most likely to occur when treatment first begins and when the dose is increased. They can be minimized by starting with a small dose, increasing the dose slowly if needed, using small doses more frequently, and taking the drug with food or at bedtime. In women, intravaginal administration can decrease or prevent nausea.",
"    </p>",
"    <p>",
"     Cabergoline has been associated with valvular heart disease in people with Parkinson disease. This appears to be dose-dependent, and the doses of dopamine agonists used for Parkinson disease (often &gt;3",
"     <span class=\"nowrap\">",
"      mg/day",
"     </span>",
"     or 20",
"     <span class=\"nowrap\">",
"      mg/week)",
"     </span>",
"     are typically much higher than those used for hyperprolactinemia (0.5 to 2",
"     <span class=\"nowrap\">",
"      mg/week).",
"     </span>",
"     So far, there are no confirmed cases of valvular heart disease in people being treated for hyperprolactinemia. However, experts recommend using the lowest dose of cabergoline necessary to lower prolactin to normal; they also recommend doing ultrasound (echocardiogram) of the heart valves in patients with prolactinomas who need higher than usual doses of cabergoline.",
"    </p>",
"    <p>",
"     <br/>",
"     Heart valve problems have not been seen in people taking bromocriptine, even in high doses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      How long is medication needed?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the prolactin level remains normal and no adenoma is seen on MRI for two or more years, a trial period without medication can be considered. However, the high prolactin level often recurs after the medication is stopped. Monitoring of the prolactin level and, less frequently, the size of the pituitary, would continue during this time. If the prolactin levels begin to rise or the adenoma grows in size, a dopamine agonist may be recommended.",
"    </p>",
"    <p>",
"     If the dopamine agonist is not effective in lowering the prolactin level or if the person cannot tolerate the medication side effects, surgery to remove the adenoma may be considered (see",
"     <a class=\"local\" href=\"#H24\">",
"      'Surgery for prolactinoma'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Considerations specific to women",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Drug therapy and menopause",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have microadenomas usually do not have to continue taking dopamine agonists after menopause. The prolactin is usually measured a few months after treatment is stopped to be sure that it is not substantially higher than before treatment. This is usually done once per year for a few years and less often thereafter. Women who have macroadenomas should continue taking dopamine agonists after menopause to keep the size of the adenoma from increasing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Estrogen and progestin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Estrogen, in combination with progestin, is a treatment option for women who have small prolactinomas, especially women who have intolerable side effects with dopamine agonists and those who do not want to become pregnant.",
"    </p>",
"    <p>",
"     The rationale for estrogen treatment is that the only known harmful effect of an elevated blood prolactin in a woman is decreased ovarian function, including diminished secretion of estrogen. Estrogen doses and regimen are discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The prolactin concentration should be monitored periodically because of the small chance that the adenoma could grow. Estrogen and progestin treatment are not recommended as the only treatment in women with large prolactinomas (&gt;1 cm).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Becoming pregnant",
"     </span>",
"     &nbsp;&mdash;&nbsp;A woman who has a lactotroph adenoma and wishes to become pregnant can usually do so with little risk to herself or her developing child. However, the woman should discuss her desire to become pregnant with an endocrinology specialist before attempting to become pregnant. Issues to address include which treatment is best before attempting to become pregnant, when to discontinue dopamine agonist treatment, the chance that the adenoma will grow during pregnancy, what would be done if it does grow, and whether or not breastfeeding is advisable. These considerations are influenced greatly by whether the adenoma was less than 1 cm (microadenoma) or greater than 1 cm (macroadenoma) prior to treatment.",
"    </p>",
"    <p>",
"     <strong>",
"      Microadenomas",
"     </strong>",
"     rarely increase in size during the course of pregnancy. The best treatment to restore fertility in women with a microadenoma is a dopamine agonist. Bromocriptine does not appear to increase the risk of miscarriage or birth defects when it is taken to restore fertility and discontinued early in pregnancy.",
"    </p>",
"    <p>",
"     Less information is available about the safety of cabergoline, although the available information does not indicate that it increases the risk of birth defects. Bromocriptine, therefore, appears to be the safest dopamine agonist to use to restore fertility, although a woman who has severe side effects from bromocriptine could reasonably choose cabergoline. Dopamine agonist treatment should be discontinued as soon as pregnancy is diagnosed. There is insufficient information about the safety of these medications during later stages of pregnancy.",
"    </p>",
"    <p>",
"     If dopamine agonists do not lower prolactin sufficiently to restore ovulation, other medications, such as clomiphene citrate or gonadotropins, may be recommended to induce ovulation. Once pregnancy is diagnosed, the dopamine agonist should be discontinued. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     During the course of the pregnancy it is possible for the adenoma to increase in size. To monitor for an increase in size, the woman should let her healthcare provider know if she develops new or worsening headaches or worsening vision.",
"    </p>",
"    <p>",
"     <strong>",
"      Macroadenomas",
"     </strong>",
"     may increase in size during the course of pregnancy. Signs that the adenoma is growing include new or worsening headaches or changes in vision.",
"    </p>",
"    <p>",
"     If vision worsens, the woman should see an ophthalmologist. An MRI may be recommended to determine if there has been an increase in adenoma size. If so, bromocriptine is usually recommended to decrease the size. There is little information about the effect of bromocriptine on the fetus during the second and third trimesters; the available information suggests that bromocriptine does not harm the fetus. If necessary, surgery to remove the adenoma can be performed during the second trimester.",
"    </p>",
"    <p>",
"     If the adenoma was greater than 2 cm in diameter or was affecting vision prior to treatment, surgery is usually recommended before the woman tries to become pregnant. Surgery is recommended because growth of the adenoma during pregnancy can potentially interfere with vision or cause headaches. Following surgery, a dopamine agonist may be recommended to restore fertility. (See",
"     <a class=\"local\" href=\"#H24\">",
"      'Surgery for prolactinoma'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a woman wishes to breastfeed, she should not resume dopamine agonist treatment until breastfeeding is completed. If there was a significant increase in the size of the adenoma during pregnancy, most experts recommend that the woman not breastfeed so that she may restart dopamine agonist treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      SURGERY FOR PROLACTINOMA",
"     </span>",
"    </p>",
"    <p>",
"     Surgery is an option when dopamine agonists are ineffective or not tolerated. Surgery may also be the best choice for a woman with very large macroadenoma who wants to become pregnant because dopamine agonists must be discontinued during pregnancy, and during this time the adenoma may grow.",
"    </p>",
"    <p>",
"     During surgery, a small incision is made in the nose (",
"     <a class=\"graphic graphic_figure graphicRef75464 \" href=\"UTD.htm?43/36/44608\">",
"      figure 2",
"     </a>",
"     ). The incision is extended through the sphenoid sinus, allowing the surgeon to visualize and remove the adenoma. An endoscope (a thin, lighted tube with a camera) may be used during surgery and to ensure that the adenoma has been removed completely.",
"    </p>",
"    <p>",
"     Surgery can often reduce the blood prolactin concentration, sometimes to normal. This is more likely for a microadenoma than a macroadenoma. Even if the prolactin is lowered to within the normal range shortly after surgery, the level may become elevated in the next several years. Potential side effects of surgery include worsening of vision, hemorrhage, and meningitis, which are all uncommon, and hormonal deficiencies. The risk of complications is less when the procedure is performed by a surgeon who has had significant experience operating on the pituitary gland.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy can shrink prolactinomas and lower blood prolactin levels, but these effects usually take several years. Therefore, radiation is used only as secondary treatment of macroadenomas, to prevent regrowth of substantial residual tissue that could not be removed during surgery.",
"    </p>",
"    <p>",
"     The possible side effects of radiation treatment include transient nausea, fatigue, loss of taste and smell, and loss of hair at specific sites on the scalp. About half of those who receive pituitary radiation therapy develop pituitary hormone deficiencies within 10 years.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784920628\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530845774\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=see_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/10/38050?source=see_link\">",
"      Patient information: Panhypopituitarism (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530845792\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=see_link\">",
"      Management of lactotroph adenoma (prolactinoma) during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=see_link\">",
"      Incidentally discovered sellar masses (pituitary incidentalomas)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Disorders",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/pituitary.cfm\">",
"      www.hormone.org/public/pituitary.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pituitary Network Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.pituitary.org\">",
"      www.pituitary.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/0/25603?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_0_25603=[""].join("\n");
var outline_f25_0_25603=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH PROLACTIN OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF HIGH PROLACTIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           DIAGNOSIS OF PROLACTINOMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PROLACTINOMA TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           MEDICATIONS TO TREAT PROLACTINOMAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           SURGERY FOR PROLACTINOMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/19/18739\" title=\"figure 1\">",
"           Brain pituitary anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44608\" title=\"figure 2\">",
"           Pituitary surgery PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25604="Model of the TSHR";
var content_f25_0_25604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Model of the TSH receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The TSHR first appears on the plasma membrane as an intact holoreceptor. This model shows the seven transmembrane domains and the large extracellular domain. The extracellular domain consists of the nine leucine-rich repeats in the ectodomain, which is the major site of TSH binding, and the 50 amino acid cleaved region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009; 38:319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25604=[""].join("\n");
var outline_f25_0_25604=null;
var title_f25_0_25605="Interstitial pneumonitis CXR";
var content_f25_0_25605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1058px;\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Interstitial pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray in a patient with interstitial pneumonitis six months after liver transplantation. Diffuse, bilateral infiltrates and marked hypoxemia are consistent with Pneumocystis carinii pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25605=[""].join("\n");
var outline_f25_0_25605=null;
var title_f25_0_25606="Fetal membranes";
var content_f25_0_25606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal membranes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25606=[""].join("\n");
var outline_f25_0_25606=null;
var title_f25_0_25607="Involvement of the central nervous system with acute myeloid leukemia";
var content_f25_0_25607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Involvement of the central nervous system with acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25607/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/0/25607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the central nervous system (CNS) at the time of acute myeloid leukemia (AML) diagnosis is uncommon and routine evaluation is not recommended for asymptomatic patients. Likewise, clinically overt CNS involvement developing at some point later during the course of treatment is uncommon, perhaps related to the administration of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    as post-remission therapy.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, clinical presentation, diagnosis, and treatment of central nervous system involvement in patients with AML. The clinical features, diagnosis, classification, treatment, and overall prognosis of AML are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of CNS involvement in patients with AML is unknown, but is thought to be considerably less common than CNS involvement in both adults and children with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The incidence of CNS leukemia appears to have decreased since the incorporation of high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , which can penetrate into the CNS, during both initial induction and post-remission therapy. Prior to the use of cytarabine, meningeal disease developed in up to 20 percent of children and 16 percent of adults with AML. An estimate of the current incidence, based upon patients treated at the author's center or in large clinical trials, is less than 5 percent of patients with AML overall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS involvement may be more common in patients with AML with a prominent monocytic component (eg, acute monocytic leukemia or acute myelomonocytic leukemia), acute promyelocytic leukemia (APL) in systemic relapse, AML with inv(16) or chromosome 11 abnormality, those with hyperleukocytosis or an elevated lactate dehydrogenase, and patients under two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The expression of the adhesion molecule CD56 on the surface of leukemia blast cells has also been associated with CNS involvement. In addition, a traumatic lumbar puncture can introduce leukemic cells into the cerebrospinal fluid. It is unclear whether all of these risk factors still apply to patients treated with modern induction regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;How AML seeds the CNS is incompletely understood. Possible mechanisms include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extension from the bone marrow of the skull through bridging veins into the subarachnoid space",
"     </li>",
"     <li>",
"      Contamination of the cerebrospinal fluid (CSF) via the choroid plexus",
"     </li>",
"     <li>",
"      Invasion of the cerebral parenchyma by way of brain capillaries",
"     </li>",
"     <li>",
"      Direct infiltration of the leptomeninges through bony lesions of the skull",
"     </li>",
"     <li>",
"      Extension along nerve roots through the neural foramina and into the extradural space",
"     </li>",
"     <li>",
"      Hemorrhage into the CNS with blood containing blasts",
"     </li>",
"     <li>",
"      Iatrogenic introduction of blasts into the CSF at the time of lumbar puncture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CNS involvement may be asymptomatic, but the vast majority of asymptomatic patients do not have CNS involvement. Patients with the following symptoms should be evaluated further for possible CNS involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of increased intracranial pressure (constant headache, lethargy, or other mental changes)",
"     </li>",
"     <li>",
"      Cranial nerve palsies (most commonly cranial nerves III, V, VI, or VII)",
"     </li>",
"     <li>",
"      Symptoms of CNS hemorrhage (seizure, altered mental status, headache, neurological deficits)",
"     </li>",
"     <li>",
"      Symptoms of spinal cord compression (back pain, weakness, paresthesias, bladder dysfunction)",
"     </li>",
"     <li>",
"      Visual changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected CNS involvement should be evaluated with a lumbar puncture. Imaging studies are selected based upon the symptoms present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic lumbar puncture (LP) is not recommended for most patients with AML in the absence of CNS symptoms. Patients who should be considered for LP include those with symptoms suggesting CNS or ocular involvement and patients with acute promyelocytic leukemia (APL) in systemic relapse. In patients with APL, LP should be deferred until correction of the coagulopathy and, in the absence of symptoms, can usually be done after a second complete response is achieved. Even if the cerebrospinal fluid examination is negative, many experts recommend prophylactic treatment with intrathecal chemotherapy in patients with APL in second remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link&amp;anchor=H7#H7\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most serious complication of LP is cerebral herniation. Patients with the following clinical risk factors should have a computed tomography or magnetic resonance imaging scan of the head prior to LP to identify a possible mass lesion and other causes of increased intracranial pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mentation",
"     </li>",
"     <li>",
"      Focal neurologic signs",
"     </li>",
"     <li>",
"      Papilledema",
"     </li>",
"     <li>",
"      Seizure within the previous week",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every effort should be taken to avoid a traumatic lumbar puncture (LP) in patients with leukemia since this can lead to seeding of the leukemic blasts into the cerebrospinal fluid (CSF). In addition, there is concern about bleeding at the site of the LP with the potential for spinal cord impingement. Thus, the most experienced clinician available should perform the LP. Many centers now refer patients to radiology to have the procedures done with the aid of fluoroscopy, which will presumably decrease the incidence of local tissue injury, although data to this effect are lacking. Prior to LP, an effort should be made to correct any underlying coagulopathy and thrombocytopenia. We generally advise NOT performing an LP in patients with coagulation defects who are actively bleeding, have severe thrombocytopenia, or an INR &gt;1.4, without correcting the underlying abnormalities.",
"   </p>",
"   <p>",
"    There is some controversy and relatively little data about the minimal platelet count at which an LP can be performed safely. A large study in children demonstrated the safety of LPs at platelet counts",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL,",
"    </span>",
"    although a larger study by the same group suggested that the rates of traumatic and bloody taps were higher with lower platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Because of the concern about the introduction of circulating leukemia cells into the CSF, many centers administer intrathecal chemotherapy when LPs are done in patients at diagnosis or in relapse.",
"   </p>",
"   <p>",
"    It is difficult to extrapolate studies of children to adults because, unlike adults, most of the children were sedated during LP and because of physical differences between adults and children. Adults have a longer length of tissue that must be traversed to access the lumbar space. This general concern is magnified in the setting of obesity resulting in difficulties in the identification of the lumbar space. Based on an experience with 195 LPs in 66 patients with acute leukemia, it was suggested that a minimal platelet count of",
"    <span class=\"nowrap\">",
"     &gt;20,000/microL",
"    </span>",
"    is desirable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/10\">",
"     10",
"    </a>",
"    ]. These authors also noted an increase in the incidence of traumatic taps at lower platelet counts. A more recent review summarized the conundrum with the statement that \"40,000 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    is a 'safe' count for lumbar puncture. It is likely that lower platelet counts may also be safe but there is insufficient published evidence to make recommendations for lower levels at this stage\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A total of 8 to 15 mL of CSF is typically removed during routine LP. Up to 40 mL of fluid can safely be removed if needed. CSF should be sent for cell count and differential, protein and glucose concentrations, gram stain and culture (if infection is suspected), cytology (examination of stained cytospin slides) and flow cytometry or immunohistochemistry if needed to identify blasts that cannot be characterized with certainty by morphology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blast cell counts can vary from as few as 5 to",
"    <span class=\"nowrap\">",
"     &gt;1000/microL.",
"    </span>",
"    Most patients have moderate elevations in CSF protein with a moderate decrease in glucose. After the administration of intrathecal therapy, cytocentrifuge preparations can demonstrate reactive ependymal cells that, particularly if the leukocyte count is low, can be difficult to distinguish from leukemic cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies used to evaluate a patient with suspected CNS involvement of AML are selected based upon the symptoms. Mass lesions are unusual in patients with CNS involvement by AML, although they have been reported in patients with inv(16) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computed tomography of the brain may be used to evaluate for signs of stroke, tumor, hemorrhage, or infection. A subset of patients with symptoms concerning for increased intracranial pressure should also undergo computed tomography (CT) scan of the head prior to lumbar puncture. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) of the brain may be useful in excluding acute or subacute stroke and multifocal inflammatory lesions or when posterior fossa or vascular lesions are suspected. In patients with cranial nerve palsies, careful examination with thin sections of the course of the nerve roots is often helpful since the spinal fluid can be 'negative' in patients with isolated nerve involvement by leukemia.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) of the spine is indicated if there are concerns of spinal cord compression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CNS leukemia is usually easily confirmed by the identification of leukemic blasts on cytocentrifuge preparations of cerebrospinal fluid (CSF) after lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective studies comparing the use of intrathecal chemotherapy, systemic chemotherapy, and cranial radiation in patients with involvement of the central nervous system (CNS) with leukemia. Most of the evidence comes from clinical experience, retrospective analyses, and the extrapolation of data from other types of carcinomatous meningitis.",
"   </p>",
"   <p>",
"    For patients with involvement of the CNS with AML without signs of cranial nerve impairment, we suggest initial treatment with intrathecal chemotherapy rather than cranial radiation or systemic chemotherapy designed to penetrate the blood brain barrier. This preference is largely based upon the known ability of intrathecal chemotherapy to clear CSF involvement in most patients relatively quickly and a desire to avoid the potential acute and long-term complications of cranial irradiation. Radiation therapy is administered in addition to intrathecal chemotherapy for patients with cranial nerve involvement or with a tumor mass that impinges on important structures (eg, the spinal cord). Radiation therapy may also be given to patients who fail to respond completely to intrathecal chemotherapy.",
"   </p>",
"   <p>",
"    Patients who develop CNS and systemic relapse simultaneously require both CNS directed therapy and systemic chemotherapy. However, even when there is no evidence of systemic relapse, systemic disease will inevitably develop if systemic therapy is not delivered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intrathecal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal (IT) chemotherapy involves the injection of chemotherapy into the cerebrospinal fluid (CSF), either directly into the lateral ventricle through a subcutaneous reservoir and ventricular catheter (eg, an Ommaya reservoir) or into the lumbar thecal sac by lumbar puncture (LP). If possible, CSF pressures should be measured in patients receiving therapy in the lumbar space. As fluid is removed, many patients will have a rapid relief of symptoms that were related to increased intracranial pressure.",
"   </p>",
"   <p>",
"    An Ommaya reservoir is often placed, either because of difficulties in performing repeated lumbar punctures or because of concern that the CSF flow does not deliver sufficient amounts of the drug from the lumbar space to the entire CNS in some individuals. Typically, the flow of CSF is from the choroid plexus in the lateral ventricles down through the aqueduct to the base of the spine and then back up along the spinal cord until it is reabsorbed over the surface of the brain. Usually the dose of chemotherapy is reduced when given directly into the ventricles (",
"    <a class=\"graphic graphic_figure graphicRef65446 \" href=\"UTD.htm?20/48/21248\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There have been no prospective trials comparing chemotherapy agents in this setting. Either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/dose",
"    </span>",
"    when administered via an LP or 12 mg when administered via an Ommaya) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/dose",
"    </span>",
"    via LP or 40 mg via Ommaya) can be used as the initial IT chemotherapy in an adult with a planned crossover to the other agent in the event of refractory disease or relapse. Young children may need a dose calculated on body weight.",
"   </p>",
"   <p>",
"    A typical schedule includes treatment two to three times per week until the CSF has cleared of leukemic cells, generally occurring after a few injections. Treatment is then given at weekly intervals for two more doses, to be followed by monthly administration, for a total of one year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Intrathecal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, intrathecal (IT) chemotherapy can be administered into the CSF via an Ommaya reservoir or by lumbar puncture (LP). Once access to the CSF is attained, the administration of chemotherapy is essentially the same. The details of accessing an Ommaya reservoir are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Technique of CSF administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perhaps one of the most important details to consider when administering IT chemotherapy is the volume of chemotherapy to be instilled. Careful attention must be paid to minimizing any change in CSF volume. Thus, equivalent volumes of CSF (usually 7 to 10 mL) should be removed prior to instilling intrathecal (IT) chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) is administered at a fixed dose of 15 mg (12 mg if administered via Ommaya), initially two to three times weekly. A variety of neurologic complications can result from intrathecal MTX therapy. These include chemical (aseptic) meningitis, delayed leukoencephalopathy, acute encephalopathy, and transverse myelopathy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H10#H10\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'IT MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    has been used for intrathecal (IT) therapy in both a conventional formulation and encapsulated within liposomes (DepoCyt). Conventional cytarabine is more commonly used for patients with CNS leukemia while the encapsulated formulation is more commonly used for patients with solid tumor metastases. The conventional formulation has a half-life of less than four hours in the cerebrospinal fluid (CSF) and is entirely eliminated within one to two days. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    maintains a therapeutic concentration of cytarabine in the CSF for up to 28 days.",
"   </p>",
"   <p>",
"    Intrathecal (IT)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    is administered at a fixed dose of 50",
"    <span class=\"nowrap\">",
"     mg/dose",
"    </span>",
"    (40 mg if administered via Ommaya), initially two to three times weekly. If IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    is administered, the usual dose is 50 mg every two weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Liposomal cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     Liposomal cytarabine",
"    </a>",
"    is associated with a higher incidence of chemical meningitis. To minimize this complication,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is administered orally (4 mg twice daily) for a total of five days, preferably initiating therapy one day before and continuing for four days after liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    instillation. Alternatively, 40 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    can be added to the intrathecal injection. The liposomal cytarabine can be continued biweekly for three injections after the CSF is cleared of leukemic cells and then monthly for a year.",
"   </p>",
"   <p>",
"    Less common neurologic complications of both the conventional and liposomal formulations of IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    include encephalopathy, seizures, and myelopathy. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H28#H28\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Thio-TEPA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thio-TEPA is an alkylating agent that can also be administered into the CSF. It is more often used to treat carcinomatous meningitis, but may have benefit against CNS leukemia, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cranial radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, intrathecal chemotherapy is the preferred treatment for patients with AML and involvement of the CNS. We generally reserve radiation therapy (RT) for patients with cranial nerve involvement (CNI) or with a tumor mass that impinges on important structures (eg, the spinal cord) or for patients who fail to respond completely to intrathecal chemotherapy. Failure should be suspected if the CSF does not clear after four to five injections or if there are increasing numbers of blasts with or without worsening symptoms. Usually, an alternative intrathecal chemotherapy agent is attempted prior to adding external beam RT.",
"   </p>",
"   <p>",
"    To avoid excess myelosuppression, cranial rather than craniospinal RT is preferred. It is important that the treatment field include the base of the brain (typically down to C2) in order to adequately cover the foramina for the cranial nerves. Patients with lower extremity weakness, or bladder or bowel dysfunction, may receive lumbosacral spine irradiation in addition to cranial irradiation, particularly if an MRI demonstrates nerve involvement at this level.",
"   </p>",
"   <p>",
"    For patients with CNI or a tumor mass that impinges on important structures, we suggest initial RT rather than intrathecal chemotherapy alone. We initiate RT (18 to 25 Gy for the brain) as soon as CNI is suspected because the effect of intrathecal therapy alone on CNI is unpredictable and the chance of nerve recovery decreases substantially the longer the deficit has been present. Magnetic resonance imaging can be helpful in confirming the presence of CNI, but treatment should not be delayed if there is a strong clinical suspicion and the imaging study cannot be obtained expeditiously.",
"   </p>",
"   <p>",
"    While cranial radiation is an effective form of CNS-directed therapy, its use is limited by acute and long-term toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Major acute toxicities include myelosuppression, mucositis, and esophagitis. Long-term toxicities include secondary neoplasms, endocrine diseases, neurocognitive dysfunction, neurotoxic effects, and growth retardation in children. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy that penetrates the CNS can serve as an adjunct to intrathecal treatment. High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and the investigational drug diaziquone (AZQ) have been reported to achieve clearance of the CNS tumor load [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Unfortunately, the relapse rate, even after initially rapidly successful therapy, is high, either in association with bone marrow relapse or independently [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25607/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patients with ocular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct involvement of the eye or vitreous is uncommon in AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the complications of acute myeloid leukemia\", section on 'Ocular involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RESPONSE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the response to CNS-directed therapy is evaluated by cerebrospinal fluid (CSF) cytology at the time of each intrathecal chemotherapy treatment. Failure should be suspected if the CSF does not clear after four to five injections or if there are increasing numbers of blasts with or without worsening symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the central nervous system (CNS) at the time of acute myeloid leukemia (AML) diagnosis is uncommon and routine evaluation is not recommended for asymptomatic patients. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with CNS involvement may be asymptomatic, but most patients without symptoms do not have CNS involvement. If involvement is suspected, further evaluation should include a lumbar puncture. Imaging studies are selected based upon the symptoms present. However, the CNS can be a sanctuary site because of poor penetration of drugs administered intravenously or orally, and patients at high risk of having occult CNS involvement with leukemia should have a lumbar puncture at the time that they enter bone marrow remission. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of CNS leukemia is usually easily confirmed by the identification of leukemic blasts on cytocentrifuge preparations of cerebrospinal fluid (CSF) after lumbar puncture. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of CNS leukemia consists of the administration of intrathecal chemotherapy, with the addition of cranial radiation in patients who do not respond fully to chemotherapy, or in whom cranial nerve involvement (CNI) is present. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with involvement of the CNS with AML, we suggest initial treatment with intrathecal chemotherapy rather than cranial radiation or systemic chemotherapy designed to penetrate the blood brain barrier (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (12 to 15",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (40 to 50",
"      <span class=\"nowrap\">",
"       mg/dose),",
"      </span>",
"      depending upon the site of administration, can be used as the initial IT chemotherapy with a planned crossover to the other agent in the event of refractory disease or relapse. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Intrathecal chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cranial nerve involvement or a tumor mass that impinges on important structures, we suggest initial radiation therapy (18 to 25 Gy for the brain) followed by intrathecal chemotherapy rather than intrathecal chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Cranial radiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/1\">",
"      Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/2\">",
"      Peterson BA, Brunning RD, Bloomfield CD, et al. Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. Am J Med 1987; 83:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/3\">",
"      Stewart DJ, Keating MJ, McCredie KB, et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981; 47:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/4\">",
"      Wolk RW, Masse SR, Conklin R, Freireich EJ. The incidence of central nervous system leukemia in adults with acute leukemia. Cancer 1974; 33:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/5\">",
"      Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/6\">",
"      Shihadeh F, Reed V, Faderl S, et al. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 2012; 118:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/7\">",
"      Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/8\">",
"      Howard SC, Gajjar A, Ribeiro RC, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 2000; 284:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/9\">",
"      Howard SC, Gajjar AJ, Cheng C, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 2002; 288:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/10\">",
"      Vavricka SR, Walter RB, Irani S, et al. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol 2003; 82:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/11\">",
"      van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010; 148:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/12\">",
"      Sanders KE, Ha CS, Cortes-Franco JE, et al. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 2004; 100:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/13\">",
"      Castagnola C, Nozza A, Corso A, Bernasconi C. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997; 82:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/14\">",
"      Thompson CB, Sanders JE, Flournoy N, et al. The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia. Blood 1986; 67:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/15\">",
"      Mayadev JS, Douglas JG, Storer BE, et al. Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. Int J Radiat Oncol Biol Phys 2011; 80:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/16\">",
"      Frick J, Ritch PS, Hansen RM, Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25607/abstract/17\">",
"      Lee EJ, Van Echo DA, Egorin MJ, et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood 1986; 67:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4521 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25607=[""].join("\n");
var outline_f25_0_25607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intrathecal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Thio-TEPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cranial radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patients with ocular involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RESPONSE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/48/21248\" title=\"figure 1\">",
"      Ommaya",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=related_link\">",
"      Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25608="Levetiracetam: Pediatric drug information";
var content_f25_0_25608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levetiracetam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"    see \"Levetiracetam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/38/35429?source=see_link\">",
"    see \"Levetiracetam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Keppra XR&reg;;",
"     </li>",
"     <li>",
"      Keppra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levetiracetam&reg;;",
"     </li>",
"     <li>",
"      Ava-Levetiracetam;",
"     </li>",
"     <li>",
"      CO Levetiracetam;",
"     </li>",
"     <li>",
"      Dom-Levetiracetam;",
"     </li>",
"     <li>",
"      Keppra&reg;;",
"     </li>",
"     <li>",
"      PHL-Levetiracetam;",
"     </li>",
"     <li>",
"      PMS-Levetiracetam;",
"     </li>",
"     <li>",
"      PRO-Levetiracetam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2875435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Neonatal Seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Limited data available: 10 mg/kg/day divided twice daily; increase dosage by 10 mg/kg over 3 days to 30 mg/kg/day; additional increases up to 45-60 mg/kg/day have been used with persistent seizure activity or clinical EEG findings. Dosing based on an open-label study of 38 patients [n=19 premature neonates GA &lt;28 weeks (birth weight: 0.41-1.33 kg); n=6 premature neonates GA: 28-36 weeks (birth weight: 1.25-1.89 kg); n=13 term neonates] which reported a decrease in seizure frequency (ie, after 1 week of therapy, 30/38 patients were seizure-free). The investigators noted that patients with extensive intracerebral hemorrhage tended to be less responsive to therapy (Ramantani, 2011). For treatment of status epilepticus, loading doses of 20-30 mg/kg/dose have been used by some centers (Abend, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dose not established, limited data available: Initial: 10 mg/kg/day in 1-2 divided doses; increase daily by 10 mg/kg to 30 mg/kg/day (maximum reported dose: 60 mg/kg/day). Dosing based on two prospective, open-label studies [n=38 (n=19, GA: &lt;28 weeks; n=6, GA: 28-36 weeks, n=13 term); n=6, GA: &gt;30 weeks], a case series (n=3, 2 days to 3 months) which showed levetiracetam was effective at increasing seizure-free interval, and a report of pediatric neurologists' NICU experience (F&uuml;rwentsches, 2010; Ramantani, 2011; Shoemaker, 2007; Silverstein, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2875546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"      see \"Levetiracetam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching from oral to I.V. formulation, the total daily dose should be the same.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents &lt;16 years:",
"     <b>",
"      Note:",
"     </b>",
"     Use oral solution in infants and children &le;20 kg; either oral solution or immediate release tablets may be used in children and adolescents &gt;20 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Myoclonic seizures:",
"     </b>",
"     Children &ge;12 years and Adolescents &lt;16 years: Oral (immediate release: tablets or solution): Initial 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily, to the recommended dose of 1500 mg twice daily. Efficacy of doses other than 3000 mg/day has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Partial onset seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 1 to &lt;6 months: Oral (immediate release: solution): Initial: 7 mg/kg/dose twice daily; increase dosage every 2 weeks by 7 mg/kg/dose twice daily as tolerated, to the recommended dose of 21 mg/kg/dose twice daily; effectiveness of lower doses has not been established; during clinical trials, the mean daily dose was 35 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &ge;6 months and Children &lt;4 years: Oral [immediate release: solution or tablets (patient weight &gt;20 kg)]:  Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily, as tolerated, to the recommended dose of 25 mg/kg/dose twice daily; may reduce daily dose if not tolerated; during clinical trials, the mean daily dose was 47 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;4 years and Adolescents &lt;16 years: Oral (immediate release):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral solution: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily, as tolerated,  to a maximum of 30 mg/kg/dose twice daily; maximum daily dose: 3000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; may reduce daily dose if not tolerated; during clinical trials, the mean daily dose was 44 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablets: Fixed-dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     20-40 kg: Initial: 250 mg twice daily, increase every 2 weeks by 250 mg twice daily to the maximum recommended dose of 750 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;40 kg: Initial: 500 mg twice daily, increase every 2 weeks by 500 mg twice daily to the maximum recommended dose of 1500 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Primary generalized tonic-clonic seizures:",
"     </b>",
"     Children 6 to &lt;16 years: Oral [immediate release: solution or tablets (patient weight &gt;20kg)]: Initial: 10 mg/kg/dose  twice daily; increase dosage every 2 weeks by 10 mg/kg/dose given twice daily, to the recommended dose of 30 mg/kg/dose twice daily. Efficacy of doses other than 60 mg/kg/day has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Status epilepticus or acute repetitive seizure activity:",
"     </b>",
"     Limited data available: I.V.: Loading dose: 50 mg/kg/dose (maximum dose: 2500 mg); followed by I.V. or oral maintenance dosing determined by clinical response; reported I.V. maintenance dose: 30-55 mg/kg/day divided twice daily (Kirmani, 2009; Ng, 2010). Dosing based on a prospective study (n=30, 6 months to &lt;15 years), several retrospective observations, and case reports (n &gt;100; youngest patient: 1 day old; reported loading dose range: 6.5-89 mg/kg) (Abend, 2009; Gallentine, 2009; Goraya, 2008; Kirmani, 2009; Ng, 2010; Reiter, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Myoclonic seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Immediate release: 500 mg twice daily; may increase every 2 weeks by 500 mg/dose to the recommended dose of 1500 mg twice daily. Efficacy of doses other than 3000 mg/",
"     <b>",
"      day",
"     </b>",
"     has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose given twice daily, to the recommended dose of 1500 mg twice daily. Efficacy of doses other than 3000 mg/day has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Partial onset seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Immediate release: Initial: 500 mg twice daily; may increase every 2 weeks by 500 mg/dose given twice daily, if tolerated, to a maximum of 1500 mg twice daily. Doses &gt;3000 mg/",
"     <b>",
"      day",
"     </b>",
"     have been used in trials; however, there is no evidence of increased benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Extended release: Initial: 1000 mg once daily; may increase every 2 weeks by 1000 mg/day to a maximum of 3000 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: 500 mg twice daily; may increase every 2 weeks by 500 mg/dose given twice daily, if tolerated, to a maximum of 1500 mg twice daily. Oral doses &gt;3000 mg/day have been used in trials; however, there is no evidence of increased benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Primary generalized tonic-clonic seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Immediate release: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose given twice daily, to the recommended dose of 1500 mg twice daily. Efficacy of doses other than 3000 mg/",
"     <b>",
"      day",
"     </b>",
"     has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose given twice daily, to the recommended dose of 1500 mg twice daily. Efficacy of doses other than 3000 mg/",
"     <b>",
"      day",
"     </b>",
"     has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents &lt;16 years (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of normal dose every 24 hours; a supplemental dose after hemodialysis is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CAPD: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CRRT: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immediate release and I.V.  formulations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 500-1500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 500-1000 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 250-750 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 250-500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     End-stage renal disease patients using dialysis: 500-1000 mg every 24 hours; a supplemental dose of 250-500 mg following dialysis is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 500-1000 mg every 24 hours (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 250-750 mg every 12 hours (Arnoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Extended release tablets:",
"     </i>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1000-3000 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1000-2000 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 500-1500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 500-1000 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     End-stage renal disease patients using dialysis: Use immediate release product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in sodium chloride 0.54%: 1500 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in sodium chloride 0.75%: 1000 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in sodium chloride 0.82%: 500 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keppra&reg;: 100 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 100 mg/mL (5 mL, 118 mL [DSC], 472 mL, 473 mL, 480 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keppra&reg;: 100 mg/mL (480 mL) [dye free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keppra&reg;: 250 mg, 500 mg, 750 mg, 1000 mg [scored; gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keppra XR&reg;: 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152832.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152832.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2875547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to meals; swallow tablets (both immediate release and extended release) whole; do not break, crush, or chew. Oral solution should be administered with calibrated measuring device (not household teaspoon or tablespoon).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: Vials: Must be diluted prior to use. Premixed 100 mL bags:  Do not dilute further prior to use. Vials and premixed bags: Do not use if solution contains particulate matter or is discolored. Discard unused portions; does not contain preservative. pH: 5.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediatric patients &lt;16 years: Dilute dose from vial in NS to final concentration 15 mg/mL; infuse over 15 minutes (Ng, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;16 years and Adults: May use premix 100 mL bags or prepare dose from vials and dilute in 100 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR; infuse over 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Others have safely used a 1:1 dilution of drug from vial with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS infused over 5-6 minutes (with doses up to 60 mg/kg) through a peripheral site in patients 4-32 years of age (Wheless, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3269043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2875543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution, tablets: Store at 25&deg;C (77&deg;F), excursion permitted to 59&deg;F to 86&deg;F (15&deg;C to 30&deg;C), keep away from heat and light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premixed solution: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vials: Store intact vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); upon further dilution  in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR, admixed solution is stable for at least 24 hours in polyvinyl chloride bags stored at controlled room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2875436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral solution and immediate release tablets: Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;1 month and adults); adjunctive therapy in the treatment of juvenile myoclonic epilepsy (FDA approved in ages &ge;12 years) and myoclonic seizures (FDA approved in adults); adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (FDA approved in ages &ge;6 years and adults); has also been used for treatment of neonatal seizures, as adjunctive therapy for the treatment of generalized epilepsy with photosensitivity and Lennox-Gastaut syndrome, monotherapy for the treatment of various seizures types, treatment of tics in patients with Tourette syndrome, prophylaxis in pediatric migraine, and bipolar disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablets: Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;16 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;16 years and adults); adjunctive therapy in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy (FDA approved in ages &ge;16 years and adults); adjunctive therapy in the treatment of primary generalized tonic-clinic seizures in patients with idiopathic generalized epilepsy (FDA approved in ages &ge;16 years and adults); temporary use in patients in whom oral administration is not feasible (FDA approved in ages &ge;16 years and adults); has also been used for treatment of refractory status epilepticus or acute repetitive seizure activity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Keppra&reg; may be confused with Keflex&reg;, Keppra XR&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LevETIRAcetam may be confused with levOCARNitine, levofloxacin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Potential for dispensing errors between Keppra&reg; and Kaletra&reg; (lopinavir/ritonavir)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F187673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Behavioral symptoms (agitation, aggression, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis and personality disorder); confusion, dizziness, fatigue, mood swings, pain, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, pruritus, rash, skin discoloration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, constipation, gastroenteritis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck pain, paresthesia, reflexes increased, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, conjunctivitis, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, cough, influenza, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, flu-like syndrome, infection, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, anemia, catatonia, hematocrit decreased, hemoglobin decreased, hepatic failure, hepatitis, leukopenia, LFTs abnormal, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression), psychotic symptoms, red blood cells decreased, suicide attempt, suicide behavior, suicide ideation, thrombocytopenia, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2875438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levetiracetam or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2875550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and decrease dose in patients with renal dysfunction. Hematologic abnormalities (small but statistically significant decreases in RBC count, Hgb, Hct, WBC count, and neutrophils) may occur. Eosinophilia has also been reported. Isolated elevations in diastolic blood pressure measurements have been reported in infants and children 1 month to &lt;4 years of age receiving levetiracetam; however, no difference was noted in mean diastolic measurements of these patients vs placebo group. Similar effects have not been observed in older children and adults. In pediatric clinical trials, the most frequently reported adverse reactions in pediatric patients 4 to &lt;16 years of age were fatigue, aggression, nasal congestion, decreased appetite, and irritability and in younger pediatric patients (1 month to &lt;4 years of age) were somnolence and irritability; additionally, children may experience a higher frequency of certain adverse effects than adults, including the following: behavioral abnormalities (37.6% vs 13.3%), aggression/hostility (10% vs 2%),  vomiting (reported in children only, 15%), and cough (9% vs 2%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2875439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuropsychiatric adverse events including somnolence, fatigue, coordination difficulties (noted  in adults only), behavioral abnormalities (eg, aggression, agitation, anxiety, anger, hostility, irritability, depression) and psychotic symptoms (psychosis, hallucinations) may occur; incidence of behavioral abnormalities may be increased in children (37.6%) versus adults (13.3%); dosage reductions may be required. CNS effects may impair physical and mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, driving or operating heavy machinery); use caution when combining with other sedating drugs or ethanol; sedative effects may be potentiated. Do not abruptly discontinue therapy; withdraw gradually to lessen chance for increased seizure frequency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe dermatologic reactions, including toxic epidermal necrolysis and Stevens-Johnson syndrome, have been reported in children and adults; onset usually within ~2 weeks of treatment initiation, but may be delayed (&gt;4 months); discontinue drug if there are any signs of a hypersensitivity reaction or unspecified rash.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2875542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Immediate release: Food delays the rate, but not the extent of absorption (bioavailability is not affected); Extended release: Ingestion of a high fat, high caloric meal prior to administration results in a higher peak concentration and longer time to peak (median time to peak delayed by 2 hours)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Developmental toxicities were observed in animal reproduction studies. Levetiracetam crosses the placenta and can be detected in the neonate at birth. Concentrations in the umbical cord at delivery are similar to those in the maternal plasma. Serum concentrations of levetiracetam may decrease as pregnancy progresses; monitor carefully throughout pregnancy and postpartum (Tomson, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Two registries are available for women exposed to levetiracetam during pregnancy: Pregnant women may enroll themselves into the North American Antiepileptic Drug (AED) Pregnancy Registry  (888-233-2334 or",
"     <a href=\"file://www.mgh.harvard.edu/aed/\" target=\"_blank\">",
"      file://www.mgh.harvard.edu/aed/",
"     </a>",
"     ). The patient or healthcare provider may contact the UCB AED Pregnancy Registry (888-537-7734).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     The North American AED registry has published data collected from pregnant women taking levetiracetam monotherapy from 1997-2011 (n=450). Eleven major malformations were diagnosed within 12 weeks of birth. The relative risk of major malformations was not increased in comparison to women with epilepsy not taking AEDs (n=442; RR 2.2, 95% CI 0.8-6.4) or in comparison to women using lamotrigine monotherapy (n=1562; RR 1.2, 95% CI 0.6-2.5) (Hern&aacute;ndez-D&iacute;az, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2875551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Seizure frequency, duration, and severity; behavioral abnormalities and neuropsychiatric adverse events; renal function; CBC; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2875552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Therapeutic range and benefit of therapeutic drug monitoring have not been established; concentrations of 6-20 mg/L (35-120 micromol/L) were attained in adult study patients receiving doses of 1000-3000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2875544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism of the antiepileptic effects of levetiracetam is unknown. Several studies suggest one or more of the following central pharmacologic effects may be involved: Inhibition of voltage-dependent N-type calcium channels; facilitation of GABA-ergic inhibitory transmission through displacement of negative modulators; reversal of the inhibition of glycine currents; reduction of delayed rectifier potassium current; and/or binding to synaptic proteins which modulate neurotransmitter release.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2875545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Approximates volume of intracellular and extracellular water; V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;4 years:  0.63 &plusmn; 0.08  L/kg (Glauser, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years:  0.72 &plusmn; 0.12 L/kg (Pellock, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.5-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not extensive; 24% of dose is metabolized by enzymatic hydrolysis  of acetamide group (major metabolic pathway; hydrolysis occurs primarily in the blood; not cytochrome P450 dependent); two minor metabolites (one via hydroxylation of 2-oxo-pyrrolidine ring and one via opening of the 2-oxo-pyrrolidine ring in position 5) are also formed; metabolites are inactive and renally excreted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 100%; bioavailability of extended release tablets is similar to immediate release tablets; tablets, oral solution, and injection are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Increased in patients with renal dysfunction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;4 years: 5.3 &plusmn; 1.3 hours (Glauser, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-12 years: 6 &plusmn; 1.1 hours (Pellock, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: Fasting infants and children &lt;4 years: 1.4 &plusmn; 0.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Fasting adults and children: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 4 hours; median time to peak is 2 hours longer in the fed state",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 66% excreted in urine as unchanged drug and 27% as inactive metabolites; undergoes glomerular filtration and subsequent partial tubular reabsorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Correlated with creatinine clearance; clearance is decreased in patients with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: 1.23 mL/minute/kg (Glauser, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children 6 months-4 years: 1.57 mL/minute/kg (Glauser, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: 1.43 mL/min/kg; 30% to 40% higher than adults on a per kg basis (Pellock, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: Standard 4-hour treatment removes ~50% of the drug from the body; supplemental doses after dialysis are recommended",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2875548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/38/35429?source=see_link\">",
"      see \"Levetiracetam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of levetiracetam. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Avoid abrupt discontinuation after prolonged use (an increase in seizure activity may result). Inform healthcare provider immediately if any of the following symptoms occur: Extreme weakness, tiredness, or sleepiness; skin rash; problems walking or moving; unusual thoughts or behavior; hallucinations or delusions; changes in behavior or mood (such as aggression, agitation, anger, anxiety, apathy, mood swings, hostility, and irritability); or depression or thoughts of suicide (",
"     <b>",
"      Note:",
"     </b>",
"     Suicide, attempted suicide, and thoughts of suicide have been reported in patients receiving levetiracetam). Avoid ethanol (may increase adverse effects). Inform healthcare provider if taking other prescription and nonprescription medications, especially pain medications, sedatives, antihistamines, or hypnotics, which may increase adverse effects. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2875554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A recent, small, retrospective study used a rapid dosage titration of levetiracetam in 8 children, 19 months to 17 years of age (mean age: 8.6 years). Full maintenance doses of levetiracetam were achieved over a titration period of 2-14 days (mean: 10 days). The drug was effective and well-tolerated; however, one patient developed adverse behavioral effects. Further studies are needed before rapid titration of levetiracetam can be routinely recommended (Vaisleib, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In a preliminary report, levetiracetam-associated behavioral abnormalities were successfully treated with pyridoxine in 5 of 6 children, 2-10 years of age; further studies are needed before this treatment can be recommended (Miller, 2002). Levetiracetam- induced psychosis (including visual and auditory hallucinations and persecutive delusions) has been reported in pediatric patients (Kossoff, 2001).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abend NS, Monk HM, Licht DJ, et al, \"Intravenous Levetiracetam in Critically Ill Children With Status Epilepticus or Acute Repetitive Seizures,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2009, 10(4):505-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/19325512/pubmed\" id=\"19325512\" target=\"_blank\">",
"        19325512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007, 89, 165.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      F&uuml;rwentsches A, Bussmann C, Ramantani G, et al, \"Levetiracetam in the Treatment of Neonatal Seizures: A Pilot Study,\"",
"      <i>",
"       Seizure",
"      </i>",
"      , 2010, 19(3):185-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/20133173/pubmed\" id=\"20133173\" target=\"_blank\">",
"        20133173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallentine WB, Hunnicutt AS, and Husain AM, \"Levetiracetam in Children With Refractory Status Epilepticus,\"",
"      <i>",
"       Epilepsy Behav",
"      </i>",
"      , 2009, 14(1):215-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/18926926/pubmed\" id=\"18926926\" target=\"_blank\">",
"        18926926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, Mitchell WG, Weinstock A, et al, \"Pharmacokinetics of Levetiracetam in Infants and Young Children With Epilepsy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(6):1117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/17442002/pubmed\" id=\"17442002\" target=\"_blank\">",
"        17442002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goraya JS, Khurana DS, Valencia I, et al, \"Intravenous Levetiracetam in Children With Epilepsy,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2008, 38(3):177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/18279751/pubmed\" id=\"18279751\" target=\"_blank\">",
"        18279751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grosso S, Cordelli DM, Franzoni E, et al, \"Efficacy and Safety of Levetiracetam in Infants and Young Children With Refractory Epilepsy,\"",
"      <i>",
"       Seizure",
"      </i>",
"      , 2007, 16(4):345-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/17368928/pubmed\" id=\"17368928\" target=\"_blank\">",
"        17368928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirmani BF, Crisp ED, Kayani S, et al, \"Role of Intravenous Levetiracetam in Acute Seizure Management of Children,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2009, 41(1):37-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/19520272/pubmed\" id=\"19520272\" target=\"_blank\">",
"        19520272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kossoff EH, Bergey GK, Freeman JM, et al, \"Levetiracetam Psychosis in Children With Epilepsy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2001, 42(12):1611-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/11879376/pubmed\" id=\"11879376\" target=\"_blank\">",
"        11879376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandelbaum DE, Bunch M, Kugler SL, et al, \"Efficacy of Levetiracetam at 12 Months in Children Classified By Seizure Type, Cognitive Status, and Previous Anticonvulsant Drug Use,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2005, 20(7):590-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/16159526/pubmed\" id=\"16159526\" target=\"_blank\">",
"        16159526",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller GS, \"Pyridoxine Ameliorates Adverse Behavioral Effects of Levetiracetam in Children,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2002, 43(Suppl 7):S62.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng YT, Hastriter EV, Cardenas JF, et al, \"Intravenous Levetiracetam in Children With Seizures: A Prospective Safety Study,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2010, 25(5):551-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/20413804/pubmed\" id=\"20413804\" target=\"_blank\">",
"        20413804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Opp J, Tuxhorn I, May T, et al, \"Levetiracetam in Children With Refractory Epilepsy: A Multicenter Open Label Study in Germany,\"",
"      <i>",
"       Seizure",
"      </i>",
"      , 2005, 14(7):476-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/16182573/pubmed\" id=\"16182573\" target=\"_blank\">",
"        16182573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, Glauser TA, Bebin EM, et al, \"Pharmacokinetic Study of Levetiracetam in Children,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2001, 42(12):1574-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/11879369/pubmed\" id=\"11879369\" target=\"_blank\">",
"        11879369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry MS and Benatar M, \"Efficacy and Tolerability of Levetiracetam in Children Younger Than 4 Years: A Retrospective Review,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(6):1123-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/17430408/pubmed\" id=\"17430408\" target=\"_blank\">",
"        17430408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramantani G, Ikonomidou C, Walter B, et al, \"Levetiracetam: Safety and Efficacy in Neonatal Seizures,\"",
"      <i>",
"       Eur J Paediatr Neurol",
"      </i>",
"      , 2011, 15(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/21094062/pubmed\" id=\"21094062\" target=\"_blank\">",
"        21094062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiter PD, Huff AD, Knupp KG, et al, \"Intravenous Levetiracetam in the Management of Acute Seizures in Children,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2010, 43(2):117-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/20610122/pubmed\" id=\"20610122\" target=\"_blank\">",
"        20610122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shoemaker MT and Rotenberg JS, \"Levetiracetam for the Treatment of Neonatal Seizures,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2007, 22(1):95-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/17608315/pubmed\" id=\"17608315\" target=\"_blank\">",
"        17608315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein FS and Ferriero DM, \"Off-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2008, 39(2):77-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/18639748/pubmed\" id=\"18639748\" target=\"_blank\">",
"        18639748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaisleib II and Neft RA, \"Rapid Dosage Titration of Levetiracetam in Children,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(3):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/18294118/pubmed\" id=\"18294118\" target=\"_blank\">",
"        18294118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheless JW, Clarke D, Hovinga CA, et al, \"Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2009, 24(8):946-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/0/25608/abstract-text/19264738/pubmed\" id=\"19264738\" target=\"_blank\">",
"        19264738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12910 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25608=[""].join("\n");
var outline_f25_0_25608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187641\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187642\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875435\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443805\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875546\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187617\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187603\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874650\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875547\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3269043\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875543\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875436\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187675\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187673\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875550\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875439\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299586\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187612\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875542\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187614\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187626\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875551\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875552\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875544\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875545\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875548\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2875554\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12910|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=related_link\">",
"      Levetiracetam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/38/35429?source=related_link\">",
"      Levetiracetam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25609="Treatment and prevention of meningococcal infection";
var content_f25_0_25609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of meningococcal infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Michael Apicella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25609/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/0/25609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neisseria meningitidis is a common cause of community-acquired bacterial meningitis in children and adults in the United States and in many other countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Causative organisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link\">",
"     \"Epidemiology of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of meningococcal disease can be quite varied, ranging from transient fever and bacteremia to fulminant disease with death ensuing within hours of the onset of clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prevention of meningococcal infection will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The microbiology, pathobiology, epidemiology, and diagnosis of N. meningitidis infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72510344\">",
"    <span class=\"h2\">",
"     Meningococcal meningitis and sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and appropriate antibiotic treatment markedly improves the outcome of meningococcal infections. The current mortality rate of meningococcal sepsis in the United States is approximately 10 to 14 percent. The supportive data are presented below [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the importance of early antibiotic therapy, meningococcal infection should be considered in the differential diagnosis of any patient with the sudden onset of a febrile illness, especially those with petechiae",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningeal signs.",
"   </p>",
"   <p>",
"    The treatment of meningococcal sepsis is a complex medical problem, requiring a team approach by physicians skilled in intensive care medicine, infectious diseases, and the management of coagulopathies. Whenever possible, treatment should be given in a facility capable of administering the full range of medical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of meningococcal infection is seriously considered, no more than 30 minutes ideally should elapse before the administration of appropriate antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/5\">",
"     5",
"    </a>",
"    ]. Blood cultures should be drawn and antibiotic therapy should NOT be delayed while waiting for lumbar puncture to be performed. Pretreatment with antibiotics can substantially diminish the probability of a positive CSF culture but the diagnosis can often still be established from the pretreatment blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of meningococcal infection\", section on 'Pretreatment with antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     Empiric therapy in non-epidemic settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of suspected bacterial meningitis, patients should be treated empirically to cover the most likely pathogens while awaiting culture results. Empiric therapy for bacterial meningitis is presented separately; the following discussion will be limited to the treatment of meningococcal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Third-generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , should be used to treat suspected (eg, Gram stain with gram-negative diplococci) or culture-proven meningococcal infection prior to susceptibility results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/6\">",
"     6",
"    </a>",
"    ]. If the organism is proven to be penicillin-susceptible, the treatment can then be switched to penicillin, although it is also reasonable to continue therapy with a third-generation cephalosporin given the excellent efficacy, convenient dosing, and affordability of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Empiric treatment during epidemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of meningitis due to N. meningitidis are reported almost every year in sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef63287 \" href=\"UTD.htm?16/45/17110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/7\">",
"     7",
"    </a>",
"    ]. Since 1995, the World Health Organization has recommended empiric treatment with one or two intramuscular injections of long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    (oily suspension); however, the continuation of production of this drug is uncertain. Although alternative drugs with proven efficacy against N. meningitidis are available (eg, benzylpenicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and intravenous or intramuscular chloramphenicol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ), protocols requiring multiple injections are impractical during an epidemic.",
"   </p>",
"   <p>",
"    Thus, investigators in Niger evaluated the effectiveness of a single intramuscular dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    compared to oily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    in a randomized non-inferiority treatment trial in 503 individuals (441 under the age of 15) with suspected disease during the acute phase of a meningococcal meningitis epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/7\">",
"     7",
"    </a>",
"    ]. The treatment failure rate and case fatality rates at 72 hours were equivalent in both treatment groups (treatment failure 9 percent in both groups; case fatality rate 6 percent with ceftriaxone compared to 5 percent with chloramphenicol). Results were similar with confirmed meningitis caused by N. meningitidis. As a result, ceftriaxone should be considered as an alternative first-line treatment to chloramphenicol for epidemic meningococcal meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Cephalosporins",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, third-generation cephalosporins are the agents of choice for meningococcal infection prior to the availability of susceptibility testing and in patients with organisms that are not fully susceptible to penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Other situations in which cephalosporins may be the drugs of choice include cases in which access to skilled medical care is lacking (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    given twice daily would simplify dosing) and for patients with hypersensitivity reactions that preclude the use of penicillin. Third-generation cephalosporin are also a reasonable alternative to penicillin, even when the isolate is penicillin-susceptible, given the excellent efficacy, convenient dosing, and affordability of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Penicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal meningitis is well treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    if the isolate is proven to be penicillin-susceptible. Penicillin can be used if the isolate has a penicillin minimum inhibitory concentration (MIC) of &lt;0.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/6\">",
"     6",
"    </a>",
"    ]. For isolates with a penicillin MIC of 0.1 to 1.0",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    treatment with high-dose penicillin is effective, but a third-generation cephalosporin is preferred.",
"   </p>",
"   <p>",
"    Penicillin can be administered intravenously or intramuscularly. The usual dose is 300,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day with an upper limit of 24 million",
"    <span class=\"nowrap\">",
"     units/day.",
"    </span>",
"    A typical regimen in adults is 4 million units IV every four hours. Penicillin should NEVER be administered intrathecally because of the danger of severe neurotoxicity.",
"   </p>",
"   <p>",
"    The target CSF penicillin concentration for the treatment of meningitis is approximately 10 times the minimum inhibitory concentration (MIC) of the organism for that drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first reports of N. meningitidis resistant to penicillin appeared in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Relative resistance to penicillin is caused by a reduced binding affinity to specific penicillin-binding proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/13\">",
"     13",
"    </a>",
"    ]. Although such resistant meningococcal strains have been infrequently reported, clinicians should be alerted to the possibility of their occurrence in unexplained treatment failures or in cases of slowly resolving meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H3#H3\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Mechanisms of bacterial resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Chloramphenicol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV up to a maximum dose of 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    is an effective substitute for the penicillin-allergic patient. However, increasing resistance of meningococcal strains to chloramphenicol worldwide could change this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During epidemics of meningococcal disease in developing countries, a single intramuscular injection of long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    is often used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Empiric treatment during epidemics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy will vary based upon the severity of initial illness and the response of the patient. For cases in which the meningococcus is fully sensitive to antibiotics, seven days of therapy is usually sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/6,15\">",
"     6,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shorter regimens have been used during epidemics of meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/7,16,17\">",
"     7,16,17",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 510 patients in Niger, a single dose of intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      was as effective as a single dose of long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      in oil [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/7\">",
"       7",
"      </a>",
"      ]. The treatment failure rate was 9 percent at three days in both groups and the mortality rate was 5 to 6 percent.",
"     </li>",
"     <li>",
"      In a prospective study of adults in New Zealand, three days of 12 million units of benzyl penicillin was an effective regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment of shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular collapse and shock are frequent early manifestations of meningococcal disease, caused largely by the bacterial product, lipooligosaccharide (LOS), which is a potent toxin. LOS interacts with a variety of cells including macrophages, neutrophils, and endothelium to initiate the release of inflammatory mediators of the shock state [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. These mediators include tumor necrosis factor-alpha, interleukin-1 and -6, and interferon-gamma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the occurrence of shock is frequent in patients with meningococcal infection, therapy should be provided in a tertiary care medical facility whenever possible. If patients with meningococcal sepsis arrive at hospitals without such capabilities, they should be treated with appropriate antimicrobial therapy and promptly transferred to a facility with a fully staffed intensive care unit. Vasopressor and aggressive fluid replacement are integral components in the management of septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is indicated for the treatment of known or suspected pneumococcal meningitis in selected adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/24\">",
"     24",
"    </a>",
"    ], and in children with Haemophilus influenzae type b meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, dexamethasone is often given initially in adults and children with bacterial meningitis while awaiting microbiologic data. Dexamethasone has not been shown to be of benefit in meningococcal meningitis and should be discontinued once this diagnosis is established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible role of pharmacologic doses of glucocorticoids in septic shock and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in bacterial meningitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Protein C concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another possible therapy for meningococcal infection is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    . While the number of patients studied has been small, protein C concentrate appears to be beneficial in patients with meningococcal sepsis and purpura fulminans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/27\">",
"     27",
"    </a>",
"    ]. However, it is an orphan drug and is difficult to obtain.",
"    <br/>",
"    <br/>",
"    The rationale for using protein C concentrate was provided by the observation that protein C activation is impaired in children with severe meningococcal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/28\">",
"     28",
"    </a>",
"    ]. In another study, the plasma protein C concentrations in patients with purpura fulminans were significantly lower than in patients with meningococcemia who did not develop purpura fulminans or multiorgan failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized double-blind controlled trial of 40 children with purpura fulminans and meningococcal sepsis found that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    was safe and led to resolution of the coagulopathy, without significant change in the rate of amputation or mortality, although there were only 12 such events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/30\">",
"     30",
"    </a>",
"    ]. Suggestion of possible benefit was also provided in an open-label study of protein C therapy in 36 patients (mean age 12 years) with purpura fulminans in whom there was improved survival and fewer amputations than predicted from historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment of complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155902323\">",
"    <span class=\"h3\">",
"     Purpura fulminans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and aggressive intervention with antimicrobials and support of vascular perfusion are keys to prevention of purpura fulminans. As noted above, studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    have shown promising results in reversing purpura fulminans once the process has begun. However, protein C concentrate is an orphan drug and is difficult to obtain. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Protein C concentrate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At times, surgical debridement of lesions and skin grafting may be necessary. Deep necrosis of limbs or digits may necessitate amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is a serious complication of meningococcemia or meningococcal meningitis. While petechiae are common in meningococcal infection, increasing numbers of petechiae, confluent ecchymoses, persistently bleeding venipuncture sites, and bleeding gums despite adequate antimicrobial therapy and supportive care are suggestive of DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary treatment of DIC is directed at the underlying infection. Other possible therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other life-threatening complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other major life-threatening complications necessitating therapy include acute respiratory distress syndrome (ARDS), neurologic sequelae ranging from coma to diabetes insipidus, nosocomial pneumonia due to superinfection or aspiration during the obtunded state, and pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericarditis can be particularly insidious and appear as a manifestation during convalescence. Pericardiocentesis is indicated in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations of meningococcal infection\", section on 'Pericarditis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"     \"Purulent pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72511200\">",
"    <span class=\"h2\">",
"     Treatment of genitourinary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal urethritis can be indistinguishable from acute gonococcal urethritis (a more common cause of genitourinary infection) based on clinical features and Gram stain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Both pathogens are susceptible to similar antibacterial agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ), so the treatment of presumed gonorrhea infections will typically be effective for patients with meningococcal infections of the genitourinary tract (including urethritis, epididymitis, and pelvic inflammatory disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link&amp;anchor=H11#H11\">",
"     \"Infectious causes of dysuria in adult men\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before antibiotics and immune serum were available, the mortality of meningococcal infection was 70 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/34\">",
"     34",
"    </a>",
"    ]. The prognosis of meningococcal disease was dramatically improved by the introduction of sulfonamides in the late 1930s, followed by penicillin a decade later. Current reported mortality rates in the United States, as reported by the Centers for Disease Control and Prevention (CDC), are 10 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4\">",
"     4",
"    </a>",
"    ]. This mortality rate is similar to that in the late 1960s despite major advancements in supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major determinant of a good outcome is the administration of appropriate parenteral antibiotics with the first suspicion of possible meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The largest published experience involved 907 patients with proven meningococcal disease in Barcelona, Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/38\">",
"     38",
"    </a>",
"    ]. A prognostic model was derived from one cohort and then validated in a second. The overall mortality rate was 5.6 percent. Receipt of antibiotics prior to hospital admission was associated with a significant and marked reduction in mortality (odds ratio [OR], 0.09; 95% CI, 0.02-0.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have attempted to establish prognostic criteria for the outcome of meningococcal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/38,41\">",
"     38,41",
"    </a>",
"    ]. In the Spanish study cited above, the major significant independent predictors of death were a hemorrhagic diathesis, focal neurologic signs, and age &ge;60 years (OR 101, 25, and 10, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased case-fatality rate is associated with outbreaks compared to sporadic meningococcal disease. The magnitude of this difference was illustrated in a retrospective analysis of cases in the United States from 1994 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/42\">",
"     42",
"    </a>",
"    ]. Active surveillance identified 668 cases, of which 229 patients (69 clusters) met the criteria of either a community-based or organizational outbreak. After controlling for age, serogroup, and clinical presentation, outbreak-associated cases were associated with a significantly higher case-fatality rate than were sporadic cases (21 versus 11 percent; odds ratio, 3.3; 95% CI, 2.0-5.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods for the prevention of meningococcal infection include antimicrobial chemoprophylaxis following identification of an index case, use of droplet precautions, vaccination prior to exposure, and avoidance of risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'Risk factors for acquisition of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365639476\">",
"    <span class=\"h2\">",
"     Droplet precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Droplet precautions should be continued for 24 hours after institution of effective antibiotics in patients with suspected or confirmed Neisseria meningitidis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of infection control\", section on 'Droplet precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antimicrobial chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial chemoprophylaxis was first used successfully to abort the spread of meningococcal infection in the 1930s [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/43\">",
"     43",
"    </a>",
"    ]. The reported attack rate for close contacts of patients with sporadic meningococcal disease is approximately 1 in 250 persons exposed (0.4 percent), which is 500 to 800 times higher than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4,44\">",
"     4,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199038116\">",
"    <span class=\"h3\">",
"     Close contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis is indicated in close contacts of patients with meningococcal infection, and should be given as early as possible following the exposure. Although \"close contact\" has not been clearly defined, it generally refers to individuals who have had prolonged (&gt;8 hours) contact while in close proximity (&lt;3 ft) to the patient, or who have been directly exposed to the patient's oral secretions between one week before the onset of the patient's symptoms until 24 hours after initiation of appropriate antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Close contacts include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Household members, roommates, intimate contacts, individuals at a child-care center, young adults in dormitories, military recruits in training centers, and sitting next to an index patient for more than eight hours on an airplane.",
"     </li>",
"     <li>",
"      Individuals who have been exposed to oral secretions (eg, intimate kissing, mouth-to-mouth resuscitation, endotracheal intubation or endotracheal tube management).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    indicated if exposure to the index case is brief. This includes the majority of healthcare workers unless there is direct exposure to respiratory secretions (as with suctioning or intubation). The attack rate in healthcare workers at risk is increased compared to the general population, but the absolute increase in risk is very small and antimicrobial prophylaxis is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4,45\">",
"     4,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199038123\">",
"    <span class=\"h3\">",
"     Timing of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of secondary disease in contacts is highest immediately after the onset of disease in the index patient. Secondary cases usually occur within 10 days of the primary case, but longer intervals have been described in rare case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/46\">",
"     46",
"    </a>",
"    ]. Because the rate of secondary disease for close contacts is highest immediately following onset of disease in the index patient, antimicrobial chemoprophylaxis should be administered as early as possible (ideally &lt;24 hours after identification of the index patient). Conversely, chemoprophylaxis administered &gt;14 days after exposure to the index case is probably of limited or no value, and is therefore",
"    <strong>",
"     not",
"    </strong>",
"    recommended by the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4\">",
"     4",
"    </a>",
"    ]. Surveillance of close contacts receiving prophylaxis for at least 10 days following exposure, as well as counseling about the signs and symptoms of meningococcal infection, would ensure prompt treatment of any secondary cases that might arise. Oropharyngeal or nasopharyngeal cultures are not helpful in determining the need for chemoprophylaxis and might unnecessarily delay institution of this preventive measure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199038180\">",
"    <span class=\"h3\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens for antimicrobial prophylaxis have been defined by the CDC, and include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef51944 \" href=\"UTD.htm?42/54/43884\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/4,47\">",
"     4,47",
"    </a>",
"    ]. These recommendations are updated regularly based upon both changes in antimicrobial susceptibility and the development of more effective therapies.",
"   </p>",
"   <p>",
"    A 2006 meta-analysis of 24 randomized or quasi-randomized clinical trials evaluated the effectiveness of antibiotic treatments for eradication of nasopharyngeal carriage at one to two weeks after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/48\">",
"     48",
"    </a>",
"    ]. Clinical efficacy of eradication could not be assessed since there were no cases of disease following antibiotics or placebo. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      were significantly effective compared to placebo at one to two weeks. Rifampin continued to be effective for up to four weeks after therapy but resistant isolates were seen.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      after one to two weeks of follow-up. No trials have evaluated ceftriaxone against placebo and the drug must be administered parenterally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is not recommended for chemoprophylaxis of close contacts of individuals with meningococcal disease in some counties in North Dakota and Minnesota due to the emergence of ciprofloxacin-resistant isolates in three patients in these states in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are alternative agents for prophylaxis in these regions (",
"    <a class=\"graphic graphic_table graphicRef51944 \" href=\"UTD.htm?42/54/43884\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One case of pneumonia caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    -resistant N. meningitidis was detected in California in 2008 as part of the United States Active Bacterial Core surveillance system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/50\">",
"     50",
"    </a>",
"    ]. Isolated ciprofloxacin-resistant isolates have also been reported from a variety of countries around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. In Spain, 10 of 5300 isolates of N. meningitidis that were collected between 1999 and 2006 had reduced susceptibility to ciprofloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Nasopharyngeal carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carriage with N. meningitidis plays an important role in the transmission of the meningococcus and the development of invasive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link&amp;anchor=H5#H5\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\", section on 'Nasopharyngeal carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although testing for nasopharyngeal carriage is not typically performed, the meningococcus is occasionally detected on throat culture obtained for some other reason. The most common indication is pharyngitis, which is not caused by N. meningitidis.",
"   </p>",
"   <p>",
"    There are no recommendations for eradicating nasopharyngeal carriage in the community outside of an outbreak or a patient with invasive meningococcal disease. There are three problems with attempting to eliminate nasopharyngeal carriage in the community:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous loss and acquisition of carriage is common. This was illustrated in a study in military recruits in which 34 percent experienced one or more change in carrier status over time [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent colonization may occur after prophylaxis. In a community-wide prophylaxis program in a semi-closed kibbutz population in Israel, the colonization rate of group B meningococcus dropped from 4.6 percent at baseline to 0 percent at three weeks; it then rose to 0.5 percent at six months and 3.9 percent (similar to the baseline level) at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antimicrobial prophylaxis has no proven clinical efficacy outside of an outbreak. The meta-analysis cited above included trials in healthy carriers [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/48\">",
"       48",
"      </a>",
"      ]. Clinical efficacy of eradication could not be assessed since there were no cases of disease following antibiotics or placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with invasive meningococcal disease, systemic antimicrobial therapy with agents other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or other third-generation cephalosporins does not reliably eradicate nasopharyngeal carriage of N. meningitidis. Thus, if other drugs have been used for treatment, the index patient should receive chemoprophylaxis for eradication of nasopharyngeal carriage before discharge from the hospital in order to prevent subsequent transmission to close contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25609/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"     \"Patient information: Adult vaccines (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"     \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"     \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early diagnosis is critical in the treatment of patients with meningococcal disease. Meningococcal infection should be considered in the differential diagnosis of any patient with the sudden onset of a febrile illness, especially those with petechiae",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningeal signs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of meningococcal sepsis is seriously considered, no more than 30 minutes should ideally elapse before the administration of appropriate antibiotics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of suspected bacterial meningitis, patients should be treated empirically to cover the most likely pathogens while awaiting the growth, speciation, and susceptibilities of bacteria from the cerebrospinal fluid. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric therapy in non-epidemic settings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningococcal meningitis is well treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      once the isolate is proven to be penicillin-susceptible. The usual dose in adults is 4 million units IV every four hours. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Penicillin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a third-generation cephalosporin, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , for the treatment of suspected bacterial meningitis while awaiting speciation and susceptibility results, in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We also recommend a third-generation cephalosporin for meningococcal infections in patients with organisms that are not fully susceptible to penicillin and in those with other contraindications to penicillin. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cephalosporins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       Chloramphenicol",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV up to a maximum dose of 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      is an effective substitute for the penicillin-allergic patient. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chloramphenicol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasopressor and aggressive fluid replacement are integral components in the management of shock. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid therapy remains controversial in the treatment of meningococcal infection, including in patients with purpura fulminans and concomitant adrenal hemorrhage (Waterhouse-Friderichsen syndrome). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) is an extremely serious complication of meningococcemia or meningococcal meningitis. The primary treatment of DIC is supportive. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Disseminated intravascular coagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The methods for the prevention of meningococcal infection include antimicrobial chemoprophylaxis following identification of an index case, use of droplet precautions for 24 hours after institution of effective antibiotics in patients with suspected or confirmed Neisseria meningitidis infection, vaccination prior to exposure, and avoidance of risk factors. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the rate of secondary disease for close contacts is highest immediately following onset of disease in the index patient, antimicrobial chemoprophylaxis should be administered as early as possible (ideally &lt;24 hours after identification of the index patient). Conversely, chemoprophylaxis administered &gt;14 days after exposure to the index case is probably of limited or no value, and is therefore",
"      <strong>",
"       not",
"      </strong>",
"      recommended. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antimicrobial chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regimens for antimicrobial prophylaxis have been defined by the United States Centers for Disease Control and Prevention, and include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef51944 \" href=\"UTD.htm?42/54/43884\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antimicrobial chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with invasive meningococcal disease, systemic antimicrobial therapy with agents other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or other third-generation cephalosporins does not reliably eradicate nasopharyngeal carriage of N. meningitidis. Thus, if other drugs have been used for treatment, the index patient should receive chemoprophylaxis for eradication of nasopharyngeal carriage before discharge from the hospital in order to prevent subsequent transmission to close contacts. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Nasopharyngeal carriage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meningococcal vaccines are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/1\">",
"      Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/2\">",
"      Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 2006; 355:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/3\">",
"      Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/4\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     Tunkel AR, Scheld WM. Acute meningitis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1083.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/6\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/7\">",
"      Nathan N, Borel T, Djibo A, et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 2005; 366:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/8\">",
"      Grubbauer HM, Dornbusch HJ, Dittrich P, et al. Ceftriaxone monotherapy for bacterial meningitis in children. Chemotherapy 1990; 36:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/9\">",
"      Marhoum el Filali K, Noun M, Chakib A, et al. Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults. Eur J Clin Microbiol Infect Dis 1993; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/10\">",
"      Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/11\">",
"      Sprott MS, Kearns AM, Field JM. Penicillin-insensitive Neisseria meningitidis. Lancet 1988; 1:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/12\">",
"      Mendelman PM, Campos J, Chaffin DO, et al. Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin-binding protein 3. Antimicrob Agents Chemother 1988; 32:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/13\">",
"      S&aacute;ez-Nieto JA, Lujan R, Berr&oacute;n S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992; 14:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/14\">",
"      Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998; 339:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/15\">",
"      Lin TY, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. JAMA 1985; 253:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/16\">",
"      Chippaux JP, Soula G, Campagne G, Rey M. [Optimizing the response to epidemics of meningococcal meningitis: report of a workshop of experts at CERMES (Niamey, Niger, 12th to 14th January 1998)]. Sante 1998; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/17\">",
"      Ellis-Pegler R, Galler L, Roberts S, et al. Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis 2003; 37:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/18\">",
"      Waage A, Brandtzaeg P, Halstensen A, et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/19\">",
"      Brandtzaeg P, Ovsteb&oslash;o R, Kierulf P. Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 1992; 166:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/20\">",
"      Girardin E, Grau GE, Dayer JM, et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/21\">",
"      Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/22\">",
"      Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/23\">",
"      Brandtzaeg P, Bryn K, Kierulf P, et al. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 1992; 89:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/24\">",
"      de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/25\">",
"      Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; :CD004405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/26\">",
"      Belsey MA, Hoffpauir CW, Smith MH. Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results. Pediatrics 1969; 44:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/27\">",
"      Alberio L, L&auml;mmle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 2001; 32:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/28\">",
"      Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/29\">",
"      White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/30\">",
"      de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/31\">",
"      Wheeler JS, Anderson BJ, De Chalain TM. Surgical interventions in children with meningococcal purpura fulminans--a review of 117 procedures in 21 children. J Pediatr Surg 2003; 38:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/32\">",
"      Katz AR, Chasnoff R, Komeya A, Lee MV. Neisseria meningitidis urethritis: a case report highlighting clinical similarities to and epidemiological differences from gonococcal urethritis. Sex Transm Dis 2011; 38:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/33\">",
"      Conde-Glez CJ, Calder&oacute;n E. Urogenital infection due to meningococcus in men and women. Sex Transm Dis 1991; 18:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/34\">",
"      Flexner S. THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS. J Exp Med 1913; 17:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/35\">",
"      Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ 2003; 327:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/36\">",
"      Andersen BM. Mortality in meningococcal infections. Scand J Infect Dis 1978; 10:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/37\">",
"      Wolf RE, Birbara CA. Meningococcal infections at an army training center. Am J Med 1968; 44:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/38\">",
"      Barquet N, Domingo P, Cayl&agrave; JA, et al. Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group. JAMA 1997; 278:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/39\">",
"      Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992; 305:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/40\">",
"      Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ 1992; 305:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/41\">",
"      Kornelisse RF, Hazelzet JA, Hop WC, et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 1997; 25:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/42\">",
"      Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006; 43:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/43\">",
"      Schwentker FF, Gelman S, Long PH. Landmark article April 24, 1937. The treatment of meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, Sidney Gelman, and Perrin H. Long. JAMA 1984; 251:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/44\">",
"      Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976; 134:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/45\">",
"      Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in health-care workers. Lancet 2000; 356:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/46\">",
"      Neal KR, Nguyen-van-Tam JS, Slack RC, et al. Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report. Epidemiol Infect 1999; 123:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/47\">",
"      Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 1988; 1:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/48\">",
"      Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2006; :CD004785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Emergence of fluoroquinolone-resistant Neisseria meningitidis--Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 2008; 57:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/50\">",
"      Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009; 360:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/51\">",
"      Enr&iacute;quez R, Abad R, Salcedo C, et al. Fluoroquinolone resistance in Neisseria meningitidis in Spain. J Antimicrob Chemother 2008; 61:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/52\">",
"      Andersen J, Berthelsen L, Bech Jensen B, Lind I. Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. Epidemiol Infect 1998; 121:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25609/abstract/53\">",
"      Block C, Raz R, Frasch CE, et al. Re-emergence of meningococcal carriage on three-year follow-up of a kibbutz population after whole-community chemoprophylaxis. Eur J Clin Microbiol Infect Dis 1993; 12:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1274 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25609=[""].join("\n");
var outline_f25_0_25609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72510344\">",
"      Meningococcal meningitis and sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric therapy in non-epidemic settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Empiric treatment during epidemics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Penicillin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chloramphenicol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment of shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Protein C concentrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H155902323\">",
"      - Purpura fulminans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other life-threatening complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72511200\">",
"      Treatment of genitourinary infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365639476\">",
"      Droplet precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antimicrobial chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H199038116\">",
"      - Close contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H199038123\">",
"      - Timing of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H199038180\">",
"      - Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Nasopharyngeal carriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1274|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/45/17110\" title=\"figure 1\">",
"      Meningitis belt map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1274|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/54/43884\" title=\"table 1\">",
"      Chemoprophylaxis N meningitidis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=related_link\">",
"      Microbiology and pathobiology of Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=related_link\">",
"      Purulent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25610="Management of atrial septal defects in adults";
var content_f25_0_25610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of atrial septal defects in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/0/25610/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/0/25610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septal defect (ASD) is the most common congenital lesion in adults after bicuspid aortic valve. Although the defect is often asymptomatic until adulthood, potential complications of an undetected ASD include atrial arrhythmias, paradoxical embolization, cerebral abscess, right ventricular failure, and pulmonary hypertension that can become irreversible and lead to right-to-left shunting (Eisenmenger syndrome).",
"   </p>",
"   <p>",
"    This topic will review the role of medical and surgical therapy and percutaneous repair in adults with ASDs.",
"   </p>",
"   <p>",
"    The pathophysiology, anatomy, natural history, and clinical features of ASDs in adults, the identification and assessment of ASDs, and issues related to ASDs in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ASDs less than 8 mm in diameter close spontaneously in infants. However, spontaneous closure is unusual in children and adults. The natural history of secundum ASDs in children was illustrated in a series of 104 patients (average age at diagnosis was 4.5 years) who had an isolated ASD &gt;3 mm in size; serial echocardiograms were performed at an interval of more than six months between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/1\">",
"     1",
"    </a>",
"    ]. Spontaneous closure of the ASD occurred in only four patients (4 percent), while ASD diameter increased in 65 percent; 30 percent of patients had more than a &gt;50 percent increase in diameter and 12 percent had an increase to &gt;20 mm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link&amp;anchor=H2#H2\">",
"     \"Management and outcome of isolated atrial septal defects in children\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in left-to-right shunting with age in many patients with uncorrected moderate to large ASDs increases the likelihood of developing symptoms. It is estimated that most patients with an ASD and significant shunt flow (ie, pulmonary to systemic flow",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    more than 2:1) will be symptomatic and require closure of the defect by the age of 40. However, many patients become symptomatic and require closure at older ages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26805166\">",
"     'RV volume overload'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Increasing defect size also has important implications for treatment, since there is the potential that ASD enlargement will be sufficient to preclude the use of percutaneous transcatheter closure with certain devices. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Percutaneous closure of secundum ASDs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DEFECT CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indication for ASD closure is the presence of a significant shunt as evidenced by right heart volume overload with or without symptoms (exercise intolerance, fatigue, dyspnea, heart failure, paradoxical emboli, arrhythmias).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26805166\">",
"    <span class=\"h2\">",
"     RV volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Larger ASDs impose a greater hemodynamic burden on the right ventricle than smaller ASDs, and therefore present a more compelling rationale for repair. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease guidelines recommend closure (surgical or percutaneous) of an ASD for right atrial and right ventricular enlargement with or without symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/9\">",
"     9",
"    </a>",
"    ]. Similarly, the 2009 Canadian Cardiovascular Society guidelines and the 2010 European Society of Cardiology guidelines recommend ASD closure in the presence of right ventricular volume overload [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the generally accepted clinical standard was to repair ASDs with a significant measured shunt, as defined by the pulmonary-to-systemic flow ratio",
"    <span class=\"nowrap\">",
"     (Qp/Qs).",
"    </span>",
"    In the absence of pulmonary hypertension,",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    is closely correlated with the size of the ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the gold standard for",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    measurement is cardiac catheterization, calculation of",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    ratio is not required to determine candidacy for ASD closure and hemodynamic cardiac catheterization is not routinely indicated before ASD closure. Doppler echocardiography can be used in select circumstances to estimate the",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    once the existence of an acceptable correlation between echocardiographic and catheterization laboratory estimates of shunt flow has been established for an individual laboratory. There are no systematic data that identify a threshold value for",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    for repair of an ASD. A",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    &gt;2:1 is a well-established indication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/13\">",
"     13",
"    </a>",
"    ], but many authors have advocated lower thresholds of 1.7:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2\">",
"     2",
"    </a>",
"    ] or even 1.5:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link&amp;anchor=H15#H15\">",
"     \"Identification and assessment of atrial septal defects in adults\", section on 'Estimation of shunt flow ratio and volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous closure of ASDs is unusual in children and adults and defect size and shunt flow can increase over time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\", section on 'Natural history'",
"    </a>",
"    .) As a result, asymptomatic patients who do not meet standard criteria for closure of the defect may do so at a later time. For this reason, serial clinical follow-up and echocardiography are typically performed every two to three years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link&amp;anchor=H16#H16\">",
"     \"Identification and assessment of atrial septal defects in adults\", section on 'Doppler echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with ASDs are asymptomatic. Clinical manifestations that may develop in patients with ASDs include exercise intolerance, fatigue, dyspnea, arrhythmias, and overt heart failure. Paradoxical embolization is a potential risk regardless of ASD size. In a series of 481 patients with a secundum ASD who were seen between 1957 and 1976 and who underwent surgery before the age of 40, more than one-half had symptoms of dyspnea and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial tachyarrhythmias, particularly atrial fibrillation and atrial flutter occur in approximately 20 percent of adult ASD patients and are often the presenting symptom. However, these arrhythmias alone are probably not an indication for defect closure since the incidence may not be significantly reduced after surgery. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Atrial tachyarrhythmias'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Paradoxical embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a PFO or, much less often, an ASD with a right-to-left shunt are at risk for stroke due to paradoxical embolization (stroke, transient ischemic attack, or peripheral emboli). Right-to-left shunting occurs in some patients at rest and in others during transient increases in right-sided pressure (eg, with a Valsalva maneuver or coughing). In addition, right-to-left shunting can be persistent in the presence of severe pulmonary hypertension.",
"   </p>",
"   <p>",
"    The relative frequency of PFO and ASD was evaluated in a series of 103 patients (mean age 52 years) with presumed paradoxical embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/16\">",
"     16",
"    </a>",
"    ]. A PFO alone was present in 81, an ASD alone in 12, and both a PFO and ASD in 10.",
"   </p>",
"   <p>",
"    Issues related to the causes, diagnosis, and management of paradoxical embolization are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease guideline indicating that closure of an ASD is reasonable in the presence of a paradoxical embolism, although data are limited. As discussed separately, the role of defect closure compared to medical therapy for the prevention of recurrent stroke in patients with patent foramen ovale is not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26805546\">",
"    <span class=\"h3\">",
"     Orthodeoxia-platypnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orthodeoxia-platypnea syndrome is a rare disorder characterized by both arterial desaturation (orthodeoxia) and dyspnea (platypnea) in the upright position with improvement in the supine position. This syndrome has been described with ASD, PFO, as well as with intrapulmonary shunting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link&amp;anchor=H13#H13\">",
"     \"Patent foramen ovale\", section on 'Platypnea-orthodeoxia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline indicating that ASD closure is reasonable to treat documented orthodeoxia-platypnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fixed pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe fixed pulmonary hypertension, defined as a pulmonary vascular resistance greater than 1200 dyne sec cm",
"    <sup>",
"     -5",
"    </sup>",
"    m2 (15 Wood units) (normal &lt;120 dyne sec cm",
"    <sup>",
"     -5",
"    </sup>",
"    m2 [1.5 Wood units]) identifies a group of patients with reduced expected survival, regardless of the mode of therapy. It has been suggested that, in this setting, maintenance of inter-atrial communication provides a mechanism to decompress the right ventricle and this may be advantageous.",
"   </p>",
"   <p>",
"    The outcomes in such patients were evaluated in a large retrospective study in which 6 percent of 702 patients with an isolated ASD (secundum or sinus venosus type) had pulmonary vascular obstructive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/19\">",
"     19",
"    </a>",
"    ]. Among these 40 patients (mean age 46 years, 34 [85 percent] of whom were women), 26 underwent surgery and 14 were treated medically. The patients with severe pulmonary hypertension did poorly: at a mean follow-up of 12 years, all four surgically treated patients died; six of nine medically treated patients died; and the remaining three patients had progression of symptoms. Survival after surgery was much better (19 of 22) in patients with less severe pulmonary hypertension.",
"   </p>",
"   <p>",
"    However, the development of percutaneous closure techniques as well as improvements in the medical management of patients with pulmonary vascular disease has reduced the risks associated with ASD repair in this setting. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pulmonary hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The syndrome of pulmonary hypertension and right-to-left shunting (Eisenmenger syndrome) presents a number of other clinical concerns, including thrombosis, bleeding, increased risk of fetal and maternal mortality during pregnancy, and consideration for lung or heart-lung transplantation. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Scuba diving and altitude exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with small ASDs who are treated medically may be at increased risk for complications when they experience high or low atmospheric pressure as with scuba diving or high-altitude climbing. Scuba diving in patients with an ASD has been associated with increased risks of decompression illness and paradoxical emboli, while high-altitude exposure has been associated with risk of increased right-to-left shunting and oxygen desaturation. Among patients with an ASD (or other intracardiac shunt), scuba diving is generally contraindicated, while consultation with a cardiologist specializing in congenital heart defects is recommended before altitude exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H15#H15\">",
"     \"High altitude, air travel, and heart disease\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19741008\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an ASD may have problems during pregnancy, including arrhythmias, thromboembolism, and bleeding. However, there is no available evidence to suggest that pregnant patients should be managed differently from nonpregnant patients with respect to the indications for ASD closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/21\">",
"     21",
"    </a>",
"    ]. Issues related to pregnancy in women with an ASD are discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURGICAL CLOSURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional surgical approach for ASD repair has been a median sternotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22\">",
"     22",
"    </a>",
"    ], although minimally invasive approaches are now available. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Minimally invasive surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pericardial or Dacron patch closure of a secundum ASD is the surgical treatment of choice. Primary closure of the defect is generally not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22\">",
"     22",
"    </a>",
"    ]. Some surgeons advocate cannulation of the superior vena cava rather than the right atrium to reduce the incidence of postoperative arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraoperative TEE demonstrates additional defects, the adequacy of repair, and detects residual flow across the surgical site (",
"    <a class=\"graphic graphic_movie graphicRef54350 \" href=\"UTD.htm?40/32/41487\">",
"     movie 1",
"    </a>",
"    ). TEE also excludes the presence of tricuspid or mitral regurgitation, either of which can occur if tension from repair on the valvular annulus distorts the geometry of leaflet coaptation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8433827\">",
"    <span class=\"h2\">",
"     Associated defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cleft mitral valve is common in patients with ostium primum ASDs. Such clefts should typically be repaired at the time of surgery to avoid the need for a second operation. Other associated congenital anomalies also may require correction, especially in the setting of ostium primum ASDs. Thus, complete echocardiographic assessment prior to surgery is mandatory in all types of ASDs. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Ostium primum ASD'",
"    </a>",
"    below.) Sinus venosus ASDs are usually associated with anomalous pulmonary veins, which are best visualized by transesophageal echocardiography (TEE), computed tomography (CT) or cardiovascular magnetic resonance (CMR). Coronary sinus ASDs are often associated with left-sided SVC, which can be visualized by various imaging techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Postoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of postoperative considerations in patients who have undergone ASD repair.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transthoracic echocardiography should be performed to evaluate the adequacy of the repair and document the expected postoperative decrease in right atrial and right ventricular size and pulmonary pressures (",
"      <a class=\"graphic graphic_movie graphicRef54350 \" href=\"UTD.htm?40/32/41487\">",
"       movie 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Beta blockers, if not contraindicated, should be given to reduce the risk of postoperative AF. The benefit is seen when therapy is begun prior to or immediately after surgery and is independent of the agent or dose used. The optimal duration of therapy is uncertain, but beta blockers are often continued until the first postoperative visit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H13#H13\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Prevention of AF and complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticoagulation is often recommended for several months after surgery in adults undergoing ASD closure because of concern about postoperative AF and the small chance that thrombus can attach to the atrial septal patch. Long-term periodic follow-up is indicated because of the late occurrence of AF, atrial flutter and stroke, particularly adults over age 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/3,14\">",
"       3,14",
"      </a>",
"      ]. Patients with preoperative atrial tachyarrhythmias are at particular risk.",
"     </li>",
"     <li>",
"      Sinus node dysfunction and prolonged atrioventricular conduction have been reported both before and after surgery. Surgery can damage the AV node or its blood supply, and some patients require a pacemaker in the postoperative period. In addition, there may be a small increase in the lifetime risk for the development of sinus and AV nodal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of ASD repair is influenced by the type of ASD, the patient's age, the size of the defect, and the presence or absence of pulmonary hypertension. The following discussion is organized in part according to the different types of ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ostium secundum ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ostium secundum ASDs account for approximately 70 percent of ASDs. Surgical and medical therapy were compared in a randomized trial of 473 adults with secundum ASD over age 40 (mean age 51) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2\">",
"     2",
"    </a>",
"    ]. After a median follow-up of 7.3 years, the following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The composite primary end point (death, pulmonary embolism, major arrhythmias, stroke, recurrent pulmonary infection, functional class deterioration, or heart failure) occurred more frequently with medical than surgical therapy (21 versus 11 percent, hazard ratio 2.0). This difference was almost entirely due to a higher incidence of recurrent pneumonia among the medically treated patients.",
"     </li>",
"     <li>",
"      The overall mortality rate was not statistically different with medical versus surgical therapy (5.8 versus 4.3 percent), but there was a nonsignificant trend toward a higher sudden death rate with medical treatment (2.9 versus 0.9 percent).",
"     </li>",
"     <li>",
"      On multivariate analysis (adjusted for age at entry, mean pulmonary artery systolic pressure &gt;35 mmHg, previous atrial tachyarrhythmia, and cardiac index &lt;3.5",
"      <span class=\"nowrap\">",
"       L/m2),",
"      </span>",
"      there was a significantly higher mortality with medical management (hazard ratio 4.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical management also appeared to be beneficial in an earlier retrospective study of 179 patients diagnosed with ASD after the age of 40 years, 91 percent of whom had ostium secundum defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/3\">",
"     3",
"    </a>",
"    ]. On multivariate analysis, surgical closure was associated with a significant reduction in 10-year mortality after adjusting for baseline characteristics (5 versus 16 percent with medical therapy, adjusted relative risk 0.31). In addition, there was a much lower likelihood of functional deterioration compared with the medical group (11 versus 34 percent, adjusted relative risk 0.21) and a higher likelihood of improved functional status (32 versus 3 percent). Improvement in functional status after surgery was most common (69 percent) in patients with New York Heart Association (NYHA) functional class III or IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptomatic relief and better than predicted survival compared to medical therapy have also been described in patients who undergo surgery at 60 years of age or older [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ostium primum ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ostium primum ASDs are typically larger than ostium secundum ASDs. However, the long-term outcome for both groups of patients appears to be similar when adjusted for defect size. The generally good outcome after surgery was illustrated in a review of 33 adults with ostium primum defects who underwent surgical closure at a mean age of 42 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/5\">",
"     5",
"    </a>",
"    ]. After a mean follow-up of 5.3 years, 85 percent were alive, asymptomatic, and in functional NYHA class I (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). All deaths occurred late after surgery and none appeared related to the ASD or its repair. The presence of increasing age, symptoms, atrial arrhythmias, mitral regurgitation, or moderately elevated pulmonary vascular resistance did not predict mortality or surgical complications.",
"   </p>",
"   <p>",
"    Ostium primum defects are frequently associated with a cleft anterior mitral valve leaflet. A cleft leaflet, even if not severely regurgitant at the time of ASD closure should be repaired to avoid the need for a second operation. Thus, complete echocardiographic assessment prior to surgery is mandatory in ostium primum defects to assess the mitral valve and detect this commonly associated abnormality. Ostium primum ASDs may also be associated with tricuspid valve abnormalities, left ventricular outflow tract obstruction, ventricular septal defects, and a more extensive defect involving the ventricular septum (atrioventricular septal defect). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/52/14154?source=see_link&amp;anchor=H26371603#H26371603\">",
"     \"Ventricular septal defect in adults\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sinus venosus ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus venosus ASD (SV-ASD) of SVC and IVC types are frequently accompanied by partial anomalous pulmonary venous drainage. The surgical outcome of patients with an SV-ASD is similar to that of patients with other types of isolated ASD when operations are performed by experienced congenital heart surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible difference in natural history was suggested in a report of 169 patients: 31 had a sinus venosus ASD and 138 had a secundum ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/25\">",
"     25",
"    </a>",
"    ]. The patients with a sinus venosus defect were more likely to have pulmonary hypertension (26 versus 9 percent) and elevated pulmonary vascular resistance (16 versus 4 percent). In addition, elevated pulmonary vascular resistance occurred at a younger age in those with a sinus venosus ASD.",
"   </p>",
"   <p>",
"    These observations suggest that patients with sinus venosus ASDs should be monitored more closely for the development of pulmonary hypertension and may require closure of the defect at a younger age.",
"   </p>",
"   <p>",
"    Surgical correction of SV-ASD defects require baffling of the anomalous right, middle, left, or any combination of these veins to the SVC or directly into the right atrium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3656?source=see_link&amp;anchor=H24#H24\">",
"     \"Partial anomalous pulmonary venous connection\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential complications following sinus venosus defect closure are baffle leak, superior vena cava stenosis, and pulmonary vein stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26805001\">",
"    <span class=\"h3\">",
"     Coronary sinus septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarest type of ASD is the unroofed coronary sinus that communicates directly with the left atrium. This type of ASD is often missed despite cardiac evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/26\">",
"     26",
"    </a>",
"    ]. The ASD may be closed by direct suture closure of the defect, closure of the mouth of the coronary sinus, or creation of an intraatrial baffle [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Perioperative mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the Mayo Clinic of 123 patients who underwent ASD repair between 1956 and 1960 noted a perioperative mortality rate of 3.3 percent in this early surgical series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/7\">",
"     7",
"    </a>",
"    ]. However, most subsequent studies described no perioperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2,3,5,8,22\">",
"     2,3,5,8,22",
"    </a>",
"    ] or a rate of about 1 percent in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/4,24,27\">",
"     4,24,27",
"    </a>",
"    ]. An exception may occur in patients &ge;60 years of age who, in one series, had a 6 percent (4 of 66) perioperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/6\">",
"     6",
"    </a>",
"    ]. All four patients required additional operative procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients do well over the long-term after successful surgical closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. As noted above, they also appear to do better than with continued medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Younger patients may have better long-term outcomes than older patients. This was illustrated in the report cited above of 123 patients of all ages who underwent surgery at Mayo Clinic for ostium secundum or sinus venosus defects between 1956 and 1960 and were followed for at least 27 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/7\">",
"     7",
"    </a>",
"    ]. The 27-year survival rates for patients in the younger two quartiles at the time of surgery (&le;11 years and 12 to 24 years) were not different from age-matched controls (97 and 93 percent). In contrast, 27-year survival was significantly less than controls for patients in the third quartile (25 to 41 years; 84 versus 91 percent) or fourth quartile (&gt;41 years; 40 versus 59 percent).",
"   </p>",
"   <p>",
"    A later report from the Mayo Clinic described the long-term outcomes in 115 patients with a sinus venosus ASD who underwent surgical repair between 1972 and 1996; 108 had complete follow-up at a mean of 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic improvement occurred in 77 percent, while deterioration occurred in 16 percent. Clinical improvement was more common with older age at surgery.",
"     </li>",
"     <li>",
"      No patient required reoperation.",
"     </li>",
"     <li>",
"      Sinus node dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a permanent pacemaker were noted in 6 percent and atrial fibrillation in 14 percent.",
"     </li>",
"     <li>",
"      Patient survival was similar to that in an age- and sex-matched normal population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Atrial tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachyarrhythmias, primarily atrial fibrillation and atrial flutter, occur in approximately 20 percent of adult patients with an ASD and are often the presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/2,3,14,28\">",
"     2,3,14,28",
"    </a>",
"    ]. The risk of these arrhythmias increases with patient age (especially over age 40) and with higher pulmonary artery pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. In a report of 211 adults, for example, the incidence of atrial fibrillation (AF) or atrial flutter prior to surgery was 1 percent for those aged 18 to 40, 30 percent for those aged 40 to 60, and 80 percent in those over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of these arrhythmias after surgical closure was evaluated in a report of 213 symptomatic adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/14\">",
"     14",
"    </a>",
"    ]. Atrial fibrillation or atrial flutter was present in 40 patients preoperatively and resolved in 16 (40 percent) at a mean follow-up of 3.8 years. New onset of these arrhythmias after surgery occurred in 7.5 percent of patients over age 40 but in none of 106 younger patients. Similar findings were noted in the review of 115 patients with sinus venosus defects cited above: atrial fibrillation occurred in 14 percent and most common with older age at repair [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to the comparative effects of surgical repair or medical therapy, some studies found no difference in the rate of AF or atrial flutter in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]. In a report of 179 patients, for example, new onset AF or atrial flutter developed with equal frequency during follow-up (15 and 17 percent with surgery and medical therapy, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/3\">",
"     3",
"    </a>",
"    ]. In another series, surgery reduced the incidence of atrial flutter in all age groups but not AF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of benefit of surgery in reducing the incidence of AF is presumably related to irreversible factors that predispose to the arrhythmia. The Cox maze or cryo-Maze procedure, performed at the time of ASD closure, decreases the long-term incidence of AF in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. This procedure involves the placement of incisions or cryo-lesions in the atria to interrupt the macro-reentrant circuits that sustain atrial flutter and fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .) The use of radiofrequency ablation to create endocardial lesions is also effective in preventing recurrences of AF, although data are limited in the patients with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with atrial fibrillation are at risk for embolic events, particularly if not appropriately anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Minimally invasive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive approaches include right parasternal or upper hemisternotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/33\">",
"     33",
"    </a>",
"    ], a right submammary bikini line incision in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22,34\">",
"     22,34",
"    </a>",
"    ], limited median sternotomy in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22,34\">",
"     22,34",
"    </a>",
"    ], a mini-median or transxiphoid sternotomy in children and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22,35\">",
"     22,35",
"    </a>",
"    ], a right axillary approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/36\">",
"     36",
"    </a>",
"    ], and a totally thoracoscopic approach with the use of a robotic system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/37\">",
"     37",
"    </a>",
"    ]. An anterolateral approach should not be used in prepubescent girls to avoid possible damage to the breast bud [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/22\">",
"     22",
"    </a>",
"    ]. Published series report good cosmetic results with these approaches with low risks of conversion to a more invasive approach or inadequate repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS CLOSURE OF SECUNDUM ASDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous device closure is an alternative to surgical closure in patients with ostium secundum ASDs that have appropriate anatomic characteristics. The United States Food and Drug Administration's Center for Devices and Radiological Health has approved two devices for percutaneous ASD closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These are the Amplatzer Septal Occluder (",
"    <a class=\"graphic graphic_figure graphicRef52160 \" href=\"UTD.htm?9/52/10050\">",
"     figure 1",
"    </a>",
"    ) and the CardioSEAL Septal Occlusion System. A modification of the CardioSEAL device, called the STARFlex device, is available in Europe and can be obtained under a humanitarian device exception in the United States.",
"   </p>",
"   <p>",
"    Antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) is given for at least six months to protect against thrombus formation in all patients receiving a percutaneous closure device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following discussion will review the efficacy and complications associated with percutaneous device closure of secundum ASD. The characteristics of the Amplatzer and",
"    <span class=\"nowrap\">",
"     CardioSEAL/STARFlex",
"    </span>",
"    devices and other devices that are still investigational are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anatomic requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative device closure is applicable only to",
"    <strong>",
"     secundum ASDs",
"    </strong>",
"    , and should not be used in patients with sinus venosus, primum or coronary sinus ASD. The ideal lesion for percutaneous closure is considered to be a defect less than 30 mm in diameter with a rim of tissue around the defect of at least 5 mm to prevent obstruction of the coronary sinus, right pulmonary veins, vena cavae, or atrioventricular valves. Approximately half to two-thirds of ASDs in adults meet these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. More than one device can be inserted to close multiple ASDs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, secundum ASD is associated with a partial anomalous pulmonary venous connection, which would not make percutaneous closure of the ASD the treatment of choice. Left-to-right shunt would persist related to the anomalous pulmonary vein after device closure. Thus, prior to percutaneous closure, a search for anomalous pulmonary veins should be undertaken, particularly if right heart chamber enlargement is out of proportion to the size of the ASD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Echocardiographic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of TEE or intracardiac echocardiography (ICE) can facilitate the deployment of percutaneous ASD closure devices. Measurement of the size and location of the ASD by TEE can help select the appropriate device. In addition, TEE and ICE can be used to guide the procedure in real time, an approach that may eliminate the need for fluoroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/47-53\">",
"     47-53",
"    </a>",
"    ]. Two- and three-dimensional TEE is particularly helpful when multiple devices are inserted to close multiple ASDs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICE has the following advantages compared to TEE. It does not require endotracheal intubation or general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]; it permits continuous monitoring during the procedure; and it may shorten the duration of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, 94 patients underwent ICE during percutaneous closure of an ASD or PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/49\">",
"     49",
"    </a>",
"    ]. All devices were deployed successfully. During the procedure, ICE identified a previously unrecognized anatomical diagnosis in 32 patients (an additional ASD or PFO, a redundant atrial septum, or an atrial septal aneurysm). Procedural complications occurred in four patients: atrial fibrillation in three and supraventricular tachycardia in one. Two of the arrhythmias resolved spontaneously and two required cardioversion with no recurrence.",
"   </p>",
"   <p>",
"    3D echocardiography enables direct and complete visualization of the ASD, so that the area of the defect can be estimated and the anatomy of the entire interatrial septum can be defined. This 3D information facilitates optimal deployment and positioning of all types of inter-atrial closure devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies have described favorable outcomes in the great majority of patients treated with percutaneous closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/45,54-60\">",
"     45,54-60",
"    </a>",
"    ]. In a series of 100 children and adults (mean age 13.3 years), the Amplatzer device was successfully implanted in 93 with a procedure time ranging from 30 to 180 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/54\">",
"     54",
"    </a>",
"    ]. The total ASD occlusion rate at three months was 99 percent. Defect closure is associated with a reduction in left atrial volume and improvements in right and left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These outcomes with the Amplatzer device persist at long-term follow-up as illustrated in a review of 151 children and young adults (mean age 11.9 years) who underwent successful closure and were then followed for a median of 78 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/57\">",
"     57",
"    </a>",
"    ]. There were no deaths or significant complications and all defects were completely closed at three years and remained closed thereafter.",
"   </p>",
"   <p>",
"    An initial experience with the CardioSEAL device involved 50 patients (median age 9.7 years); 22 percent had multiple ASDs and 38 percent had a deficient rim of atrial tissue (&lt;4 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/59\">",
"     59",
"    </a>",
"    ]. After a mean follow-up of 9.9 months, all patients were asymptomatic. A small residual shunt was present in 46 percent of patients without evidence of hemodynamic consequences.",
"   </p>",
"   <p>",
"    Percutaneous ASD closure improves functional capacity, even in asymptomatic patients as illustrated in a study of 32 adults who underwent ASD closure at a mean age of 43 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/60\">",
"     60",
"    </a>",
"    ]. The mean baseline",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    was 2.0. At six months, cardiopulmonary exercise testing demonstrated a significant improvement in peak oxygen uptake with exercise compared to testing obtained before closure (25.6 versus 21.9",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min). There was a significant correlation between the magnitude of the functional benefit and the baseline",
"    <span class=\"nowrap\">",
"     Qp/Qs,",
"    </span>",
"    but even patients with",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    &lt;2.0 had significant functional improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, severe fixed pulmonary hypertension is considered a contraindication to surgical repair of an ASD. However, advances in the medical management of patients with pulmonary vascular disease together with the development of percutaneous closure techniques may make ASD closure feasible in this setting. It has been suggested that patients with a net left-to-right shunt, a pulmonary vascular resistance less than 800 to 960 dyne sec cm(-5) m2 (10 to 12 Wood units), and a resting systemic arterial oxygen saturation &ge;90 percent might benefit from ASD closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of percutaneous closure was demonstrated in a report of 29 patients with a secundum ASD and a baseline peak pulmonary artery pressure &gt;40 mmHg (mean 65 mmHg) in whom an Amplatzer device was implanted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/61\">",
"     61",
"    </a>",
"    ]. Complete ASD occlusion was achieved in 28 patients (97 percent). Immediately after the procedure, the mean peak pulmonary artery pressure decreased to 54 mmHg; at a mean of 21 months, it decreased further to 31 mmHg. There were no procedural complications. Functional status was improved after the procedure and was maintained at a mean of 21 months. Six of twelve patients who had atrial fibrillation at baseline recovered sinus rhythm by discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Comparison to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data comparing surgical and percutaneous closure of a secundum ASD suggest that the rate of procedural success is comparable or possibly better with surgery, but that the rate of complications and length of hospital stay may be reduced with the percutaneous approach. It is likely that percutaneous closure will replace surgical closure in many patients, especially elderly patients and others with significant operative risks.",
"   </p>",
"   <p>",
"    The best comparative data come from a study of 442 children and young adults undergoing percutaneous closure with the Amplatzer device (median age 9.8 years) and 154 undergoing surgery (median age 4.1 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/62\">",
"     62",
"    </a>",
"    ]. The rate of procedural success was significantly higher with surgery (100 versus 96 percent), while the percutaneous closure group had significant reductions in complication rate (7 versus 24 percent) and mean hospital stay (1.0 versus 3.4 days). There were no deaths in either group. Similar short-term differences were noted in another report comparing 61 patients who underwent surgical closure (median age 20 years) with 61 who underwent closure with an Amplatzer device (median age 12 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first study also described long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/62\">",
"     62",
"    </a>",
"    ]. At 12 month follow-up of patients treated with the Amplatzer device, a residual shunt was present in 1.5 percent; one patient required a second procedure to correct a residual shunt at 24 month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with trans-catheter closure of a secundum ASD include device embolization or malposition, arrhythmias (usually atrial but include sudden death), and device",
"    <span class=\"nowrap\">",
"     erosion/perforation",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/54,56,62,64,65\">",
"     54,56,62,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Early",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and frequency of early complications were evaluated in a report of 417 patients (mean age 27 years) who underwent secundum ASD closure with the Amplatzer or",
"    <span class=\"nowrap\">",
"     CardioSEAL/STARFlex",
"    </span>",
"    device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/56\">",
"     56",
"    </a>",
"    ]. Thirty-four patients (8.6 percent) experienced a complication during hospitalization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Device embolization or malposition requiring surgery in 2.4 percent and managed percutaneously in 1.0 percent. In another series of 124 patients, 6.5 percent required surgery for device malposition or embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial fibrillation or supraventricular tachycardia in 2.4 percent.",
"     </li>",
"     <li>",
"      Other complications (heart block, pericardial effusion, thrombus formation on the left atrial appendage, iliac vein dissection, groin hematoma) in 2.2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Device arm fractures, which are occasional complications with the CardioSEAL device (14 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/59\">",
"     59",
"    </a>",
"    ], are much less common with the STARFlex modification [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient atrioventricular block has been described with a frequency ranging from 1 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/54,66\">",
"     54,66",
"    </a>",
"    ]. Atrioventricular block may be more common with larger devices and smaller patients. This problem appears to resolve or improve spontaneously in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Cardiac perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac perforation, which can present as hemopericardium, pericardial effusion, cardiovascular collapse, or sudden death, is an uncommon complication of the Amplatzer septal occluder. In a review of 24 cases reported to the manufacturer, 14 had proven cardiac perforation with hemopericardium, five had hemopericardium alone, and three had proven cardiac perforation and fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/67\">",
"     67",
"    </a>",
"    ]. These events, which involved the left atrium, right atrium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aorta, occurred as early as the first day, and as late as three years after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Thrombus formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) is given for at least six months to all patients receiving a percutaneous closure device to protect against thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Thrombus formation can occur in the left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which thrombus formation occurs was evaluated in a review of 407 consecutive patients with an ASD and 593 consecutive patients with a PFO who were treated with a variety of devices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/40\">",
"     40",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombus on the device was detected by TEE at four weeks in 14 patients (1.4 percent) and at six months in six patients (0.6 percent). The overall rate of thrombus formation was 1.2 percent in patients with an ASD and 2.5 percent in patients with a PFO.",
"      <br/>",
"      <br/>",
"      After the investigators discontinued use of anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy after implantation, thrombus occurred in only one of 183 patients (0.5 percent) treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Thrombus formation was significantly more common with the CardioSEAL and STARFlex devices than with the Amplatzer device (5.9 versus 0 percent). An intermediate rate of 3.6 percent was noted with the ASDOS device.",
"     </li>",
"     <li>",
"      The thrombus resolved in 17 of 20 patients after anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ; in the remaining three patients, the thrombus was removed surgically. Four of the 20 patients suffered embolic events (strokes in three and a transient ischemic attack in one).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Left atrial thrombus formation with transient ischemic attacks has been described as late as three years after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, sudden death can occur after percutaneous device implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/56,65\">",
"     56,65",
"    </a>",
"    ]. The frequency with which this might occur was addressed in a review of three databases involving 777 patients who received a device for an ASD or VSD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/65\">",
"     65",
"    </a>",
"    ]. At a median follow-up of 25 months, sudden death occurred in nine patients (1.2 percent); three had undergone device closure of an ASD alone. Patients who experienced sudden death were more likely to have had multiple devices inserted and to have a history of serious tachyarrhythmias, severe valve regurgitation, one or more cardiac surgeries, pulmonary hypertension, and ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Device erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential long-term complication is erosion of the device, which is estimated to occur in 0.1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/69\">",
"     69",
"    </a>",
"    ]. Risk factors for device erosion include deficient aortic rim (seen in 25 of 28 cases), deficient superior rim, and an oversized device. In addition, there have been rare cases of pericardial effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longevity in patients with an unoperated ostium secundum ASD spans the reproductive years. ASD is the most common repaired or unrepaired lesion occurring in pregnant women with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Many of these women are unaware of their heart defect prior to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the gestational increase in cardiac output and stroke volume, young women with an uncomplicated ASD generally tolerate pregnancy, even multiple pregnancies, with no apparent ill effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/72\">",
"     72",
"    </a>",
"    ]. However, after age 40, otherwise uncomplicated secundum ASDs are accompanied by an increased incidence of supraventricular arrhythmias, especially atrial fibrillation or atrial flutter, that may cause symptoms, right ventricular failure and increase the probability of venous stasis and thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/71,73\">",
"     71,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important concern is the risk of paradoxical embolization from leg or pelvic veins because emboli carried by the inferior vena cava tend to be directed across the ASD into the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Meticulous leg care and ambulation minimizes venous stasis during gestation and in the puerperium and reduces the risk of paradoxical embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Paradoxical emboli'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also important, but less well known, are the potentially deleterious effects of acute blood loss. Hemorrhage during delivery results in a rise in systemic vascular resistance and a fall in systemic venous return, a combination that augments the left-to-right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pulmonary vascular disease occurs pregnancy should be avoided due to the high risk of maternal and fetal mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of Eisenmenger syndrome\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Repaired ostium secundum ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have successfully undergone childhood closure of an ostium secundum ASD and have no significant residua can anticipate pregnancy devoid of maternal risk. Successful closure of the defect also eliminates the hazard of paradoxical embolization.",
"   </p>",
"   <p>",
"    Residual postoperative sequelae are few and insignificant except for late-onset atrial tachyarrhythmias with frequency related to age at intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/7\">",
"     7",
"    </a>",
"    ]. Percutaneous device closure of ASDs is being performed more frequently, and adverse pregnancy-related concerns have not been described.",
"   </p>",
"   <p>",
"    A literature review of studies published between 1985 and 2007 found the following rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with ASDs (combined repaired and unrepaired) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, cardiac complications were uncommon. Arrhythmias occurred in 1 of 123 pregnancies, heart failure in none of 132 pregnancies, and cardiovascular events (myocardial infarction, stroke, cardiovascular mortality) in 2 of 149 pregnancies.",
"     </li>",
"     <li>",
"      With respect to the fetus, premature delivery occurred in 10 of 168 pregnancies (6 percent), fetal mortality in 7 of 291 pregnancies (2.4 percent), perinatal mortality rate 5 of 291 pregnancies (1.7 percent), and recurrent congenital heart disease of any type in 6 of 291 pregnancies (2.1 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ASDs occur sporadically. Familial ASD with conduction defect is an autosomal dominant trait. Genetic syndromes with skeletal abnormalities associated with ASD include a variety of heart-hand syndromes, of which Holt-Oram syndrome is best known. Because of the possibility of familial occurrence, a careful family history should be taken in patients with ASD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PARTICIPATION IN SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ASD can have a varying degree of impact on the right heart and on cardiac performance during athletic activity. As delineated by the 2005 36th Bethesda Conference on Eligibility Recommendations for Competitive Athletes with Cardiovascular Abnormalities, the recommendations for athletics in patients with an untreated ASD vary with the severity of the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with small defects, normal right heart volumes, and no pulmonary hypertension can participate in all sports.",
"     </li>",
"     <li>",
"      Athletes with a large ASD and normal pulmonary artery pressure can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Athletes with an ASD and mild pulmonary hypertension can participate in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ). Patients with associated pulmonary vascular obstructive disease who have cyanosis and a large right-to-left shunt cannot participate in competitive sports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athletes with an ASD of moderate-to-large size should have the defect closed surgically or by a percutaneous catheter technique as described above. The recommendations for athletics in patients with a treated ASD are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three to six months after the operation or intervention, patients can participate in all sports unless one or more of the following is present: (1) evidence of pulmonary hypertension; (2) symptomatic atrial or ventricular tachyarrhythmias or second- or third-degree heart block; and (3) evidence of myocardial dysfunction.",
"     </li>",
"     <li>",
"      Patients with any of these abnormalities should have an exercise evaluation and an individualized exercise prescription with respect to competitive sports. After such an evaluation, athletes can participate in all sports, assuming pulmonary hypertension, right heart dysfunction, and arrhythmias are absent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association guidelines on endocarditis prophylaxis concluded that an isolated ASD or a repaired ASD were associated with a negligible risk of endocarditis and that antibiotic prophylaxis was",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/81\">",
"     81",
"    </a>",
"    ]. The very low risk of endocarditis was illustrated in a review of 882 adults with a secundum ASD; only three had a history of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis is recommended for six months after device closure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ASA WITH ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atrial septal aneurysm (ASA) is defined as redundant and mobile interatrial septal tissue in the region of the fossa ovalis with phasic excursion of at least 10 to 15 mm during the cardiorespiratory cycle. ASA is commonly associated with PFO or one or more atrial septal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/83\">",
"     83",
"    </a>",
"    ]. The prevalence, clinical manifestations of ASA and treatment to prevent stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Atrial septal aneurysm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A perforated aneurysm may be associated with a significant left-to-right shunt and present with clinical and hemodynamic features of an ASD. Perforated aneurysms can be closed surgically or percutaneously, depending upon their morphology. In a retrospective review of 50 patients, perforated aneurysms were classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/0/25610/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A - aneurysm with persistent foramen ovale",
"     </li>",
"     <li>",
"      Type B - aneurysm with single ASD",
"     </li>",
"     <li>",
"      Type C - aneurysm with two perforations",
"     </li>",
"     <li>",
"      Type D - aneurysm with multiple perforations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    32 had systemic thromboembolism or transient ischemic attacks, eight presented with dyspnea on exertion, and ten were asymptomatic but had significant left to right shunt and right ventricular volume overload. Transcatheter device closure using an Amplatzer or CardioSEAL device was possible in all eighteen patients with a type A aneurysm. In the nine patients with a type B aneurysm, five had successful device closure, while four required surgery. Device closure was achieved in all 10 patients with a type C aneurysm, but four had a residual shunt. All thirteen patients with a type D aneurysm underwent surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/31/6642?source=see_link\">",
"       \"Patient information: Atrial septal defect (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19634896\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main indication for ASD closure is the presence of a significant shunt as evidenced by right heart volume overload with or without symptoms (exercise intolerance, fatigue, dyspnea, heart failure, paradoxical emboli, arrhythmias). (See",
"      <a class=\"local\" href=\"#H26805166\">",
"       'RV volume overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD closure is reasonable in the presence of a documented paradoxical embolism. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Paradoxical embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD closure is suggested to treat documented orthodeoxia-platypnea. (See",
"      <a class=\"local\" href=\"#H26805546\">",
"       'Orthodeoxia-platypnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with an ASD (or other intracardiac shunt), scuba diving is generally contraindicated. Consultation with a cardiologist specializing in congenital heart disease is recommended before altitude exposure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Scuba diving and altitude exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young women with an uncomplicated ASD generally tolerate pregnancy well. Women over 40 years old have an increased risk of supraventricular arrhythmias, especially atrial fibrillation or atrial flutter that may cause symptoms of right ventricular failure and increase the probability of venous stasis and thromboembolism. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meticulous leg care and regular ambulation minimize venous stasis during gestation and in the puerperium and reduces the risk of paradoxical embolization. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous device closure is an alternative to surgical closure in patients with ostium secundum ASDs that have appropriate anatomic characteristics. Surgery is required for closure of ostium primum ASD, sinus venosus ASD, and coronary sinus septal defects. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Percutaneous closure of secundum ASDs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30291431\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Drs. Martin St. John Sutton and Susan Wiegers for their contributions as authors to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/1\">",
"      McMahon CJ, Feltes TF, Fraley JK, et al. Natural history of growth of secundum atrial septal defects and implications for transcatheter closure. Heart 2002; 87:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/2\">",
"      Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum atrial septal defects in patients &gt;40 years old. A randomized clinical trial. J Am Coll Cardiol 2001; 38:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/3\">",
"      Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med 1995; 333:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/4\">",
"      Horvath KA, Burke RP, Collins JJ Jr, Cohn LH. Surgical treatment of adult atrial septal defect: early and long-term results. J Am Coll Cardiol 1992; 20:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/5\">",
"      Burke RP, Horvath K, Landzberg M, et al. Long-term follow-up after surgical repair of ostium primum atrial septal defects in adults. J Am Coll Cardiol 1996; 27:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/6\">",
"      John Sutton MG, Tajik AJ, McGoon DC. Atrial septal defect in patients ages 60 years or older: operative results and long-term postoperative follow-up. Circulation 1981; 64:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/7\">",
"      Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med 1990; 323:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/8\">",
"      Fiore AC, Naunheim KS, Kessler KA, et al. Surgical closure of atrial septal defect in patients older than 50 years of age. Arch Surg 1988; 123:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/9\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/10\">",
"      Silversides CK, Dore A, Poirier N, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: shunt lesions. Can J Cardiol 2010; 26:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/11\">",
"      Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/12\">",
"      Fuse S, Tomita H, Hatakeyama K, et al. Effect of size of a secundum atrial septal defect on shunt volume. Am J Cardiol 2001; 88:1447.",
"     </a>",
"    </li>",
"    <li>",
"     Vick GW III. Defects of the atrial septum Including atrioventricular septal defects. In: Science and Practice of Pediatric Cardiology, 2nd, Garson A Jr, Bricker JT, Fisher DJ, Neish SR (Eds), Williams &amp; Wilkins, Baltimore 1998. p.1141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/14\">",
"      Gatzoulis MA, Freeman MA, Siu SC, et al. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999; 340:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/15\">",
"      Rostad H, S&ouml;rland S. Atrial septal defect of secundum type in patients under 40 years of age. A review of 481 operated cases. Symptoms, signs, treatment and early results. Scand J Thorac Cardiovasc Surg 1979; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/16\">",
"      Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc 2004; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/17\">",
"      Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003; 139:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/18\">",
"      Mess&eacute; SR, Silverman IE, Kizer JR, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/19\">",
"      Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/20\">",
"      Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/21\">",
"      Landzberg MJ. Closure of atrial septal defects in adult patients: justification of the \"tipping point\". J Interv Cardiol 2001; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/22\">",
"      Hopkins RA, Bert AA, Buchholz B, et al. Surgical patch closure of atrial septal defects. Ann Thorac Surg 2004; 77:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/23\">",
"      Bink-Boelkens MT, Meuzelaar KJ, Eygelaar A. Arrhythmias after repair of secundum atrial septal defect: the influence of surgical modification. Am Heart J 1988; 115:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/24\">",
"      Attenhofer Jost CH, Connolly HM, Danielson GK, et al. Sinus venosus atrial septal defect: long-term postoperative outcome for 115 patients. Circulation 2005; 112:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/25\">",
"      Vogel M, Berger F, Kramer A, et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/26\">",
"      Attenhofer Jost CH, Connolly HM, Danielson GK, et al. Clinical features and surgical outcome in 25 patients with fenestrations of the coronary sinus. Cardiol Young 2007; 17:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/27\">",
"      Ghosh S, Chatterjee S, Black E, Firmin RK. Surgical closure of atrial septal defects in adults: effect of age at operation on outcome. Heart 2002; 88:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/28\">",
"      Berger F, Vogel M, Kramer A, et al. Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Ann Thorac Surg 1999; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/29\">",
"      Oliver JM, Gallego P, Gonz&aacute;lez A, et al. Predisposing conditions for atrial fibrillation in atrial septal defect with and without operative closure. Am J Cardiol 2002; 89:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/30\">",
"      Bonchek LI, Burlingame MW, Worley SJ, et al. Cox/maze procedure for atrial septal defect with atrial fibrillation: management strategies. Ann Thorac Surg 1993; 55:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/31\">",
"      Sandoval N, Velasco VM, Orjuela H, et al. Concomitant mitral valve or atrial septal defect surgery and the modified Cox-maze procedure. Am J Cardiol 1996; 77:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/32\">",
"      Crandall MA, Daoud EG, Daniels CJ, Kalbfleisch SJ. Percutaneous radiofrequency catheter ablation for atrial fibrillation prior to atrial septal defect closure. J Cardiovasc Electrophysiol 2012; 23:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/33\">",
"      Byrne JG, Adams DH, Mitchell ME, Cohn LH. Minimally invasive direct access for repair of atrial septal defect in adults. Am J Cardiol 1999; 84:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/34\">",
"      Vida VL, Padalino MA, Boccuzzo G, et al. Minimally invasive operation for congenital heart disease: a sex-differentiated approach. J Thorac Cardiovasc Surg 2009; 138:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/35\">",
"      Bichell DP, Geva T, Bacha EA, et al. Minimal access approach for the repair of atrial septal defect: the initial 135 patients. Ann Thorac Surg 2000; 70:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/36\">",
"      Dave HH, Comber M, Solinger T, et al. Mid-term results of right axillary incision for the repair of a wide range of congenital cardiac defects. Eur J Cardiothorac Surg 2009; 35:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/37\">",
"      Ak K, Aybek T, Wimmer-Greinecker G, et al. Evolution of surgical techniques for atrial septal defect repair in adults: a 10-year single-institution experience. J Thorac Cardiovasc Surg 2007; 134:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/38\">",
"      Schwetz BA. From the Food and Drug Administration. JAMA 2002; 287:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/39\">",
"      Inglessis I, Landzberg MJ. Interventional catheterization in adult congenital heart disease. Circulation 2007; 115:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/40\">",
"      Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/41\">",
"      Braun MU, Fassbender D, Schoen SP, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 2002; 39:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/42\">",
"      Brandt RR, Neumann T, Neuzner J, et al. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr 2002; 15:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/43\">",
"      Ferreira SM, Ho SY, Anderson RH. Morphological study of defects of the atrial septum within the oval fossa: implications for transcatheter closure of left-to-right shunt. Br Heart J 1992; 67:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/44\">",
"      Prokselj K, Kozelj M, Zadnik V, Podnar T. Echocardiographic characteristics of secundum-type atrial septal defects in adult patients: implications for percutaneous closure using Amplatzer septal occluders. J Am Soc Echocardiogr 2004; 17:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/45\">",
"      Carminati M, Chessa M, Butera G, et al. Transcatheter closure of atrial septal defects with the STARFlex device: early results and follow-up. J Interv Cardiol 2001; 14:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/46\">",
"      Cao Q, Radtke W, Berger F, et al. Transcatheter closure of multiple atrial septal defects. Initial results and value of two- and three-dimensional transoesophageal echocardiography. Eur Heart J 2000; 21:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/47\">",
"      Hellenbrand WE, Fahey JT, McGowan FX, et al. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol 1990; 66:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/48\">",
"      Ewert P, Berger F, Daehnert I, et al. Transcatheter closure of atrial septal defects without fluoroscopy: feasibility of a new method. Circulation 2000; 101:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/49\">",
"      Earing MG, Cabalka AK, Seward JB, et al. Intracardiac echocardiographic guidance during transcatheter device closure of atrial septal defect and patent foramen ovale. Mayo Clin Proc 2004; 79:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/50\">",
"      Bartel T, Konorza T, Arjumand J, et al. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. Circulation 2003; 107:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/51\">",
"      Zanchetta M, Onorato E, Rigatelli G, et al. Intracardiac echocardiography-guided transcatheter closure of secundum atrial septal defect: a new efficient device selection method. J Am Coll Cardiol 2003; 42:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/52\">",
"      Mullen MJ, Dias BF, Walker F, et al. Intracardiac echocardiography guided device closure of atrial septal defects. J Am Coll Cardiol 2003; 41:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/53\">",
"      Boccalandro F, Baptista E, Muench A, et al. Comparison of intracardiac echocardiography versus transesophageal echocardiography guidance for percutaneous transcatheter closure of atrial septal defect. Am J Cardiol 2004; 93:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/54\">",
"      Chan KC, Godman MJ, Walsh K, et al. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart 1999; 82:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/55\">",
"      Fischer G, Kramer HH, Stieh J, et al. Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder. Eur Heart J 1999; 20:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/56\">",
"      Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002; 39:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/57\">",
"      Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol 2005; 45:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/58\">",
"      Salehian O, Horlick E, Schwerzmann M, et al. Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects. J Am Coll Cardiol 2005; 45:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/59\">",
"      Pedra CA, Pihkala J, Lee KJ, et al. Transcatheter closure of atrial septal defects using the Cardio-Seal implant. Heart 2000; 84:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/60\">",
"      Giardini A, Donti A, Formigari R, et al. Determinants of cardiopulmonary functional improvement after transcatheter atrial septal defect closure in asymptomatic adults. J Am Coll Cardiol 2004; 43:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/61\">",
"      de Lezo JS, Medina A, Romero M, et al. Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension. Am Heart J 2002; 144:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/62\">",
"      Du ZD, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002; 39:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/63\">",
"      Berger F, Vogel M, Alexi-Meskishvili V, Lange PE. Comparison of results and complications of surgical and Amplatzer device closure of atrial septal defects. J Thorac Cardiovasc Surg 1999; 118:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/64\">",
"      Berdat PA, Chatterjee T, Pfammatter JP, et al. Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J Thorac Cardiovasc Surg 2000; 120:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/65\">",
"      Perry YY, Triedman JK, Gauvreau K, et al. Sudden death in patients after transcatheter device implantation for congenital heart disease. Am J Cardiol 2000; 85:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/66\">",
"      Suda K, Raboisson MJ, Piette E, et al. Reversible atrioventricular block associated with closure of atrial septal defects using the Amplatzer device. J Am Coll Cardiol 2004; 43:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/67\">",
"      Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol 2005; 45:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/68\">",
"      Ruge H, Wildhirt SM, Libera P, et al. Images in cardiovascular medicine. Left atrial thrombus on atrial septal defect closure device as a source of cerebral emboli 3 years after implantation. Circulation 2005; 112:e130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/69\">",
"      Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 2004; 63:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/70\">",
"      Zuber M, Gautschi N, Oechslin E, et al. Outcome of pregnancy in women with congenital shunt lesions. Heart 1999; 81:271.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff, JK. The Clinical Recognition of Congenital Heart Disease, 6th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/72\">",
"      McFaul PB, Dornan JC, Lamki H, Boyle D. Pregnancy complicated by maternal heart disease. A review of 519 women. Br J Obstet Gynaecol 1988; 95:861.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Pregnancy and cardiovascular disease. In: Heart Disease, Braunwald E (Ed), WB Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/74\">",
"      Harvey JR, Teague SM, Anderson JL, et al. Clinically silent atrial septal defects with evidence for cerebral embolization. Ann Intern Med 1986; 105:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/75\">",
"      Pitkin RM, Perloff JK, Koos BJ, Beall MH. Pregnancy and congenital heart disease. Ann Intern Med 1990; 112:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/76\">",
"      Loscalzo J. Paradoxical embolism: clinical presentation, diagnostic strategies, and therapeutic options. Am Heart J 1986; 112:141.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK, Child JS. Congenital Heart Disease in Adults, 2nd ed, WB Saunders, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/78\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/79\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"    <li>",
"     Liberthson, R. Arrhythmias in the athlete with congenital heart disease &mdash; Guidelines for participation. From North American Society of Pacing and Electrophysiology Expert Consensus Conference on Arrhythmias and the Athlete, May 6, 1998.",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/82\">",
"      Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/0/25610/abstract/83\">",
"      Ewert P, Berger F, Vogel M, et al. Morphology of perforated atrial septal aneurysm suitable for closure by transcatheter device placement. Heart 2000; 84:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1417 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25610=[""].join("\n");
var outline_f25_0_25610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19634896\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR DEFECT CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26805166\">",
"      RV volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Paradoxical embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26805546\">",
"      - Orthodeoxia-platypnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fixed pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Scuba diving and altitude exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19741008\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURGICAL CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8433827\">",
"      Associated defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Postoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ostium secundum ASD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ostium primum ASD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sinus venosus ASD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26805001\">",
"      - Coronary sinus septal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Perioperative mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Atrial tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Minimally invasive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PERCUTANEOUS CLOSURE OF SECUNDUM ASDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anatomic requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Echocardiographic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Comparison to surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Early",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Cardiac perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Thrombus formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Sudden death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Device erosion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Repaired ostium secundum ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PARTICIPATION IN SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ASA WITH ASD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19634896\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30291431\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1417|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10050\" title=\"figure 1\">",
"      Amplatzer septal occluder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 2\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1417|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/32/41487\" title=\"movie 1\">",
"      TTE with color Doppler post-ASD repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=related_link\">",
"      Devices for percutaneous closure of a secundum atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3656?source=related_link\">",
"      Partial anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/31/6642?source=related_link\">",
"      Patient information: Atrial septal defect (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/52/14154?source=related_link\">",
"      Ventricular septal defect in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_0_25611="Time zone shift PI";
var content_f25_0_25611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for time zone shifts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Try to choose daytime flights to minimize sleep loss.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. If traveling at night or for long distance, try to travel in business or first class to allow sleep during the flight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Avoid large meals, caffeine, and alcohol during your normal sleep period.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Drink water.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. If the flight is 8 hours or more in length and occurs during your destination sleep period, consider the use of a short-acting hypnotic during the flight (this would contraindicate the use of any alcohol during the flight) and for the first few nights after arrival.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Some research suggests that melatonin can help to alter circadian rhythms. Usage guidelines are available, but melatonin is sold only as a health food substance and is not approved by the FDA. Typical use is 5 mg at the desired bedtime for 4 nights after arrival in a new time zone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Avoid important meetings on the day after arrival.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Avoid distance driving or other sedentary behavior on the day of arrival.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Bright light can either maintain or help to shift circadian rhythms depending upon the time of exposure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Arendt, J, Stone, B, Skene, DJ. Sleep disruption in jet lag and other circadian rhythm-related disorders. In: Principles and practice of sleep medicine, 4th ed, Kryger, M, Roth, T, Dement, WC (eds), Saunders, New York 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25611=[""].join("\n");
var outline_f25_0_25611=null;
var title_f25_0_25612="Criteria for HLH";
var content_f25_0_25612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (1) Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peak temperature &gt;38.5&deg;C for seven or more days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (2) Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spleen palpated &gt;3 cm below the left costal margin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (3) Cytopenia involving two or more cell lines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin &lt;9.0 g/dL, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelets &lt;100,000/&micro;L, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absolute neutrophil count &lt;1000/&micro;L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (4) Hypertriglyceridemia or hypofibrinogenemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fasting triglycerides &gt;2.0 mmol/L, or more than 3 standard deviations (SD) above the normal value for age, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibrinogen &lt;1.5 g/L, or more than 3 SD below the normal value for age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (5) Hemophagocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Demonstrated in bone marrow, spleen, or lymph node; no evidence for malignancy. (See text).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        <strong>",
"         (6)",
"        </strong>",
"        &nbsp;Hepatitis",
"        <span class=\"subtitle2_single\">",
"        </span>",
"        <span class=\"subtitle2\">",
"        </span>",
"        <span class=\"subtitle2\">",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (7) Low or absent natural killer cell activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (8) Serum ferritin level &gt;500 &micro;g/L (although &gt;3000&nbsp;&micro;g/L is a more realistic cut off to exclude infections and autoimmune diseases. See text).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        (9) Soluble CD25 (sIL-2 receptor) &gt;2400 U/mL (note age-related norms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The diagnosis of HLH requires the presence of five of the above criteria. If a patient meets only four criteria and the clinical suspicion for HLH is high, one must initiate appropriate treatment, as delays may be fatal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the appropriate clinical setting, the diagnosis is justified by a positive family history of HLH; parental consanguinity is only suggestive of HLH.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Henter JI, et al. Semin Oncol 1991; 18:29.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25612=[""].join("\n");
var outline_f25_0_25612=null;
var title_f25_0_25613="RB ILD versus IPF";
var content_f25_0_25613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Symptoms and signs in RB-ILD versus IPF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical symptoms and signs at presentation in 18 patients with respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) compared to 59 patients with idiopathic pulmonary fibrosis (IPF). Cough and dyspnea were the most common presenting symptoms in both patient groups. Rales were common findings on physical examination in RB-ILD, whereas clubbing was rarely seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from King, TE Jr, Mortenson, RL, Immunol Allergy Clin North Am 1992; 12:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25613=[""].join("\n");
var outline_f25_0_25613=null;
var title_f25_0_25614="Prevalence and pred value";
var content_f25_0_25614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of disease prevalence on predictive values",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Consider a population of 2000 people and a diagnostic test that is 90 percent sensitive and specific. The positive and negative predictive values of the test vary when the prevalence of the disease is varied. Left panel: If the prevalence of the disease is high at 50 percent, the positive and negative predictive values will be similar to the sensitivity and specificity (90 percent, respectively). Right panel: In contrast, if the prevalence of the disease is only 1 percent, the positive predictive value decreases (8 percent) and the negative predictive value increases (99 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25614=[""].join("\n");
var outline_f25_0_25614=null;
var title_f25_0_25615="Toe towel curls";
var content_f25_0_25615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toe towel curls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The toes are curled around a towel as pictured. The toes should be alternately curled and straightened. This exercise is performed for one to two minutes, twice daily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_0_25615=[""].join("\n");
var outline_f25_0_25615=null;
